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Summary
Bioreducible antitumour agents are prodrugs which are intended to be inactive 
in their own right, but are able to undergo metabolic reduction to produce toxic species 
which can damage biomolecules. This reduction may occur readily in solid tumours due 
to two factors which are unique to them, a) tumour hypoxia; and b) the expression of 
high levels of reductase enzymes. Each of these factors can promote specific 
cytotoxicity to the tumour and in principle could create a selective antitumour agent.
A series of N-oxides of heterocyclic aliphatic amines was prepared for 
evaluation as bioreducible drugs. N-oxides (A) of cis- and rra>w-2,6-disubstituted N- 
methyl-piperidine were prepared with X equal to carbamate or halogen. The free bases 
were designed to be bifunctional alkylating agents via aziridine ion formation. The cis- 
isomer was synthesised by hydrogenation of a derivative of dipicolinic acid followed 
by reduction to produce the diol from which the leaving groups were attatched. The 
trans-isomer was synthesised by ring closure of a pimelic acid derivative with 
methylamine followed by acidic epimerisation, from which the diol was obtained and 
derivatised. In total, 22 mostly novel compounds were synthesised and tested against 
two human colon carcinoma cell lines, HT 29 and BE cells under oxic and hypoxic 
conditions. HT 29 cells produce high amounts of DT-diaphorase which is a reductase 
enzyme that favours a 2e- reduction pathway, whilst BE cells contains no DT- 
diaphorase. IC50 values were also measured for selected compounds. The results 
showed that the free bases are toxic against both cell lines and the N-oxides are non­
toxic. This suggested that the mono-Af-oxides were not reduced under hypoxic 
conditions which implies that the reduction potentials of the compounds are not in the 
correct range for cellular reductants.
/  \Me
(B)(A)
Bis-N-oxides (B) of 1,4-disubstituted piperazines were also prepared and 10 
mainly novel compounds were synthesised and tested in the same biological systems. 
These N-oxides also did not give any evidence of being reduced under hypoxic 
conditions but did have reduced toxicity in comparison to the free bases. IC50 values 
were measured for these compounds and the values indicated that the free bases were 
up to 1000-fold more toxic than the corresponding bis-N-oxides.
In attempts to modify the reduction potentials of the piperidine Af-oxides, a 
series of bis-piperidine-bis-W-oxides (C) of varying carbon chain length were prepared 
by a general route by linking two methyl pipecolinate molecules with a selection of 
diacid chlorides followed by reduction and introduction of the X group. 20 
predominantly novel compounds were prepared and evaluated for toxicity and 
selectivity. There was little evidence of hypoxic/oxic selectivity by the N-oxides 
although their toxicity was substantially reduced compared to the free bases. The 
toxicity of the free bases did seem affected by the length of the carbon chain, and the 
compounds with a four carbon chain were most toxic by several orders of magnitude.
(C)
Cobalt is known to form stable octahedral Co(III) complexes with a range of 
aliphatic amines and the reduction potentials of such complexes fall within an
reduction results in release of the ligands and it has been suggested that this may be 
incorporated into the design of novel bioreducible antitumour agents. A range of 
diamines, triamines and tetraamines with alkylating functionality were synthesised and 
complexed to Co(III). The polyamines were formed by a general route starting with 
amino acids and using mixed anhydride methodology to attach the nitrogen mustard 
functionality.
The amines were obtained as hydrochloride salts and IC50 values were obtained. All 
were reasonably toxic, the most toxic having IC50 values in the p  molar region. Five 
cobalt complexes, such as D, were isolated and tested for oxic/hypoxic selectivity, two 
of which had been synthesised before. Of these, two showed promising selectivity, 
exhibiting greater toxicity under hypoxic conditions than under oxic conditions, 
although further testing is required.
appropriate range so that bioreduction to the Co(II) species is likely to occur. This
♦
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Chapter 1
Introduction
1.1 Cancer
A cancer represents a population of cells within the body which escapes 
from normal control mechanisms and continues to increase until, unless treated, it leads 
to the death of the host. Once an individual cell, or group of cells, escapes from these 
normal constraints the resulting uncontrolled replication leads to the formation of a 
tumour mass. As this increases in size and age, the cells tend to resemble the parent tissue 
less and less. They become undifferentiated and lose the specific characteristics which 
initially distinguished them. The growth will invade and destroy surrounding normal 
tissues and clumps of cancer cells may break off into the lymphatic vessels or the veins 
and be carried to distant sites, forming secondary growths or metastases (It is these two 
properties - invasion of adjacent structures, resulting in tissue damage, and the ability to 
produce metastases - that distinguishes cancers from benign growths). Eventually, if left 
untreated, involvement of vital organs or general debility will lead to death.1
The tumour may be controlled by surgical removal, by killing the growing cells 
with ionising radiation or by chemical means. Surgery and radiotherapy are only 
successful if the lesion is still localised so that it may either be completely excised or 
covered by a field of radiation. These local methods of treatment have only limited value 
once the disease has disseminated, offering symptom control in certain circumstances, 
but having no potential for cure at this late stage. Chemical methods of treatment may be 
used for both local and metastastic lesions. Such drug treatment involves either endocrine 
therapy, altering the hormonal environment of certain tumours and thereby slowing their 
growth, or the administration of cytotoxic drugs. Cytotoxic drugs act against the tumour 
by interfering with cell division thereby slowing down or reversing the growth of the 
cancer.
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1.2 Cancer Chemotherapy2
Cancer chemotherapy made its initial tangible thrust in 1941 when Huggins and 
Hodges reported that the sex hormone oestrogen was useful in the treatment of prostatic 
cancer in men. Later, Farber and associates noticed that folic acid treatment of anaemic 
children with acute leukaemia led to a worsened leukaemia condition. This suggested the 
use of antifolic acid compounds for the treatment of leukaemia.
Wartime research on chemical warfare agents led to the discovery of the nitrogen 
mustards, although it had first been noted in the First World War that mustard gas 
produced a profound fall in white cell counts with damage to marrow and lymphatic 
tissue. In 1946, the first studies of cytotoxic therapy for the treatment of leukaemias and 
lymphomas were reported as the underlying pathological process of these cancers is 
excessive white cell formation by either the bone marrow or the lymphatic system. The 
agent used was nitrogen mustard as this is less irritant to normal tissue compared to 
mustard gas. The initial results were encouraging and can be seen as the first steps on the 
path of the development of cytotoxic chemotherapy.3
Throughout the last 40 years, the search for effective small-molecule anticancer 
agents has been one of the significant goals of medicinal chemistry. Somewhat less than 
40 agents are in clinical use today and can be classified as follows.
a) Alkylating agents - The alkylating agents used in cancer therapy form covalent bonds 
with a number of biologically active molecules including nucleic acids, proteins, amino 
acids and nucleotides and have the potential to damage cell membranes, deplete amino 
acid stores and inactivate enzymes. Although alkylation of these enzymes will eventually 
inhibit mitosis, it is generally considered that the formation of cross-linkages between 
DNA chains is the more important action. Alkylating agents are chemically diverse drugs 
which have the common property that they may undergo transformation to produce 
reactive intermediates which are electron deficient.
2
The family of nitrogen mustards contains several drugs which are in common 
clinical use, such as chlorambucil (1), melphalan (2) and cyclophosphamide (3).
P—
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Each of these are bifunctional with two chloroethyl groups which form the reactive 
electron-deficient groups responsible for alkylation of DNA.
The most common site of alkylation of DNA is the N-7 position on the base 
guanine. The reactions leading to alkylation of guanine (5) are illustrated in Scheme 1 for 
nitrogen mustard (4). First, formation of the highly reactive positively charged aziridine 
ring occurs. This intermediate may then bind covalently with the electronegative N-7 
group on a guanine base, resulting in alkylation (6). This may lead to mispairing with 
thymine or to strand breakage. The second chloroethyl side chain may undergo a similar 
reaction leading to covalent binding with another base on the opposite strand of DNA, 
leading to formation of a cross-link.
Nitrogen mustard (4) is still used clinically (e.g. as part of the four-drug "MOPP" 
protocol for Hodgkins' disease), but its reactivity makes it unstable and liable to cause 
irritation at the injection site.
3
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Scheme 1
The nitrosoureas BCNU (7) and CCNU (8) are lipid-soluble drugs which have 
the potential for penetration into the central nervous system for treatment of intracranial 
tumours. These drugs are effective for treatment of experimental tumours in mice, but 
have only limited clinical application. They tend to cause prolonged myelosuppression, 
probably because of direct effects on bone marrow stem cells.
4
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Busulfan (9) is used for the treatment of chronic myelogenous leukaemia. The 
electron-deficient groups of bulsulfan are sulfonates and these can form covalent bonds to 
alkylate DNA and may form cross-links.
H3C — S O (CH2)4  O S CH
Thio-TEPA (triethylenethiophosphoramide) (10) is an example of the aziridine 
group of drugs and is now used primarily for local instillation in the bladder for treatment 
of patients with superficial bladder cancer.
n — p— n :
ZZ
(10)
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Antimetabolites - Antimetabolites are compounds that have a similar structure to 
essential metabolites which are required in the cell for synthesis of nucleic acids and 
proteins so that the cell can divide. The cell may then be duped into incorporating the 
mimic compound and as a result either the new nuclear material will be unable to fulfil its 
function or enzyme inhibition will prevent protein synthesis. One example is methotrexate 
which is a folic acid antagonist.
c") Natural Products - This heterogenous group of compounds includes doxorubicin, 
bleomycin, the vinca alkaloids (such as vincristine), epipodophyllotoxins, mitomycin C 
and anthracyclines. Doxorubicin appears to intercalate DNA which can lead to partial 
unwinding of the DNA helix, although the mechanisms of the underlying toxicity remain 
variable, complex and only partially understood; probably mainly by involving inhibition 
of topoisomerase 2. Bleomycin causes DNA strand breakage through a complex 
sequence of reactions that involves the binding of a bleomycin-ferrous iron complex to 
DNA. The vinca alkaloids principle mode of action is to bind to tubulin, an intracellular 
protein. This prevents microtubule formation and hence halts mitosis. Microtubules are 
involved in a number of functions, including mitosis, transport of solutes, cell movement 
and maintaining the structural integrity of the cell. Mitomycin C is derived from a 
Streptomyces species and requires activation to an alkylating metabolite by reductive 
metabolism. This compound is discussed further in Chapter Two. The group of 
anthracyclines act as antimitotic antibiotics. Antibiotics are beneficial in the treatment of 
infections because they inhibit the multiplication of bacteria. In the 1950s, it became 
apparent that some of the compounds had a similar inhibitory effect on dividing tumour 
cells.
e) Miscellaneous Compounds - These include non-classical alkylating agents, such as 
cisplatin, and enzyme therapy.
Most of the major developments in cancer therapy over the last 25 years have 
been in the field of drug treatment. The advances have frequently been dramatic and 
impressive, with cure now possible in a number of previously fatal conditions, such as 
acute leukaemia, advanced lymphoma, a number of childhood malignancies, metastatic
6
testicular cancer and choriocarcinoma. Unfortunately, however, cancers curable with 
chemotherapy form only a small proportion, less than 10%, of all malignant tumours and 
it is the older modalities of surgery and radiotherapy which still account for the great 
majority of cancer cures today. This is especially true in the solid tumours, the 
carcinomas and the sarcomas, which account for over 90% of cancers. In these instances, 
with the possible exception of early breast cancer and a few uncommon conditions, 
chemotherapy has yet to make any significant impact on cure rates or survival times.
1.3 Drug Selectivity
Selectivity of existing anticancer agents is still most unsatisfactory. Almost all 
agents in clinical use owe their limited use to a selective toxicity towards proliferating 
cells, and, as a consequence, are toxic to normal tissues with high rates of cell turnover.
Achieving selectivity for tumour cells, along with the development of drug 
resistance, has always been the limiting factor in the development of cytotoxic substances 
as anticancer drugs. Recent research in tumour biology has shown that solid tumours are 
structurally very complex. Cells in solid tumours exist in a number of distinct 
microenvironments, which can be defined largely by the accessibility of the cells to 
oxygen. In most solid tumours, this is dictated by the limitation of tumour vascular 
networks, which, although stimulated to develop by angiogenesis factors secreted by 
tumour cells,4 remain growth-limiting on the tumour.5 This microenvironmental 
heterogeneity provides a level at which to seek tumour selectivity. Unique and potentially 
exploitable microenvironmental factors which cells in solid tumours experience include 
poor venous drainage, low intracellular pH due to increased glycolysis, a primitive 
vasculature and chronic hypoxia.6*7
7
1.4 Tumour Hypoxia
For a solid tumour to reach a diameter greater than a few millimetres, it must 
develop its own vascular network.4 This vasculature is not efficient and results in many 
cells existing in a state of chronic (irreversible) hypoxia because of their relatively long 
distance from the nearest blood vessel. Another type of hypoxia, acute hypoxia, caused 
by the spasmodic closing off of a blood vessel due to compression by the growing 
tumour, has also been demonstrated in animal tumours.8 The two forms of hypoxia are 
shown schematically in Figure 1 9
Anoxic necrotic 
Chronically hypoxic Cfity
viable coll Permanently closed 
capillary
Temporarily open 
capillary
Acutely
hypoxic viable \ #  
cell
Figure 1
Hypoxic cells have been demonstrated to exist in human solid tumours4*10 and have been 
shown to be resistant to radiation treatment and chemotherapy.11 Despite these 
difficulties, the hypoxic microenvironment is an attractive target since nearly all normal 
tissue is well perfused, and drugs which could be activated only in hypoxic regions offer 
the possibility of being truly selective for solid tumours.12
To gain selectivity in this way, it is necessary to design a prodrug which is 
inactive in its own right, but can undergo metabolic reduction in hypoxic cells to release a 
toxic species which can then damage biomolecules in situ. These prodrugs are termed
8
hypoxia-selective cytotoxins and because they are activated by reductive 
biotransformations, they are commonly referred to as bioreductive drugs. They would in 
fact be more correctly termed bioreducible drugs.
1.5 Reductase Enzymes
A second dimension of selectivity can be introduced as it is known that a number 
of reductase enzymes are hyperexpressed in some solid tumours. This approach has been 
termed 'Enzyme-directed Bioreductive Drug Development'.13 The enzymes concerned 
are able to catalyse reduction of bioreducible agents. Some examples include cytochrome 
P-450, cytochrome P-450 reductase, xanthine oxidase, aldehyde oxidase and DT- 
diaphorase. Since different enzymes participate to different extents with various 
bioreducible agents, and even catalyse activation in one case and protection in another, it 
follows that if an enzyme profile is known for an individual tumour, then a 
complementary drug can be chosen for treatment. The enzyme specificity data could also 
be used to modify the structure of a bioreducible agent to suit the catalytic preference of a 
particular activating reductase which might be hyperexpressed in a particular tumour. 
Conversely, it should be possible to design out activity with respect to an activating 
enzyme that predominates in normal tissue.
1.6 Bioreducible Agents
Bioreducible agents are thought to act in vivo and in vitro through their initial 
activation upon enzymatic one electron reduction to produce metabolites, which are 
considerably more cytotoxic than the parent compound. Such bioreduction is critically 
dependent upon such factors as oxygen tension, the redox potential of the agent and 
temperature, the latter reflecting the rate of enzymatic steps. Oxygen acts by protecting 
against formation of reduced metabolites of the agents through 'futile cycling', a process 
which generates superoxide at the expense of the one electron reduced intermediate of the
9
bioreducible agent. Therefore their preferential cytotoxicity towards hypoxic cells is as a 
consequence of the protective role of oxygen under aerobic conditions. Agents which 
exhibit such bioreducible properties may have potential application as chemotherapeutic 
agents of hypoxic cells commonly found in tumours. There are currently four functional 
groups which are under investigation for use as bioreducible agents, all of which are 
known to be reduced metabolically via pathways which can be inhibited by oxygen. The 
reduction potential of the prodrug must lie within the range required for cellular 
reductants i.e. between -200 and -400 mV vs normal hydrogen electrode.
a) Nitro to amine.
r - n o 2  ► r - n h 2
b) Quinone to hydroquinone.
OH
OH
c) A-Oxide to tertiary amine.
R3N+-0 - ---------- ► R3N
d) Transition metal complexes.
M(m)L6 ---------- ► MdI)(H20 ) 6 + 6 L
1.7 Aims of This Project
Achieving selectivity between cancer cells and normal cells is of fundamental 
interest. The area of bioreducible drugs is still a relatively new area of cancer research and 
this field is reviewed in Chapter 2. The potential to develop new hypoxia selective 
cytotoxins which could act as bioreducible drugs is considerable. Accordingly, this 
research project was directed primarily to the synthesis of novel heterocyclic prodrugs
10
containing Af-oxides which might be activated under hypoxic conditions to release toxic 
species. These compounds can be divided into 3 groups.
i) Mono A-oxides cis- (11) and trans- (12) 2,6-disubstituted A-methylpiperidine-Af- 
oxides in which X is a leaving group such as a halogen or a carbamate. It was hoped that 
the non-toxic A-oxide would be reduced in the tumour cell to form a toxic alkylating 
species.
(11) (12)
Both the cis- and trans-isomers were to be synthesised as the difference in spatial 
arrangements may be important in cross-linking of DNA. The rationale for choosing 
these compounds and the work related is described in Chapters 3 and 4.
ii) Incorporation of another /V-oxide to produce a bis-N-oxide can be achieved by making 
piperazine derivatives (13) and this work is discussed in Chapter 5.
N+ + N‘
(13)
iii) By joining together two piperidine rings with a carbon chain of varying length (14), a 
series of derivatives containing bis-A-oxides can be obtained and their biological activity 
compared. Their synthesis is described in Chapter 6.
11
n = 1, 2 or 3
(14)
The possibility of using metal complexes as bioreducible drugs has recently been 
dem onstrated.14 A number of diamines with alkylating functionality have been 
synthesised and complexed to cobalt(III) such as compound (15).
Co
(15)
Synthesis of cobalt complexes containing nitrogen mustards is discussed in Chapter 7.
Detailed study of the activation of these prodrugs by reductase enzymes and 
cytotoxicity tests of the potential toxic species are presented in Chapter 8.
12
Chapter 2
Bioreducible Drugs
2.1 Hypoxia and Resistance
Hypoxic cells are those existing at an oxygen concentration which is suboptimal 
for cell growth and metabolism, but sufficient to maintain viability. Cells that are severely 
hypoxic at the time of irradiation are about three times more resistant to ionising radiation 
than aerobic ones. Hypoxia protects against radiation because molecular oxygen is a 
potent radiosensitiser. When cells are irradiated with X-rays or y-rays, only a small 
fraction of the lethal damage results from direct interactions between radiation photons 
and DNA. Instead, most damage is produced indirectly. Absorption and scattering of the 
photons by atoms results in the ejection of high energy electrons. As these fast moving 
electrons travel through the cell, they interact with nearby atoms, producing a track of ion 
pairs. These short lived ions react with each other and nearby molecules to produce a 
wide variety of free radicals and reactive species. Chemical reactions between these 
species and critical biological molecules (such as DNA) produce biologically important 
damage that can kill, injure or mutate the cell. When oxygen molecules are present at the 
time of irradiation, these extremely electron-affinic molecules participate in the chemical 
reactions that lead to the production of biologically significant damage, causing an 
increase in the number and severity of the lesions over those produced in the absence of 
oxygen.
In addition to exhibiting resistance to radiation, hypoxic cells can be more 
resistant to various chemotherapeutic agents, since hypoxic cells may be blocked or 
slowly moving through the cell cycle, and can also be too distant from the nearest blood 
vessel to allow sufficient concentrations of the drug to reach the cells.
To overcome this problem of tumour hypoxia, fractionated treatment is used in 
clinical radiotherapy, where the tumour is re-oxygenated between treatments. A number
13
of ways to improve delivery of oxygen to tumours have been explored15 but most interest 
has been in the development of chemicals which can take the place of oxygen in 
radiosensitising hypoxic cells. These have been termed electron-affinic radiosensitisers. 
These electron affinic compounds take the place of oxygen by transferring an electron to 
the initially formed DNA radicals, but are not so actively metabolised, so that they can 
reach the hypoxic interior of solid tumours.
2.2 Nitroimidazole Radiosensitisers
Following on from early work with the 5-nitroimidazole metronidazole, the first 
radiosensitiser to show some clinical activity was the 2-nitroimidazole derivative, 
misonidazole (16).16 However, this compound had limited potency and efficacy, and the 
high concentrations required caused neurotoxicity. This led to developing analogues 
which focused on improving the pharmacokinetics of misonidazole (16),17 to improve 
cell uptake (and thus potency) while lowering the relative uptake into the brain. Two 
analogues currently in clinical trials are etanidazole and pimonidazole. Etanidazole (17) 
has the advantage of relative exclusion from nervous tissues,18 and doses three times that 
of misonidazole can be given to patients before neurotoxicity is observed. Pimonidazole 
(18) is a more potent agent, and accumulates in tissue by virtue of the basic piperidine 
function.19’20 It was predicted that its basicity would enhance its excretion in acid urine, 
leading to a shorter elimination half-life and reduced normal tissue exposure.21 It was 
further hoped that its basicity might lead to concentration in areas of low pH such as are 
commonly thought to occur in tumours. This, together with its higher electron affinity, 
would be expected to confer greater potency than misonidazole.
14
CH
OH
OH
NONO
(17)(16)
OH
NO
(18)
One strategy for improving the radiosensitisation of the 2-nitroimidazoles was to 
attach to the molecule an alkylating agent which would bind the drug covalently to DNA. 
The most well studied compound is the aziridine analogue, RSU-1069 (19),22 which 
does show greater radiosensitisation. Unfortunately, clinical trials showed dose-limiting 
gastrointestinal toxicity,23 but the derivative RB 6145 (20)24 which is a prodrug of RSU 
1069 and contains a masked aziridine moiety is less toxic and is now in preclinical 
development.
Br
OH OH
NO NO
(19) (20)
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2.3 Bioreducible Cytotoxins
During the development of nitroimidazoles it was recognised that these agents 
express the ability to kill radiobiologically hypoxic cells to a greater extent than oxic 
cells.25 This hypoxia-selective cytotoxicity is now recognised as offering an alternative 
strategy for eliminating hypoxic cells. Indeed, it may be preferable to kill hypoxic cells 
with a cytotoxin rather than sensitising them to radiation, so optimisation of hypoxia- 
selective cytotoxicity is a key objective in the design of drugs to overcome the oxygen 
problem in radiotherapy. Reasons which support this view include:
a) Hypoxia selective cytotoxins (HSCs) can turn hypoxia to their advantage if a high 
proportion of tumour cells spend some of their time in a hypoxic state and can thus be 
eliminated by frequent treatment with a HSC.26
b) Bioactivation of the HSC in hypoxic tumour microenvironments may produce an 
active species which can diffuse locally to attack surrounding oxic cells.
d) HSCs have potential application in chemotherapy as well as radiotherapy if hypoxic 
cells are commonly resistant to available chemotherapeutic agents.
Two broad mechanisms for selective toxicity against hypoxic cells can be 
distinguished. The first is the exploitation of hypoxic cell biochemistry, such as with 
glucose analogues which are selectively toxic because of the dependence of hypoxic cells 
on high rates of anaerobic glycolysis.27 The second involves the use of prodrugs which 
are activated under hypoxia or by high levels of reductase enzymes found in tumour 
cells.28 HSCs of this class are widely referred to as bioreducible drugs since the 
biotransformation by which they are activated is a reductive one. The original idea29 
suggested that hypoxia in tumours might generate a reducing environment conducive to 
such reactions. Existing bioreducible agents make use of oxygen-sensitive 
biotransformation of four different types of functionality : nitro, quinone, N-oxide and 
transition metal complexes. These will now be discussed separately in the following 
sections.
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2.4 Nitroaromatics and Nitroheterocyclics
Many nitroaromatics are selectively toxic under hypoxic conditions because the 
first reduction of the nitro group (Scheme 2) to more toxic products is inhibited by 
oxygen, resulting in preferential metabolism in hypoxic cells.30
D 1 e — 1 e 1 e . 1 e 2 e
R-N 02 » R-N02  ►R-NO — R-NOH ~ R - N H O H — ►R-NH2
- /  'o2 o2
Scheme 2
The 2-nitroimidazole misonidazole (16) shows a hypoxic selectivity of ca 20-fold 
but has low cytotoxic potency (millimolar).31 In comparison, RSU-1069 (19) not only 
has much higher cytotoxicity, but also shows enhanced selectivity for hypoxic cells {ca 
50-100-fold).16 While the predominant mechanism of cytotoxicity of this compound 
under aerobic conditions is DNA monoalkylation by the aziridine, reductive metabolism 
converts it into a much more toxic bifunctional alkylating agent capable of cross-linking 
DNA.32 It has been demonstrated that the major sites for adduct formation upon the 
deoxyribosenucleotides are the phosphate groups and purine bases. These interactions are 
in competition with the slow hydrolysis of RSU-1069 to yield the corresponding 
aziridine ring-opened hydroxylated product which is inert to interactions with DNA.
CB 1954 (21)33 is an agent which shows dramatic antitumour selectivity towards 
the rat Walker 256 tumour. The basis of the sensitivity is that CB 1954 forms DNA 
interstrand crosslinks in Walker cells but not in insensitive cells. Crosslink formation is 
due to the aerobic reduction of CB 1954 by the enzyme DT-diaphorase. The 4- 
hydroxylamine cannot crosslink DNA directly but requires further activation by a non- 
enzymatic reaction with a thioester (such as acetyl coenzyme A). The bioactivation of CB 
1954 is shown in Scheme 3. The initial step is the reduction of CB 1954 by the enzyme 
DT-diaphorase to form the hydroxylamine product which can then react with thioesters to
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produce DNA reactive species. It is postulated that this is the N-acetoxy derivative (22). 
The major product of this reaction is however, the reduced amino compound that does 
not react readily with DNA.
Y7
NHOHDT-diaphorase^
NAD(P)NAD(P)H
NONO
(21)
Thioester 
e.g. Acetyl CoA
DNA Adducts NH
CHDNA interstrand 
crosslinks
NONO
(22)
Scheme 3
The bioactivation of CB 1954 results in a vast increase in its cytotoxicity and the 
resulting dose modification can be up to 100,000-fold. Although this compound 
possesses the latent cytotoxicity required of a prodrug, this approach is thwarted by the 
intrinsic poor rate of reduction of CB 1954 by the human form of the enzyme DT- 
diaphorase.
In attempts to improve the intrinsic cytotoxicity of the 2-nitroimidazoles, while 
preserving their selectivity, they have been attached to various types of reversible DNA- 
binding carriers. In such a manner, the phenanthridinium analogue, NLP-1 (23) shows
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10-100-fold greater potency than misonidazole as a hypoxia-selective cytotoxin, even 
though the compound does not bind particularly well to DNA.34
(23)
A related approach involves the use of compounds which exhibit both hypoxia 
selectivity and DNA affinity in the same chromophore. The best known examples are 1- 
nitroacridines, such as nitracrine (24). This compound shows very potent HSC activity 
against tumour cells in culture,35 but is not active against hypoxic cells in solid tumours 
in vivo where it is suggested that it binds too tightly to DNA, resulting in slow 
extravascular diffusion.36
CH
CH
(24)
An alternative strategy for providing very cytotoxic species on reduction is the use 
of nitroaromatic compounds as prodrugs for the release of toxic moieties. In these 
compounds, a DNA-alkylating moiety is activated by cellular reduction of the nitro 
group. Since the stability and alkylating reactivity of aromatic nitrogen mustards is
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determined almost entirely by the electron density on the nitrogen,37 conversion of the 
powerfully electron-withdrawing nitro group into the electron-donating hydroxylamine or 
amino metabolites activates the mustard considerably.38 One of the earliest attempts used 
nitroreduction as the trigger for methide generation.39 o-Nitrobenzyl halides such as (25) 
showed moderate hypoxic selectivity in vitro, and were much more potent than 
nitroimidazoles of similar reduction potential.
NhNO NHNH
Br NuNu
-HBr
(25)
Mononitrophenyl mustards such as (26) have little hypoxic selectivity in cell 
culture, because the reduction potential {ca.-520 mV) is too low to allow appreciable 
reduction.40 However, some dinitrocarboxamide analogues such as SN 23862 (27) with 
higher reduction potentials {ca.-450 mV) have more recently been shown to be highly 
selective for hypoxic cells (70-80-fold) in cell culture 41
NO NO
CONH
(26) (27)
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The release of the much more toxic phosphoramide mustard (28) following 
reduction of a 3-nitroquinoline (29) has recently been cited.42 The increased basicity on 
reduction to the electron-donating hydroxylamine or amine is proposed as triggering 
intramolecular base-catalysed elimination of the phosphoramide (Scheme 4). Compound
(29) was shown to be 11 -fold more toxic to hypoxic than aerobic HT-29 human colon 
tumour cells.
Scheme 4
A similar idea proposes that nitrobenzyltetrakis(chloroethyl)phosphorodiamidates
(30) can be reduced to leave the corresponding aniline derivative which will then activate 
the alkylating moiety (Scheme 5) 43 Initial results have shown these compounds can be 
up to 90-fold selective towards hypoxic cells via alkylation of DNA.
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J  N(CH2CH2C1)2
(30)
CH
O— P —N(CH2CH2C1)2 
N(CH2CH2C1)2
Scheme 5
A series of novel bis(nitroimidazolyl)alkanecarboxamides such as (31) have 
recently been prepared by Denny and Wilson44 to act as bis-bioreducible agents possibly 
by generating DNA crosslinking agents when both nitro groups are reduced to reactive 
species. This compound (31) showed a high degree of toxicity with time under hypoxia 
which suggests that these compounds may be bis-bioreducible agents, with slow 
reduction at the redox centre of lower potential (5-nitroimidazole) generating a bis- 
reactive molecule under hypoxia.
NO
CH
(31)
22
The same authors have also shown that another bis-bioreducible agent can achieve 
very high levels of hypoxic selectivity (> 1000-fold). The aliphatic N-oxide derivative 
(32) of the DNA intercalating bioreductive agent nitracrine45 has been synthesised.46 
This compound is of particular interest since the formally neutral side chain might be 
expected to decrease DNA binding and, consequently, cytotoxicity. Full activation 
appears to require reduction of both the N-oxide (to increase physical DNA binding) and 
nitro groups (to generate reactive metabolites); both steps being inhibited by oxygen.
+N"
(32)
2-Nitroaryls of general structure (33) have been proposed as bioreducible drugs, 
capable of releasing cytotoxic aminoaniline mustards (34) on bioactivation 47 This 
concept allows separate optimisation of the substituent effects influencing nitro-group 
reduction and mustard reactivity by electronically decoupling the nitro group and the 
mustard.
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Scheme 6
In this design (Scheme 6), reduction of the nitro amide to the corresponding 
amine is followed by a spontaneous cyclisation to the tetrahedral intermediate. 
Breakdown of this results in formation of the lactam and release of the amine. The net 
conversion would expel an aromatic mustard bearing an amine substituent, which will be 
a much more reactive alkylating agent than the starting amide, due to an enhanced electron 
release.
2.5 Quinones
Reduction of variously substituted 1,4-benzoquinones represents a second major 
biotransformation which can be inhibited by molecular oxygen. Like the nitroaromatics,
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the quinones undergo 1-electron reduction, first to the semiquinone, and then another 1- 
electron reduction to the hydroquinone. The semiquinone radical is capable of being 
scavenged by oxygen in oxygenated normal tissues, resulting in a hypoxia-selective 
metabolism, although direct oxygen-irreversible two-electron reduction pathways (e.g. 
by the enzyme DT-diaphorase13) are also possible. The reduced quinones generally have 
low toxicity, so those in use usually contain potential alkylating functionality which is 
activated upon reduction.
The quinone-containing antitumour antibiotic, mitomycin C (MMC) (35) was in 
clinical use as an anticancer agent well before the development of synthetic quinones as 
bioreducible alkylating agents, and can be considered as the prototype for this class since 
reduction to the semiquinone or dihydroquinone activates its alkylating activity.48 The 
proposed mechanism for the activation of mitomycin C can be seen in Scheme 7 49
Following reduction to the mitomycin semiquinone radical anion (36), the C-l 
position of the aziridine ring is activated and this results in alkylation at the N-2 position 
of guanine in DNA (37). Subsequent loss of the carbamate group leads to the formation 
of an additional reactive centre at C-10 (38), which then alkylates at a second 
neighbouring guanine N-2 forming a bis-adduct (39).50 Both inter- and intra-strand links 
can be formed. Computer modelling shows that the bis-adduct fits snugly into the DNA 
minor grove with minimal distortion of the Watson-Crick double helix, possibly reducing 
the probability of damage recognition and repair. MMC is not as selectively toxic to 
hypoxic cells (ca . 2-5-fold) as the 2-nitroimidazoles and is markedly cell-line 
dependent.51 It has been shown to provide improved survival as a supplement to 
radiotherapy of head and neck tumours52, although it has not been established that its use 
in this context is a consequence of hypoxic cytotoxicity.
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DNA
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(38)(37)
DNADNA
-le
NHNH
(39)
Scheme 7
26
The limited hypoxic differential of MMC has stimulated a search for more 
selective analogues. Synthetic aziridinyl quinones, such as the indoloquinone E09 (40) 
synthesised by Oostveen and Speckamp53 has hypoxic selectivity much superior to MMC 
in vivo.
OH
OH
CH
(41)(40)
Reduction of E09 will activate the hydroxyl leaving groups and also the aziridine, 
giving a total of three reactive centres generated in the molecule as a result of bioreductive 
metabolism. The two aziridine moieties in diaziquone (41) are similarly activated on 
reduction, resulting in the formation of potentially lethal crosslinks,54 but is similar to 
MMC in that it has only modest selectivity for hypoxic cells.55
Another approach has been to investigate the role of C-10 in alkylation processes 
by preparing compounds in which the nucleophilicity at C-l is reduced substantially by 
substituting a cyclopropane ring for the aziridine ring 49 Such a compound (42), named a 
cyclopropamitosene, on reductive activation followed by elimination of the carbamate, 
could generate a powerful electrophile capable of alkylating DNA at C-10.
OCONH
(42)
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Under hypoxic conditions, the potency of the methoxy derivative is increased 34-fold. 
Both analogues acted as substrates for DT-diaphorase56 and are better substrates than 
MMC at physiological pH, although they are inferior to indolequinone E09 in this 
respect.
2.6 N -O xid es
Several //-oxides have been described as cytotoxic agents and some are believed 
to be intrinsically cytotoxic. These include the pyrrolizidine alkaloid N-oxides, as 
illustrated by indicine N-oxide (43).57 Indicine N-oxide underwent intensive preclinical 
evaluation and was the subject of three Phase II clinical trials until evidence of severe 
hepatotoxicity halted its progress. The mechanism of action was thought to involve 
metabolic allylic oxidation and dehydration into alkylating species but only after its 
reduction to the indicine free base.
/ P  ,
"L J
— < 
HO^
CHOH
|
c h 3
1
o (43)
In the course of studies of non-nitro hypoxic cell radiosensitisers, the 
benzotriazine di-N-oxide SR4233 (44) was found to have a cytotoxicity 20-200-fold 
greater under hypoxic than under aerobic conditions in culture.58 In vivo activity is 
excellent when it is combined with both single dose and fractionated radiotherapy, and 
the compound is now in clinical trials.
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(44)
SR 4233 undergoes a 1 e~ reduction to a free radical,59 which was difficult to 
detect because of its extreme instability. It causes double strand breaks to a much greater 
extent in hypoxic cells, but covalent binding to DNA and protein cannot be detected. The 
proposed mechanism requires the 1 e~ reduction product to act as an oxidising radical 
which abstracts hydrogen from bases in DNA.59 The two and four electron reduction 
products are inactive, suggesting that the hypoxic selectivity of SR 4233 is due to the 
removal of the oxidising radical by this route in oxygenated cells.60
Synthesis of novel N- and ^-mustards as potential prodrugs activated by 
bioreductive processes has been reported.61 The synthesis of chlorambucil N-oxide (45) 
and the S-oxide analogue plus other derivatives, and initial biological activity were 
reported. Results showed that although all the compounds were cytotoxic, none had 
greater activity under hypoxic conditions, although a nitro derivative (46) showed greater 
activity than chlorambucil.
NO
O—
(46)(45)
A variety of enzyme systems are known to catalyse the reduction of aliphatic 
amine N-oxides and to be inhibited by oxygen. Liver cytochrome P450 enzymes can
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reduce62 imipramine /V-oxide (47), while extensive reduction of Ro 31-0313 (48), the 
piperidinyl-N-oxide metabolite of pimonidazole, has been observed in mice 63
NO
N =
OH
(48)
(47)
While the reduction of aliphatic N-oxides is facile, there tends to be no toxic 
species generated as there is in the reduction of the other types. There is therefore a need 
to link reduction of the N-oxide to the enhancement of cytotoxic potency. This can be 
achieved through the use of a DNA intercalator as seen previously with nitracrine N- 
oxide and also with Af-oxides of DNA binding topoisomerase II inhibitors. As 
conventional bioreducible agents are either intrinsically toxic and/or require chronic 
hypoxia to maintain their cytotoxicity, the use of /V-oxides of DNA affinic agents as 
prodrugs that can be bioreduced to persistent, oxygen insensitive cytotoxic agents may 
avoid both these problems. This is illustrated with AQ4N (49), which can be reductively 
activated to a DNA affinic, potent cytotoxic agent AQ4 (50).64
30
OH OH
OH OH
(50)(49)
Results have shown that AQ4N has no intrinsic binding affinity to DNA and has 
low cytotoxicity. Under hypoxic conditions, AQ4N can be reduced in vitro to a DNA 
affinic agent with a 10-100-fold increase in cytotoxicity.
Another possibility is to use the N-oxide reduction to activate a nitrogen mustard. 
White et al.65 have shown that the N-oxide (51) of mechlorethamine is reduced 
selectively under hypoxic conditions to form the more reactive des-N-oxide nitrogen 
mustard.
, / \
(51)
Nitromin (51) is selectively toxic in Walker rat tumour cell cultures under hypoxic 
conditions, but with a modest selectivity of only about 4-fold. This aspect appears to 
have resurrected interest in nitromin and a one electron reduction intermediate, the 
nitrogen anion radical has been proposed to explain the DNA strand breakage observed 
in addition to DNA crosslinking in cells treated with nitromin.66
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Tamoxifen W-oxide (52) has been described but is no less toxic than tamoxifen.67 
This was taken to indicate, with other evidence, that the amine functionality of tamoxifen 
did not contribute to its anti-oestrogenicity or influence the intrinsic antitumour activity of 
this molecule.
CH
CH
(52)
2.7 Transition Metal Complexes
Although metals are important redox centres in biological systems, little work has 
been done to explore their possible application in the context of hypoxia-selective 
cytotoxins. Pt(II) complexes with nitroimidazoles are known to be selectively toxic to 
hypoxic cells,68 but the active redox centre is the nitroaromatic ligand rather than the 
metal itself. Various metals form substantially-inert co-ordination complexes with 
nitrogen ligands: for example Co(NH3)63+ has a displacement halflife69 of 6 x 109 s. One 
electron reduction to a Co(II) complex results in enormous labilisation of such ligands.70 
Hypoxia-selective metabolism is therefore possible, with ligand displacement by water to 
form the very stable hexa-aquo Co(II) cation competing (in oxygenated cells) with 
reoxygenation of the Co(II) complex by molecular oxygen (futile metabolism). Such 
compounds are capable of hypoxia-selective cytotoxicity provided that the free ligands are 
much more cytotoxic than when metal bound. Recent studies71 show this to be the case,
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since complexes of aziridine with Co(III) (53) are greatly stabilised with respect to 
hydrolysis. Such compounds are not hypoxia selective, probably because the reduced 
Co(II) forms are too labile, but related complexes using chelating alkylating agents as 
ligands (15) do show limited hypoxia-selective cytotoxicity in vitro.14
NO
Co
NO
Br­
e l ’
(53)
(15)
2.8 Enzymology of Bioreduction
A number of enzymes are able to catalyse reduction of bioreducible agents.72 The 
importance of understanding the enzymes involved in bioreduction is rapidly gaining 
widespread recognition13 and it is becoming clear that many different enzymes are 
involved in the production of toxic bioreduction products. Enzymes known to be 
involved in bioreductive metabolism include cytochrome P-450, cytochrome P-450 
reductase, xanthine oxidase, aldehyde oxidase, carbonyl reductase and DT-diaphorase, 
together with mitochondrial reductases and probably many others as well. In contrast to 
the other enzymes mentioned, DT-diaphorase is an obligate 2e" donating enzyme.73 Thus 
it reduces quinones directly to the hydroquinone, bypassing the semiquinone free radical. 
Cytochrome P-450 reductase is predominantly involved in the early stages of 
bioactivation of the benzotriazine, SR 4233, while cytochrome P-450 is involved in the 
later stages.54 Cytochrome P-450 reductase also plays a critical role in the activation of 
mitomycin C,28 whereas DT-diaphorase is much more important for E09.74
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The conventional approach to bioreducible drug development has involved 
screening for selective activity in hypoxic versus oxic cells in vitro. In general, hypoxic 
cell potency is predicted quite efficiently by one-electron redox potentials,75 and this was 
a dominant consideration in the synthesis of new agents along with lipophilicity and 
charge. However, these factors cannot routinely predict for bioreducible cytotoxicity, 
particularly in vivo. The growing appreciation of the key role of bioreductive enzymes 
has led to the concept of enzyme-directed bioreductive drug development.13 It is 
proposed that the antitumour selectivity of bioreducible agents can be enhanced by not 
only tumour hypoxia, but in addition by increased expression of key reductase enzymes 
in cancer cells. It may also be possible that further selectivity will be gained by tailor- 
making drugs to be activated specifically by particular reductases that are expressed at 
high levels in tumours. Initial results have shown that alterations of the chemical structure 
of mitomycin C and E09 produce startling results in the reductive metabolism by DT- 
diaphorase.76
Since different enzymes participate to different extents with the various 
bioreducible agents, and even catalyse activation in one case and protection in another, it 
follows that the activity of a given drug might be enhanced by administrating it to patients 
with a particular tumour enzyme profile. So a tumour rich in DT-diaphorase might be an 
excellent target for E09 but could be resistant to SR 4233 as this enzyme would miss out 
the toxic 1 electron reduction product. As DT-diaphorase has been reported to show a 
high level of expression in some human colon, breast, lung and liver tumours,76 these 
may be good targets for E09 therapy.
With further information of this type it seems possible that the bioreductive 
enzyme profile of human tumours could be used to guide the choice of bioreducible 
antitumour agent in individual patients.
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2.9 Conclusions
The first bioreducible drugs, represented by misonidazole and mitomycin C, 
respectively lacked the potency and selectivity to be effective in vivo. The second- 
generation agents, represented by SR 4233, RB 6145 and E09 have greater activity 
against hypoxic cells in mouse tumours and are now in clinical trials or preclinical 
development. Although these drugs may not be perfect, it is hoped that they will establish 
whether bioreducible drugs have a place in cancer chemotherapy today. This leaves 
exciting possibilities for rational design of new drugs capable of exploiting 
microenvironmental features in tumour cells.
It should be noted that bioreducible drugs may not necessarily exert significant 
activity as single agents. A 'clean' bioreducible drug would be expected to eradicate the 
hypoxic cells in the tumour but not the oxic cells. The general specificity of bioreducible 
agents for hypoxic cells means that in vivo testing should incorporate studies of the 
bioreducible agent in combination with treatments which will kill oxic cells. This might 
be radiation, conventional cytotoxics such as cyclophosphoramide, cisplatin and 
doxorubicin, or perhaps even endocrine therapy and targeted radiotherapy.
It is likely that interest in bioreductive drug development will continue to grow. 
This is due to a number of reasons.
a) The proposed basis of selectivity is well grounded in tumour biology, and can be 
readily modelled in tissue culture, unlike conventional anticancer agents, where there is 
little understanding of selectivity.
b) The mechanism of tumour selectivity (oxygen-inhibited bioactivation) is well 
understood in principle at the biochemical/chemical level and offers great scope to the 
medicinal chemist.
c) The conditions which make tumours sensitive to bioreducible agents (lack of oxygen 
and presence of activating enzymes) can be assessed so potential exists for developing 
assays which will help predict individual tumour sensitivity. Bioreducible agents are
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unusual among prodrugs in that activation occurs locally in the tumour, making this 
approach advantageous.
d) If designed appropriately, bioreducible agents might provide diffusible cytotoxic 
products. As such, they have the potential to target local systems with delocalised effects, 
which will then overcome the fundamental problem of tumour heterogeniety.
Of all the areas of anticancer drug development, the field of bioreducible drugs 
offers the most potential for rational design. Although dependent on reductase enzymes 
for activation, the target is primarily a physical condition (lack of oxygen). Strategies to 
maximise the extravascular diffusion, selectivity of activation and toxicity of the reduced 
produgs depend primarily on a knowledge of chemistry, and this class of compounds 
should be an attractive goal for the medicinal chemist.
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C hap ter 3
The Synthesis of ci\*«2,6-Disubstituted P ip erid in es
3.1 Introduction
An obscure publication in Japanese reported significant antitumour activity for
2,6-bis(halomethyl)piperidines and related compounds (stereochemistry unspecified).77
Stereochemistry
unspecified
X= I, Br, Cl.
It seemed feasible that these toxic compounds could be incorporated into a 
prodrug which could release the toxic compounds after bioactivation. An N-oxide of an 
7V-alkylated piperidine might be less toxic if the mode of action of these compounds is by 
aziridine formation followed by attack by nucleophilic biological molecules such as DNA. 
This N-oxide would then act as a prodrug if it was reduced in hypoxic 
microenvironments such as solid tumours, to produce a toxic intermediate, in this case a 
bifunctional alkylating agent via aziridine formation. To this end, A-methyl-A-oxides of
2,6-disubstituted piperidines with cis- (11) and trans- (12) stereochemistry with X= 
halogen or carbamate (novel compounds) have been prepared in this work for evaluation 
as bioreducible drugs.
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(11) (12)
3.2 Piperidine Alkaloids
One of the reasons for the interest in the synthesis and stereochemistry of 
piperidine derivatives is their wide occurrence in natural products. Some of these 
alkaloids have toxic properties and the possibility of making analogues which may be 
pharmacologically active is another reason for interest.
Six-membered rings containing nitrogen are common among alkaloids although 
biosynthetic studies have shown that they are formed by a number of different 
pathways.78 In many of these alkaloids, (e.g. lobelia and lupin alkaloids), the amino-acid 
lysine serves as the precursor of the piperidine ring. In others, (e.g. hemlock group) the 
nitrogen appears to have been inserted into a straight carbon chain derived from acetate 
units. The toxic properties of the poison hemlock have been known since antiquity, and 
extracts were used in ancient Greece for the execution of criminals. One of the earliest 
contributors to hemlock literature was Plato, who described the death of Socrates from 
hemlock poisoning. Five alkaloids have been isolated from hemlock, of which the major 
one is coniine (54). This compound has neuromuscular blocking effects.
(54)
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An excellent review on the chemistry and pharmacology of the piperidine 
alkaloids appears in 'Alkaloids', edited by Pelletier.79
The Taiwanese creeping shrub Piper arborescens has been found to contain three 
cytotoxic pyridone alkaloids of the general structure (55).80
A minor subgroup of the piperidine alkaloids contains the 2-alkyl-6-methyl- 
piperidine skeleton.81 Some representatives are 2,6-dimethylpiperidine (56), the pine 
alkaloid pinidine (57),82 alkaloids of the fire-ant venom (58)83 and hydroxylated 
alkaloids such as prosopine (59).84 The venoms of the fire ants of the species Sobnopsis 
xyloni, S. geminata, S. richteri and S. invicta were found to contain a series of alkaloids, 
most of which are fra«5-2-methyl-6-alkylpiperidines with small amounts of the cis- 
isomer.85 These are used to block neuromuscular transmission86 and are also employed 
as antibacterial agents.87
O
R1 (55)
Me R
H Me £  (CH2)nMe hi
R = Me (56)
R = CH2CH=CH2 (57)
n=10 ,  12, 14 HO 
(58)
N ^ (C H 2)10CHOHMeHOHoC
(59)
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Norlobelandinine has been isolated from Lobelia polyphylla,88 Lobelanidine (60) 
reacts with iodine to give lobeline (61) and lobelanine (62).89 The action of the latter two 
alkaloids, along with 1,2,6-trimethylpiperidine (63) and 2,6-diphenylethylpiperidine (64) 
on respiration and blood pressure has been examined.90 The alkaloids affect both these 
properties while the other two piperidines have no effect on respiration but cause a 
decrease in blood pressure.
c h 2r
R = R1 = CHOHPh (60) 
R = CHOHPh
R1 = COPh
(61)
R = R' = COPh (62)
R =R* = Me (63) 
R = H,
R1 = CH2CH2Ph 
(64)
3.3 Methods of Synthesising cis-2,6-Disubstituted Piperidines
The most common way of achieving the cis-stereochemistry in cis-2,6- 
disubstituted piperidines is by catalytic hydrogenation of pyridine rings.91 One such 
example is the synthesis of 1 -methyl-cw-2,6-bis(chlorornethyl)piperidine (66)92 which 
was used as an intermediate towards the synthesis of bicyclic systems such as 3,9- 
oxazabicyclo[3.3.1]nonane (67). The synthesis started with the catalytic hydrogenation 
of 2,6-lutidine (65).
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Me- Me
Me
(66)(65) (67)
A general approach to cis-2,6-dialkyl piperidines has been obtained via 
intramolecular acyl nitroso Diels-Alder cycloadditions.93 This reaction is highly regio- 
and stereo-selective and could have great potential for alkaloid synthesis. Key features 
involved in this approach are an intramolecular Diels-Alder cycloaddition of the acyl 
nitroso compound (68) and a stereoselective introduction of an alkyl side chain (R') into 
the C-8 position of the oxazinolactam ring (69) followed by reductive cleavage of the N- 
O bond (Scheme 8).
(68)
OH
(69)Scheme 8
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An enantioselective route to ds-2,6-bis(hydroxymethyl)piperidine in a seven step 
synthesis has been published.94 This involved an asymmetric cleavage of the 'fork-head' 
ketone of 9-azabicyclo[3.3.1]nonan-3-one (70) to give a cw-2,6-disubstituted piperidine 
derivative (71) in 93% ee (Scheme 9). The obtainable diol may be an important chiral 
building block for the synthesis of many naturally occurring piperidine alkaloids.
TMSQ
2. NaBH,
3. CH9N^
OH C 0 2Me 
(71)(70)
Scheme 9
The first enzymatic asymmetrisation of a piperidine system was published by 
Chenevert and Dickman.95 Hydrolysis of A- be nzy l oxyca r bony l - c i s -2 , 6-  
bis(acetoxymethyl)piperidine (72) in the presence of Aspergillus niger lipase gave the 
corresponding (2R, 6S )-mono-acetate (73) in good chemical yield and very high optical 
purity (ee > 98%).
(73)(72)
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3.4 Synthesis of N -M ethyl-cis-2,6-(hydroxym ethyl)p iperid ine
This compound (74) was considered a key intermediate in the formation of the 
target compounds (11) and (12).
Me Me OHOH
(74)X = OCONHR 
Cl, Br
A number of methods have been reported in the literature in which the common 
starting material is dipicolinic acid. The first attempt to synthesise the hydroxyl 
compound can be seen in Scheme 10.
h o 2c ^  n
(75)
1. Pt02, H2
CH3C02H
C 0 2H 2. c. HC1 H 0 2Cx N " C 0 2H
H 2
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h c o 2h
h 2c o
NaHC03
BH3-THF
N - ^ ////%  h o 2c xxXXX 7/////c o 2h
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(74)
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Scheme 10
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Anderson and Soine96 reported the synthesis of cw-2,6-piperidinedicarboxylic 
acid hydrochloride (76) by hydrogenation of dipicolinic acid (75) in acetic acid using 
Adams' catalyst, followed by acidification. This method was repeated by us to give the 
ds-product in 90% yield. A-Methylation was carried out by heating at reflux a mixture of 
the ds-piperidine, formic acid, formaldehyde and sodium bicarbonate. The first step in 
the reaction is the conversion of the hydrochloride salt into the free base using sodium 
bicarbonate. The nitrogen lone pair can then attack the formaldehyde and this is followed 
by dehydration to give the immonium ion. Formic acid acts as a hydrogen donor and 
reduces the immonium group to give the required A-methyl derivative (77). The next step 
involved reduction of the acid groups by diborane to give the desired diol (74). However, 
this reduction did not occur due to the extreme insolubility of the starting diacid in THF. 
Attempts to solubilise it by making the diester were then tried. The diacid (77) was 
dissolved in methanol and HC1 gas was bubbled through for 30 minutes, but no reaction 
took place, as was the case when thionyl chloride and methanol were tried, probably due 
to the same reason. Esterification using 2,2-dimethoxypropane and conc. HC1 did appear 
to work over the course of a few days, but significant isomerisation to the trans-product 
had also occurred. It was therefore decided to esterify at an earlier stage in the synthesis, 
as reported by Barnes and Fales.97 To this end, dipicolinic acid (75) was heated at reflux 
in thionyl chloride for 48 hours before the acid chloride was reacted with ethanol in 
quantitative yield to produce the diester (78) (Scheme 11). In the IR spectrum, a carbonyl 
stretching band at 1745 cm*1 and aromatic vibrations at 1576, 1532 and 1481 cm*1 were 
evident. The *H NMR peaks were as expected for the compound with the usual 
substitution pattern for the pyridine as a doublet of doublets at 5 8.07 and a doublet at 8  
8.30. The main peak in the mass spectrum was for m/z 150 due to loss of one ester 
group, and a small molecular ion was observed.
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1. Pt02 H2
2. Pd-C, H2CO, H2
MeOH Me OH
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Scheme 11
The next step was to hydrogenate the diester (78) and N-methylate the product as 
before. We chose to follow the method of Feldkamp et a / . 98 where 2-, 3-, and 4- 
(hydroxymethyl)piperidines were synthesised in a programme to find new antispasmodic 
agents. In their procedure, hydrogenation of the pyridine ring was carried out in aqueous 
acetic acid with Adams' catalyst. Isolation of this unmethylated piperidine derivative 
proved unnecessary because A-methylation could proceed in the same solution by using a 
reductive methylation procedure. This meant exchanging the platinum catalyst for 
palladium-on-charcoal and adding a slight excess of aqueous formaldehyde. This solution 
was then hydrogenated to afford the methylated product. This latter step was 
advantageous as the authors had reported difficulties in their attempts to methylate using 
formic acid and formaldehyde. Thus we isolated diethyl N-methyl-c/.s-2,6 -piperidine 
dicarboxylate (79) in a yield of 50% as white crystals. In the IR spectrum the 
characteristic carbonyl stretch was found at 1730 cm' 1 whilst new bands had appeared at 
2861 c m 1 indicating CH stretch and 1376 c m 1 corresponding to CH3 symmetrical
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deformation. The multiplet in the JH NMR spectrum at 8  1.52 - 1.68 was due to the ring 
CH2 protons. The equivalent protons at C-2 and C- 6  appeared as a doublet of doublets at 
8  2.69. In the 13C NMR spectrum, the two methylene signals at 8  22.7 and 8  29.1 were 
in a ratio of 1 : 2, and correspond respectively to C-4 and C-3 plus C-5. The methine 
signal came at 8  67.9 while the A-methyl was at 8  41.8. One quaternary signal was seen 
at 8  172.5 which was attributed to both carbonyl carbons. In the mass spectrum, the 
parent ion was observed at m/z 243, whilst the largest ion was at m/z 170 due to loss of 
an ester group.
This diester (79) could now be readily reduced in THF with lithium aluminium 
hydride to the diol (74). The reduction of the unmethylated cis- piperidine with UAIH4 to 
the diol has been reported in the literature" without any isomerisation to the trans- 
isomer. This reduction was successfully carried out in a yield of 97% to afford A-methyl- 
cis-2,6-bis(hydroxymethyl)piperidine (74) as a clear oil. A broad band at 3374 cm ' 1 
indicated OH stretch and the carbonyl band had disappeared in the IR spectrum. The 
NMR spectrum of the diol (74) can be seen in Figure 2. The A-methyl peak had shifted 
slightly to 8  2.21, as had the methine protons, to a new position of 8  2.26. The two 
diastereotopic CH2 protons next to the OH appeared as two doublet of doublets at 8  3.39 
and 8  3.70 due to strong vicinal coupling and weak geminal coupling. The 13C NMR 
spectrum showed similar shifts for the A-methyl peak, now at 8  34.9, while the 
equivalent carbons at C-2 and C- 6  were located at 8  64.1. The new methylene signal at 8
63.5 belonged to the carbons next to the hydroxyl groups.
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3.5 Synthesis of y V -M e th y l-c is -2 ,6 -b is (a m in o c a r b o n y I o x y m e th y l) -  
piperidines
Now that we had prepared our key intermediate in a satisfactory overall yield of 
47%, we could concentrate on putting on appropriate leaving groups. We had decided on 
making carbamates because:
a) their reasonable stability allowed easy handling although they could be displaced in 
physiological conditions;
b) their ease of formation; and
c) carbamates are usually crystalline and therefore can be purified and characterised 
easily.
RNCO
^  Sn(Bu)2(OAc) 2
Me
OH Me
(74)
OH
NHR RHN
R = -'Pr (80) 
= -Et (81) 
= -Ph (82)
The bis-carbamates were made using an appropriate isocyanate, the diol and a 
catalytic amount of dibutyl tin diacetate. 100 This reaction goes quickly and cleanly at 
room temperature in dichloromethane to produce high yields of the corresponding bis- 
carbamate. The ethyl, isopropyl, phenyl and p-nitrophenyl bis-carbamates were 
synthesised. The mechanism of reaction is assumed to take place as in Scheme 12.
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Af-Methyl-c/s-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine (80) was 
prepared in good yield as white crystals. In the IR spectrum, the carbonyl absorption was 
at 1690 cm -1 and a band at 1370 cm' 1 was indicative of an isopropyl group. The ^  
NMR spectrum showed a doublet at 6  1.14 for the isopropyl methyl protons, while the 
CH was found at 8  3.81 as a multiplet. The A-methyl signal came at 8  2.33 as a singlet 
while the two protons at C-2 and C- 6  were a multiplet at 8  2.28. The methylene protons 
next to the carbamate had shifted downfield to a new position of 8  4.10 and appeared as a 
multiplet. In the 13C NMR spectrum two signals were observed for the isopropyl methyl 
groups at 8  23.0 and 8  23.5. This may be due the 7i-bonding between the nitrogen atom 
and the carbonyl carbon atom slowing the rotation about this bond, thus leaving two 
environments for the methyl groups. A similar effect is seen with dimethylformamide but 
with greater effect as the two methyl groups are joined directly to the nitrogen. The N- 
methyl signal and the methine signal of C-2 and C- 6  were similar to that found in the diol
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and were observed at 8  37.7 and 8  63.3 respectively. The methylene carbons next to the 
carbamate had shifted slightly from their position in the diol to 8  66.9 while the new 
carbonyl carbon signal was observed at 8  155.7. No molecular ion was present in the 
mass spectrum, the heaviest ion found was at m/z 314 which corresponded to loss of the 
N-methyl. The largest ion found was at m/z 213 which was due to the loss of two NH*Pr 
groups.
Preparation of the bis(ethyl carbamate) (81) was achieved in a similar manner, 
although this compound could not be crystallised as only an oily solid was obtained after 
a week in the freezer. The spectra of this compound were very similar to that of the 
isopropyl carbamate although this time a molecular ion was observed in the mass 
spectrum.
Af-Methyl-c/.y-2,6-bis(phenylaminocarbonyloxymethyl)piperidine (82) was 
obtained as white crystals after column chromatography. The IR spectrum showed a 
slight carbonyl shift to 1700 c m 1 and the characteristic aromatic bands at 1600 c n r1 and 
1525 cm-1. The monosubstitution pattern of the aromatic ring was obvious with strong 
bands at 750 cm*1 and 690 cm*1. In the NMR spectrum, the peaks were all shifted 
slightly downfield compared to the aliphatic carbamates. Thus the TV-methyl singlet came 
at 8  2.43 while the two protons at C-2 and C- 6  were observed as a multiplet at 8  2.55. 
The methylene protons adjacent to the two carbamate groups were found at the chemical 
shift of 8  4.26 as a multiplet. In the aromatic region, the para-protons were observed as a 
triplet at 8  7.07, but the ortho- and meta-protons overlapped with each other between 8  
7.27 and 7.37 to give a multiplet. The 13C NMR spectrum again showed similarities to 
the aliphatic carbamates with the N-methyl signal observed at 8  36.4. Signals at 8  118.6, 
123.3 and 128.9 are typical of a phenyl ring and correspond respectively to the ortho-, 
para- and meta-carbons. The two quaternary signals at 8  137.8 and 8  153.3 were 
attributed to the aromatic quaternary carbon and carbonyl carbon respectively. Again, no 
molecular ion was observed in the mass spectrum, but the usual fragmentation products 
at m/z 247, 213 and 110 did appear.
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Synthesis of the bis(nitrophenyl carbamate) (83) posed more of a problem. This 
was due to two main reasons, the first being the impurity of p-nitrophenyl isocyanate and 
the second due to the poor solubility of the product. Purification was obtained using a 
gravity alumina column, eluting with toluene : ether 2 :1  to leave bright yellow crystals, 
but the yield was poor (58%). The IR spectrum showed the carbonyl stretch to have 
shifted to 1725 c n r1. The aromatic bands appeared at 1600 cm-1 and 1505 cm*1 with a 
strong band at 850 cm*1 indicating para-disubstitution. The two strong bands at 1545 and 
1330 cm*1 are due to asymmetrical and symmetrical stretching of the NO bonds. The 
NMR spectrum, taken in d6 -acetone showed the N-methyl singlet at 8  2.35 with the 
protons at C-2 and C- 6  at 6  2.40. In the aromatic region, signals at 8  7.75 and 8  8.17 are 
typical of an AA'BB' system. In the 13C NMR spectrum, the N-methyl signal and the C- 
2 and C- 6  carbons appeared at 8  38.0 and 63.4 respectively while the methylene carbons 
next to each carbamate had shifted slightly downfield to 8  68.3. The aromatic methine 
signals came at 8  118.6 and 125.7, corresponding to the ortho- and meta-protons 
respectively. Three quaternary carbons were present, the CNH signal appearing at 8
143.2, the CNO2 signal at 8  146.4 and the carbonyl signal at 8  154.0. The parent ion did 
not survive in the mass spectrum, but the fragmentation pattern of the molecule was 
consistant with the structure.
3.6 Synthesis of A f-M ethyl-cis-2,6-bis(halom ethyl)piperidines
Compounds with halogen leaving groups were also synthetic targets due to the 
reported activity of the unmethylated disubstituted piperidine system.77 Halogens are also 
present in a number of conventional nitrogen mustards, whose pharmacology is well 
documented. 101
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MeOH Me
(74)
OH
X = C1 (66) 
= Br (84) 
= 1 (85)
N-M ethyl-ci$-2,6-bis(chloromethyl)piperidine (6 6 ) was synthesised by 
dissolving the diol (74) in dichloromethane and adding it dropwise at 0 °C to an excess of 
thionyl chloride. This reaction went in good yield and the product was isolated as the free 
base which is quite stable if kept at 0 °C (no noticeable change after 6  months). Although 
this compound has been made before,92 no characterisation had been reported. The IR 
spectrum showed the usual CH stretching peaks at 2939 cm*1 with the NCH2 bands at 
2860 and 2787 c m 1. A medium intensity band at 674 cm -1 was assigned to the C-Cl 
stretch. The *H NMR spectrum of (6 6 ) was very similar to that of the diol, with the N- 
methyl peak at 6  2.32 and the methylene protons next to the chlorines showing two 
doublet of doublets at 5 3.53 and 6  3.63. Again the 13C NMR spectrum showed the 
usual N-methyl at 8  37.0, and the C-2 and C- 6  methine carbons at 8  64.2 while a new 
signal at 8  47.3 was attributed to the methylenes adjacent to the chlorines. The largest 
fragment in the mass spectrum was obtained at m/z 160 which corresponded to loss of 
one chlorine atom.
The corresponding dibromo compound (84) was made from the diol (74) using 
phosphorus tribromide in a similar fashion to that described above. However, the yield 
was disappointing at only 23%, possibly due to quick formation of the amine salt, 
rendering the compound insoluble in the solution and thus unable to react, even with 
heating at reflux over long periods of time (72 hours). Again, the spectra were similar to 
that of the diol. The IR showed the C-Br band at 570 cm*1, while in the *H NMR
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spectrum, the methylene protons adjacent to the bromines appeared at 8  3.41 and 8  3.50 
as two doublet of doublets. The respective carbon signal was found at 8  36.5 in the 13C 
NMR spectrum. In the mass spectrum, the parent ion was observed at m/z 284, with the 
main fragment being loss of CH2Br.
Attempts to make the corresponding diiodo compound (85) from the dibromo 
compound (84) by Finkelsteins method102 were futile as the product, which appeared to 
form due to observation of the precipitation of sodium bromide, could not be isolated.
3.7 Synthesis of A -M e th y I -c is -2 ,6 -b is (a m in o c a r b o n y lo x y m e th y l) -  
piperidine A -O xides
Tertiary amines and other basic nitrogen compounds react readily with hydrogen 
peroxide or peracids to give the A-oxides. The reaction depends on the nucleophilicity of 
the amine and the electrophilicity of the peroxide. Pyridine and other less basic 
nucleophilic nitrogen heterocycles require a peracid such as trifluoroperacetic acid. For 
our purposes, ra-chloroperoxybenzoic acid (mCPB A) was the most suitable to use due to 
ease of handling.
The A-oxides were obtained simply by mixing the disubstituted piperidine with 
the peracid in dry acetone. After careful removal of the solvent, the residue was 
chromatographed on an alumina column to remove the acid residues. In general, good 
yields were obtained with the exception of the bis(nitrophenyl carbamate). In this case, 
the lack of solubility of the starting bis-carbamate prevented reaction.
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O Me
mCPBA
Me
NHR RHNRHNNHR
R = ‘Pr (8 6 ) 
= Et (87) 
= Ph (8 8 )
A-Methyl-cw-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine TV-oxide (8 6 ) 
was obtained as white crystals. The IR spectrum was similar to that of the free base, with 
the carbonyl stretch present at 1680 cm*1, and the new band at 920 cm’ 1 was assigned to 
the A-oxide. The *H NMR spectrum can be seen in Figure 3. The A-methyl singlet had 
shifted considerably downfield to 8  3.18 as expected, due to the influence of the positive 
charge on the nitrogen. Accordingly, the signal attributed to the methine protons at C-2 
and C- 6  appeared at 8  3.52 as a multiplet. The methylene protons at C-7 and C-8  had also 
changed considerably, occurring as a doublet at 8  4.05 and a doublet of doublets at 8  
4.61. The 13C NMR spectrum showed that all the ring methylene carbons had grouped 
together to become one signal at 8  25.4, as had the isopropyl methyl groups at 8  22.9. 
The A-methyl signal had shifted to 8  55.8, and the methine signal for C-2 and C- 6  
appeared at 8  76.2. The quaternary carbonyl carbon was present in a similar position at 8
157.3. As there was only one set of carbon signals in this spectra, this indicated that 
although two diastereoisomers could be formed, the reaction only yielded one isomer. 
The mass spectrum showed no parent ion.
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The bis(ethyl carbamate) N-oxide (87), unlike its free base, was obtained as white 
crystals. This compound had similar spectra to the isopropyl derivative, with the carbonyl 
stretch at 1730 c m 1 and N-O stretch at 920 c n r 1 in the IR spectrum. The NMR 
spectrum showed the shifting of the N-methyl to 8  2.96, where it became part of a 
multiplet with the methylene protons of the bis(ethyl carbamate). Again, the doublet at 8  
3.89 and the doublet of doublets at 8  4.30 were attributed to the methylenes at C-7 and C- 
8 . The 13C NMR spectrum showed a similar story with the N-methyl moved to 8  55.4 
and the C-2 and C- 6  carbons at 8  75.6. Unexpectedly, a parent ion was found at m/z 317 
in the mass spectrum along with the expected fragmentation pattern.
N-Methyl-cw-2,6-bis(phenylaminocarbonyloxymethyl)piperidine N-oxide (8 8 ) 
was isolated as white crystals. The IR spectrum was almost identical to the free base with 
the addition of a band at 920 cm-1 which was attributed to the N-O stretch. This time, the 
N-methyl had not shifted quite so far downfield in the *H NMR spectrum and appeared at 
8  2.87, as was the case with the protons at C-2 and C - 6  which had their multiplet 
positioned at 8  3.13. The familiar pattern of the C-7 and C- 8  methylene groups was in 
evidence at 8  4.00 and 4.52. Multiplets at 8  6.82, 7.02 and 7.29 in the ratio of 1:2:2 
corresponded to the para-, meta- and ortho-aromatic protons. The 13C NMR spectrum 
showed one diastereoisomer present with the N-methyl signal at 8  55.9 and the C-2 and 
C- 6  methine carbons at 8  76.2. The mass spectrum showed no parent ion, but the usual 
fragmentation pattern.
3.8 Synthesis of N -M ethyl-cis-2,6-bis(halom ethyl)piperidine N -O xides
As before, oxidation of the amine was achieved using mCPBA. This tended to 
give slightly discoloured oils which could not be purified further due to the small 
amounts being used and uncertainty of the stability of the compounds at higher 
temperatures.
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O Me
CH
X = C1 (89) 
= Br (90)
Af-Methyl-c/s-2,6-bis(chloromethyl)piperidine N-oxide (89) was obtained as a 
yellow oil which required storage in the freezer to prevent further discolourisation. In the 
IR spectrum, an additional band at 910 cm-1 was attributed to the N-O stretch. The lH 
NMR spectrum showed shifting of the N-methyl as expected to 8  2.80 as was the same 
with C-2 and C- 6  protons which appeared at 5 3.21. Again, the two doublet of doublets 
at 8  3.88 and 4.17 were due to the C-7 and C- 8  methylene protons. The 13C NMR 
spectrum showed one diasteroeisomer and was similarly affected with the AT-methyl 
signal at 8  44.6 and the signal for C-2 and C- 6  at 8  80.9. A large (9.4%) parent ion was 
found at m/z 2 1 1  in the mass spectrum.
The dibromo derivative (90) was prepared in a similar way to the dichloro 
compound and was also obtained as a yellow oil which was unstable. The compound 
yielded similar spectra to that of the dichloro derivative.
57
Chapter 4
Synthesis of lra/!£-2,6-Disubstituted Piperidines.
4.1 Methods of Synthesising /ra/fs-2,6-Disubstituted Piperidines.
The family of /ra/i5 -2 ,6 -disubstituted piperidine alkaloids includes a number of 
products exhibiting notable biological activity.91 Despite interest in the pharmacological 
properties of these compounds, there are few general, stereoselective methods for their 
synthesis. The reduction of substituted pyridine derivatives103 or various intramolecular 
cyclisations104 have generally yielded product mixtures of the cis- and trans-isomers. 
However, in the past ten years, a number of approaches have been made to combat the 
problem.
Hydride reduction of cyclic imines (91)105 can be manipulated to give either cis- 
or frans-stereochemistry, depending on the reagent and conditions.
(91)
The reaction of tetrahydropyridine N-oxides (92) with trifluoroacetic anhydride in 
dichloromethane at 0 °C (Polonovski-Potier reaction) 106 afforded 5 ,6 -dihydropyridinium 
salts (93) . 107 Treatment with potassium cyanide, followed by reduction gave a series of 
rra«s-2,6-dialkyl-piperidines (94) (Scheme 13).
58
(92) (93)
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Scheme 13
Cycloadditions of alkenes with tetrahydropyridine N-oxides (95) followed by 
reductive cleavage has furnished trans-2>6 -dialkylpiperidines (96) (Scheme 14).108 The 
cycloaddition of an alkene to an N-oxide takes place preferentially by orthogonal 
approach of the alkene to the nitrone in a conformation in which the 2 -alkyl substituent is 
equatorial, to give an isoxazolidine which will furnish a fra«.s-2 ,6 -dialkylpiperidine by 
reductive cleavage of the N-O bond.
.OHH HOAc
Me Me1 Me1Zn
CoH
Scheme 14
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Alkylation and reduction of bicyclic carbamates, via the aza-Achmatowicz 
reac tio n 109 using chemoenzymatic methods, also gives the trans-isomer in a 
stereospecific reaction (Scheme 15).110
OMe
MeO
2. 10 mol% TfOH,
2 mol H20 , THF MeOHN
OH
OH
NH
Scheme 15
Wasserman et al. have shown that an imine-epoxide rearrangement followed by 
hydride reduction proves a mild, efficient method for the formation of trans-2 ,6 - 
disubstituted piperidines111 and have used that procedure for the synthesis of the fire-ant 
venom alkaloid, solenopsin A112 in which the cis : trans ratio is 1:99.
Using the same methodology, the same group has also synthesised trans- 
piperidine-2 ,6 -dicarboxylic acid, 113 commonly known as teneraic acid, which can be 
isolated from the red alga Porphyra tenera 114 in which the cis:trans ratio is 15:85 
(Scheme 16).
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4.2 Synthesis of ^V-M ethyl-lra/i.?-2,6-bis(hydroxymethyl)piperidine
By analogy with the c/s-series of compounds, N -m e th y \- tra n s -2 y6- 
bis(hydroxymethyl)-piperidine (97) was seen as a key intermediate. Steps were therefore 
taken to synthesise this compound.
A route had been devised to trans-2,6-piperidinedicarboxylic acid in work to 
synthesise enzyme inhibitors of the diaminopimelate pathway to L-lysine. 115 We repeated 
this work (Scheme 17) and so pimelic acid (98) was converted into the diacid chloride by 
warming with thionyl chloride. 116 The a-positions were then brominated using bromine, 
with iodine as a catalyst. This is the Hell-Volhard-Zelinsky reaction where only the 
carbon a  to an acid chloride is halogenated. Addition of ethanol at the end of the reaction 
converted the diacid chloride into the diethyl ester (99).
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2. Br,
C ° 2H 3  EtOH Et° 2C
(98) Br Br
(99)
NH
CONHCONH
(100)
(76) (102)
Scheme 17
Cyclisation of diethyl a,a'-dibromopimelate was carried out in a sealed tube with 
liquid ammonia. After three days, the tube was opened and the ammonia was allowed to 
evaporate off leaving 2,6-piperidinedicarboxamide as a mixture of isomers. Separation of 
the isomers was achieved by careful crystallisation. On addition of iced water, the 
remaining solid was filtered off and dried. This is the cis-isomer (100) which was 
identified by its melting point (lit. 117 m.p. 226-228 °C) and by subsequent hydrolysis of 
the diamide to the diacid which showed that the hydrolysis product was indeed the cis-
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2,6-piperidine dicarboxylic acid. Concentration of the filtrate obtained above gave the 
fra/ty-diamide (101) as white crystals. This isomer was also identified by its melting point 
(lit. 117 m.p. 265-269 °C). The separated c/s-and /ra«j-2,6-piperidinedicarboxamides 
were hydrolysed to the corresponding diacids by heating at reflux in 1 0 % barium 
hydroxide solution followed by acidification. The isomers were identified by their 
different melting points117»96 and the c/s-isomer (76) was identical to the product of the 
hydrogenation of dipicolinic acid, which is known to give solely the cw-product.
The intention next was to Af-methylate the trans-diacid (102) using formaldehyde 
and formic acid, followed by reduction of the diacid using borane-THF. However, it was 
decided at this point to try to find a new route to the rra«s-isomer (97) because of the poor 
yields obtained in the above method (25% for the diamide and 45% after hydrolysis).
h o 2c
NaHC03
H2CO
h c o 2h  ►-
c o 2H h o 9c'
b h 3-th f
N' COoH
Me
f i
(102)
OH Me OH 
(97)
4.3 An A lternative Synthesis of A f-M ethyl-frfl/is-2 ,6 -b is(hydroxym ethyl)- 
p iperid ine
After a search through the literature, it was discovered that esters of /^-substituted 
piperidines had been synthesised as part of a search for improved local anaesthetics. 118 
In a similar procedure to that described above, the reaction of a dihalogenated ester with 
three molar proportions of the appropriate primary amine gave a piperidine derivative. 
Although not reported here, methylamine has been used before in this reaction, 119 but 
yields of product were poor.
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Diethyl a,a'-dibromopimelate (99) was prepared in good yield and obtained as a 
colourless oil. Cyclisation with methylamine was carried out at reflux for 24 hours. After 
an acid-base work up and column chromatography, a pale yellow oil was obtained.
Questions of stereochemistry now arise. If the diethyl a,a'-dibromopimelate is 
the meso-isomer, the resulting piperidine diethyl esters should have the meso-cis (79) 
configuration. If the dibromo diester is a racemic mixture, the products should be the 
racemic frans-piperidine esters (103). It was quite obvious from the NMR data that the 
product was a mixture of the isomers in a 1 : 1 ratio. The NMR spectrum showed the 
usual complex multiplet for the ring methylenes between 8  1.48 and 1.95. Two distinct 
singlets of equal intensity were observed for the N-methyl at 5 2.21 and 2.40 one of 
which corresponds to the cw-isomer and the other to the frans-isomer. The protons a  to 
the nitrogen also came as two multiplets, one at 5 2.80 and the other at 8  3.78. This large 
difference in chemical shift is consistent with literature reports, 120 as the protons are 
more shielded in the c/s-isomer ( 8  2.80) than in the trans-isomer ( 8  3.78). This is 
reported to be due to the presence of naa*-type hyperconjugative interaction in the cis- 
isomer, 121 where, in the most populated conformation, cis (eee), the two CH bonds are
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flw/i-coplanar with the nitrogen lone pair. The 13C NMR spectrum showed two signals 
for each carbon, further supporting the presence of two isomers. The N-methyl carbons 
appeared at 8  40.6 and 42.1, while the C-2 and C- 6  methine carbons had a greater 
difference, consistent with the *H NMR spectrum, with signals at 8  61.6 and 68.2. In the 
IR spectrum, the carbonyl stretch band appeared at 1731 c m 1, whilst a small amount of 
the parent ion nt/z 243 was found in the mass spectrum.
There now remained two alternatives. Either to separate the isomers by column 
chromatography, or to epimerise one centre in the cw-isomer to give wholly the trans- 
isomer.
Conformational Analysis of Piperidine Systems
There have been several reports in the literature on epimerisations in 2,6- 
disubstituted piperidine rings. In basic conditions, it is possible to convert, through 
repetition, the cw-isomer into the trans. Barnes and Fales97 noticed that their sample of 
dimethyl Af-methyl-cw-2,6 -piperidine dicarboxylate (79) isomerised to the /raws-isomer 
during attempted acyloin condensation in alkaline conditions (Scheme 19). They also 
observed that even on standing, the diester was gradually isomerised and they concluded 
that the tertiary nitrogen was a strong enough base to cause some enolisation.
OEtOEtOEt
Me
(79)
Me
(103)
Me
Scheme 19
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Another example quotes epimerisation of C-2 in 1,2,6-trimethyl-4-piperidone 
(104)122 using ButNH 2 -H2 0  at 50 °C. This is believed to occur via a ring opened 
species.
Me
NHMe MeMe Me Me
MeMe
(104)
Me
Scheme 20
Using similar conditions, the alkaloid, solenopsin A (105) which has haemolytic, 
insecticidal and antibiotic activities, has been made through epimerisation of the cis- 
compound using KlQBu. 123
(105)
In the preparation of Af-benzyl-2-cyano-6-methyl-piperidine, Husson et al.124 
noted that the molecule preferred a conformation where the cyano group is pseudoaxial. 
There appeared to be a gain in stabilisation energy when the cyano group is pseudoaxial, 
which was sufficiently large to prevent ring inversion to the alternate and a priori more 
stable diequatorial conformer.
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NC
CN
transCIS
This preferred orientation of the nitrile group has been likened to the 'anomeric 
effect' observed in pyranose sugars. 125 When a polar group is located on a carbon a  to a 
heteroatom instead of being in the equatorial position, it prefers the axial position. An 
explanation of this is that the lone pairs of the polar group connected to the carbon can be 
stabilised by overlapping with an anti-bonding orbital of the bond between the carbon and 
the heteroatom, i.e. there is a higher coefficient on the electropositive a-carbon.
NC
A review on the conformation equilibria of nitrogen-containing saturated 
heterocycles has been published by Crabb and Katritzky. 126
It seemed feasible that complete conversion of the mixture of cis- and trans- 
diesters to the single trans-isomer would be possible. Following literature precedence, the 
mixture of isomers was dissolved in xylene and small pieces of fresh sodium were 
added. The mixture was then heated at reflux for 24 hours after which it was discovered 
that 30% of the cis-isomer remained. Unsatisfied with this result, we then attempted 
acidic epimerisation, by heating the mixture of isomers in conc. HC1 in a sealed tube at 
100 °C for 18 hours (Scheme 21). After the reaction had cooled and the pressure was
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released, the resulting hydrochloride salt precipitate (106) was removed by filtration and 
analysed. The *H NMR spectrum showed a singlet at 6  2.75 corresponding to three 
protons and a multiplet at 6  3.77 for two protons. In the 13C NMR spectrum, only one 
set of signals could be seen, with the N-methyl signal coming at 6  42.7 and the a  protons 
resonating at 6  67.9. Definitive proof that we had obtained 100% pure W-methyl-frans-
2 ,6 -piperidinedicarboxylic acid hydrochloride (106) was obtained from the melting point 
which was not identical to that of an authentic sample of the cis isomer which had been 
made by hydrogenation. In the IR spectrum, a carbonyl stretching band at 1745 cm-1 and 
a hydroxyl band at 3440 cm-1 from the carboxylic acids were evident. The mass spectrum 
of the diacid showed a very small molecular ion at m/z 187. The largest ion, m/z 142 was 
due to loss of one carboxyl group.
Me OH Me OH
(106) (97)
Scheme 21
There now remained only the problem of the reduction of the acid groups to the 
corresponding diol (97). Reduction of acids is normally facile using diborane. However, 
in this case, the starting acid is highly insoluble, either as the amino acid or as its 
hydrochloride salt.
Diborane is a dimer although it acts as if it were the monomer, BH3 . In THF, 
however, the reagent exists as the monomer, in the form of an acid-base complex with 
the solvent. Unlike complex hydride anions, which are nucleophilic, boranes are 
electrophilic and combine with the lone pair of the oxygen. The mechanism (Scheme 22) 
for the reduction of carboxylic acids using diborane was first established by Brown and
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Heim . 127 Each acid group requires three active hydride equivalents for reduction to the 
alcohol.
OCOR
3 RC02H
b h 3 B— OCOR
I
O
o
X ,R 0 =
OCOR
R + 3 H 2 OCOR
OCH2R
i
o ^ N > 3 [RCH20B =0] + 2 H2
r h 2c o  o  o c h 2r
3H20
3 RCH2OH + 3 B(OH) 3
Scheme 22
Fortunately, in a large excess of borane-THF, kept at reflux for 48 hours, 
reduction of the hydrochloride salt to the diol (97) occured in good yield. The IR and 
mass spectra were of a similar pattern to the ds-isomer, although there were subtle 
differences in the NMR spectra. The N-methyl peak came at 8  2.32 (c/. cis,5 2.21) and 
the C-2 and C- 6  protons were at 8  2.43 (c/. cis, 8  2.26) as a multiplet in the NMR 
spectrum. The methylenes adjacent to the hydroxyl groups were again slightly different, 
appearing as a doublet of doublets at 8  3.45 and 3.91. The 13C NMR spectrum was 
almost identical to that of the ds-isomer.
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4.4 Synthesis of A r-M e th y I- f ra / is -2 ,6 -b is (a m in o c a rb o n y lo x y m e th y l) -  
p ip erid in es
The bis-carbamate derivatives of the trans-diol were prepared in an analogous 
manner to those of the cw-series in similar yields.
N-Methyl-fra«.y-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine (107) was 
obtained as white crystals after purification. The IR and mass spectra were almost 
identical to those of the c/s-compound. In the NMR spectra, only slight differences in 
chemical shift were observed, such as the ring methylene protons which had resolved 
into two separate multiplets, found at 5 1.40 and 5 1.68 in the ratio 1 : 2, corresponding 
to C-4 : C-3 and C-5. The 13C NMR spectrum showed similar patterns, where the C-4 
methylene carbon had shifted to 6  25.6, compared to 8  23.7 in the cw-compound. Only 
one methyl signal was observed for the isopropyl groups. The largest difference in 
properties was observed for the melting points of the two compounds in which the trans- 
isomer melted at a temperature of 40 °C higher than the cw-isomer.
RNCO
Me
OH Me
(97)
OH
NHR RHN
R = -!Pr (107) 
= -Et (108) 
= -Ph (109)
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The bis(ethyl carbamate) (108) derivative also had identical spectra to that of its 
c/s-isomer, except for the •H NMR spectrum in which the ring methylenes had been 
resolved as in the previous compound. Also, the protons on C-2 and C- 6  had shifted 
downfield and were now part of a complex multiplet involving the methylenes of the 
bis(ethyl carbamate) at 8  3.09-3.27. Again, the largest difference came in the melting 
points, where this time the trans-isomer would not even solidify, remaining a colourless 
oil.
N-M ethyl-fra«5 -2 ,6 -bis(phenylaminocarbonyloxymethyl)piperidine (109), 
acquired as white crystals had small differences from the ds-isomer in the NMR spectra, 
but this could be due to the different deuteriated solvent used, in this case, d6-DMSO. 
The NMR spectrum can be seen in Figure 4. For example, the N-methyl singlet 
appeared at 8  2.32, compared to 8  2.43 in the cis-isomer, and the C-2 and C- 6  methine 
protons came as a multiplet at 8  2.35, in comparison to the cis-compound where they 
appeared at 8  2.54. The melting points of the cis- and frans-isomers differed by 15 °C 
with the fra/is-isomer melting at the lower temperature of 130 - 132 °C.
The bis(p-nitrophenyl carbamate) (110) caused the same problems as before with 
purity but yellow crystals were obtained after column chromatography. Again, no 
noticeable difference in the spectra was apparent, but the melting points of the isomers 
differed by 30 °C, with the trans-isomer melting at 49 °C and the cis-compound melting at 
78-80 °C.
4.5 Synthesis of A -M ethyl-traft5-2,6-bis(haIom ethyl)piperidines
These compounds were prepared in the same manner as for the ds-isomers using 
thionyl chloride and phosphorus tribromide in equivalent yields to give oils as the 
products. Both the chloro- (111) and bromo- (112) compounds had similar spectra to 
their corresponding ds-analogues, and gave correct accurate mass spectra
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OH Me OH Me
(97)
X = C1 (111) 
= Br (112)
4.6 Synthesis of A T -M eth y l-lra /is-2 ,6 -b is(a m in o ca rb o n y Io x y m eth y l)-  
piperidine AT-Oxides
mCPBA was again used as the oxidising agent to form the N-oxides in analogous 
conditions to those of the cw-series. Again, the N-oxide of the p-nitrophenyl derivative 
could not be made.
mCPBA
Me
NHR RHNRHNNHR
R = ‘Pr (113) 
= Et (114) 
= Ph (115)
A^-Methyl-/ra«5-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine N-oxide 
(113) was prepared in reasonable yield as white crystals. Similar IR and mass spectra to 
the c/s-series were not a surprise and again only small differences in the NMR spectra
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emerged. The most notable difference in the !H NMR spectrum was the shift of the 
methine protons at C-2 and C-6, from 6 3.52 in the cis-isomer to 5 3.30 in the trans- 
isomer. This time, even the melting points were quite similar, with the fra/w-isomer 
melting at 177 °C and the cw-isomer melting at 180 °C.
In the bis(ethyl carbamate) derivative (114), the NMR spectrum showed the 
same difference as found above. The protons a  to the nitrogen were shifted to 8 3.38 in 
the fra/w-isomer, compared to 8 3.61 in the cw-isomer. No difference in the 13C NMR 
spectrum was apparent for these two methine carbons. The melting points of the two N- 
oxides could be compared, unlike their free bases and it was obvious that the two 
compounds were different, with the fra/w-compound melting at 178 °C and the cw-isomer 
melting at 158 °C.
N-Methyl-rr<2/is-2,6-bis(phenylaminocarbonyloxymethyl)piperidine N-oxide 
(115) was obtained as white crystals and had similar spectra to its cw-counterpart. The 
lH NMR spectrum can be seen in Figure 5. The N-methyl and a  protons did resonate at 
different chemical shifts to those in the cry-compound (8 3.15 and 3.59 respectively 
compared to the ciy-isomer 8 2.87 and 3.43) but whether this is due to the different 
deuteriated solvents employed (d$ DMSO and d* MeOD) or some stereoelectronic effect 
is unknown. Their two melting points were quite similar at 178 °C for the fra/u-isomer 
and 170 °C for the c«-isomer.
4.7 Synthesis of A-M ethyl-lra/is-2,6-bis(halom ethyl)piperidine N -O xides
The same procedure used in the ds-series was followed to make these A-oxides. 
The yields were poor due to difficulties in purifying the products. Although the products 
were coloured, it seemed that in each case, it was only a very small impurity that was 
present.
Again, similar spectra to the dy-series were obtained.
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4.8 C onclusions
A range of novel compounds have been prepared and characterised by a 
synthetically useful route. The biological testing data of these compounds can be seen in 
Chapter 8. It was now decided to investigate similar molecules that could incorporate two 
N-oxides which would then have different reduction potentials. It is crucial in the 
development of these compounds that the reduction potentials lie in the correct range in 
order to be reduced in the hypoxic cells. Two different types of molecule were chosen to 
synthesise due to the availability of starting materials and their similarity in structure to 
those compounds already made, so rational comparisons could be made regarding their 
biological activity. This work is presented in the next two chapters.
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Chapter 5
Synthesis of 1,4-Disubstituted Piperazines
5.1 Introduction
The piperazine structure is present in many pharmacologically active compounds 
and there has been much interest in the pharmaceutical and herbicidal128 application of 
such compounds. Some selected examples will now be briefly mentioned.
New TV-substituted piperazine derivatives (118) have been prepared as drugs for 
improving the functional disorder of the brain by inhibiting calcium uptake of the cranial 
nerve.129
NH
(118)
A similar type of compound (119) is a GABAa  receptor blocker.130 The authors 
suggest that the antidepressant and anti-psychotic effects as well as the convulsions, 
anxiety, panic attacks and insommnia caused by this compound may be due to GABAa  
receptor blockade.
HN
(119)
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The synthesis and pharmacological screening of a group of piperazine derivatives 
(120) showing analgesic activity have recently been published.131
(120)
Other 1,4-disubstituted piperazines (121) have shown immunotropic activity, 
with marked suppressive effect.132
Me Me
(121)
Similarly, compounds of type (122) have undergone pharmacological and 
physical tests.133
RO OR
R = -xylyl (122) 
-anisyl
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Several types of derivatives of 1,4-disubstituted piperazines have been shown to 
have anticancer activity. Compounds such as (123) inhibit Lewis' pulmonary carcinoma 
amongst others.134
> <
COMeMeOC
Af,AT-Bis(cyclopropylmethyl)piperazine dihydrochloride (124) is a novel inotropic 
compound which shows potassium channel blocker activity and has antimuscarinic 
activity.135
HN NH
2C1
(124)
l,4-Bis(2-chloroethyl)piperazine (125) has been prepared before,136 along with 
20 other (3-chloroethylamine derivatives of mono-, bi- and polyfunctionality where the 
authors were making N-oxides in order to decrease the toxicity of nitrogen mustard 
compounds.
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Their findings included the following.
a) The necessity of two or more P-chloroethylamine groups in the molecule in order to be 
effective in cancer retardation. This polyfunctionality was also true in the case of the N- 
oxides.
b) A decrease in toxicity was generally far more dominant than a decrease in effectiveness 
when the tertiary amines were changed into their N-oxides. Accordingly, the 
chemotherapeutic index was improved with Af-oxide formation.
They reported that both the free base and the bis-A-oxide of the piperazine derivative 
were active against tumour cells, but not as effective as nitromin (Chapter 2), which they 
took forward to clinical trials.
5.2 Synthesis of 1,4-Disubstituted Piperazines
The piperazine series of derivatives was chosen so that two N-oxides could be 
incorporated into each molecule, thereby altering the reduction potential of the compound, 
which is important in the activation of such compounds. Another factor in choosing these 
compounds was the ease of formation from convenient starting materials. The same set of 
derivatives as before were chosen as targets so a rational comparison of the different 
systems could occur.
We started with the readily available l,4-bis(2-hydroxyethyl)piperazine (126) 
and, in the same manner as before, reacted it with a number of isocyanates to produce a 
range of bis-carbamates in excellent yield. Although the starting diol is sparingly soluble 
in dichloromethane, as the reaction proceeded, the very soluble bis-carbamate was 
produced. In this manner the reaction was known to be complete when a clear solution 
was obtained.
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NHR
OH
R-N=C=0 R = Et (127) 
= Pr* (128) 
= Ph (129)
O  N 0 2 (130)
HO
(126)
RHN
l,4-Bis(2-isopropylaminocarbonyloxyethyl)piperazine (128) was obtained as 
white crystals. The IR spectrum showed bands at 2780 and 2810 c m 1 which relate to the 
N-CH2 stretch, and a carbonyl band at 1690 cm*1. The isopropyl group was evident due 
to a strong signal at 1365 c n r1, corresponding to C(CH3)2 . In the *H NMR spectrum, a 
multiplet appeared at 6 2.60 which had an integral of 12 H. The methylene group next to 
the carbamate came further downfield at 8 4.16 as expected. A broad singlet at 8 4.83 
was attributed to the NH of the carbamate. The 13C NMR spectrum showed three 
methylene signals, at 8 53.1, 57.1 and 61.5, with intensities of 2:1:1. Therefore, the ring 
methylenes were assigned the signal at 8 53.1. The signal at 8 61.5 was similar to that 
found for the methylene next to the carbamate in previous examples, so the signal at 8
57.1 was attributed to the exocyclic N-CH2. A parent ion m/z 344 was found as a small 
percentage in the mass spectrum, whilst the largest fragment at m/z 125 corresponded to 
loss of both carbamate groups plus a methylene group.
The bis(ethylcarbamate) (127) behaved in a similar fashion to that of the iso- 
propyl carbamate and was obtained as white crystals. The spectra were consistent with 
the structure and full analytical data were obtained.The ]H NMR spectrum of this 
compound can be seen in Figure 6.
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Figure 6
5 9
l,4-Bis(2-phenylaminocarbonyloxyethyl)piperazine (129) was made as above, 
but the resulting bis-carbamate was also insoluble in dichloromethane, and a heavy white 
precipitate formed during the reaction. However, as all the diol had reacted, it was easy to 
purify the product by recrystallisation with methanol. The expected bands were apparent 
in the IR spectrum, with the carbonyl stretch occurring at 1700 cm-1. The !H NMR 
spectrum was run in d^-DMSO and signals were obtained at 8 2.52 (singlet) and 8 2.63 
(triplet) in a ratio of 2 : 1. The triplet was obviously the exocyclic N-CYL2 which was also 
coupled to the triplet at 8 4.22 which corresponded to the adjacent methylene group. In 
the 13C NMR spectrum, the methylenes appeared at the same shifts and same ratios as in 
the previous examples. No parent ion was found in the mass spectrum, just the expected 
fragmentation pattern.
The bis(p-nitrophenylcarbamate) derivative (130) behaved similarly to the 
bis(phenylcarbamate) in that it precipitated as it was being formed. This presented 
problems when purification was attempted due to the extreme insolubility of the 
compound. Crystallisation was therefore very difficult as solubility was only obtained 
with DMSO, from which the compound was unrecoverable. However, repeated washing 
of the material with hot methanol rendered a solid pure enough for good analytical data to 
be obtained.
The production of the bis(2-haloethyl)piperazines was also attempted. 1,4-Bis(2- 
chloroethyl)piperazine hydrochloride (125) was prepared using thionyl chloride. The 
product was kept as the dihydrochloride salt to stop any decomposition, which would 
occur if the nitrogens were liberated to the free base. All spectra obtained were consistent 
with the structure. The *H NMR spectrum was similar to that of the bis(phenyl 
carbamate), where the ring N-CH2 groups were distinguishable from the exocyclic N- 
CH2 , and appeared as a singlet at 8 3.77. The exocyclic methylenes gave signals at 8 
3.70 and 3.94 and were coupled to each other.
Attempts to make the dibromo compound were numerous, but futile. Phosphorus 
tribromide was used initially, but the insolubility of the starting diol prevented any 
reaction taking place as the starting material just clumped together on addition of the
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reagent. Heating for long periods of time did not improve the situation. Then a mixture of 
triphenylphosphine and bromine was tried, but no product could be isolated. Carbon 
tetrabromide with triphenylphosphine was also used, but only starting material was 
isolated. In both the last two cases, bromination probably happened, but attempts to 
isolate the free base failed probably because of aziridinium formation and hydrolysis back 
to the alcohol. Problems with removal of triphenylphosphine and its oxide were also 
encountered. At this stage it was decided not to pursue this synthesis.
5.3 Synthesis of 1,4-Disubstituted Piperazine bis-A -O xides
The majority of the piperazine derivatives were oxidised in the same manner as 
before using mCPBA. As all the products were insoluble in the solvent used (acetone), it 
was easy to follow the progress of each reaction by the formation of a white precipitate.
NHRNHR
R = Et (131) 
= Pr* (132) 
= Ph (133)
per acid
(134)
RHNRHN
l,4-Bis(2-isopropylaminocarbonyloxyethyl)piperazine bis-N-oxide (132) was 
prepared in reasonable yield and obtained as white crystals. In the IR spectrum, a new 
band at 980 cm-1 indicated the formation of the AT-oxide. The solubility of the compound
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had decreased substantially and NMR spectra were only obtainable in d^-DMSO at 333K. 
The *H NMR spectrum showed a multiplet at 5 3.63 which corresponded to the ring N- 
CH2 protons. Two broad singlets at 8 3.98 and 4.58 corresponded to the exocyclic 
methylenes, with the protons next to the carbamate occurring the furthest downfield. 
From the 13C NMR spectrum, it appeared that only one diastereoisomer wa present and 
the three methylene signals appeared at 8 57.3, 58.6 and 67.8, this time in the ratio 1:2:1. 
Evidently, the ring methylene carbons are more affected by the presence of the oxygens 
than the acyclic ones. This can be seen in the diagram below, where more effect from the 
axial oxygens can be envisaged with the ring carbons than the equatorial methylene 
groups.
No molecular ion was found in the mass spectum; indeed, the compound seemed to fall 
apart very easily into small, recognisable fragments.
The bis(ethylcarbam ate)-bis-A-oxide (131) was more soluble than the 
bis(isopropylcarbamate) and a NMR spectrum was obtained in D2O which can be 
seen in Figure 7. This shows the methylene protons as four different types of proton in a 
AA'BB' system.
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Figure 7
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There also appeared in the !H NMR spectrum two doublets at 8 3.24 and 4.12 with two 
broad singlets at 8 3.50 and 4.44, all of equal intensity. In assigning the signals, it was 
assumed that as the methylene protons next to the carbamate had always appeared the 
furthest downfield, they would do so again, so those protons were assigned the singlet at 
8 4.44. Since the methylene protons next to that carbon would be coupled to it, it seemed 
logical that the singlet at 8 3.50 would belong to those protons. The two doublets 
remaining were more difficult to assign. From the diagram it appears that Hb and Hb* are 
more affected by the oxygen than the Ha and Has and so would have a signal further 
downfield. Thus Ha was assigned 8 3.24 and Hb assigned 8 4.12. Although the 
difference could be seen in the !H NMR spectrum, there was still only the three 
methylene signals in the 13C NMR spectrum as before, indicating the presence of one 
diastereoisomer.
The same pattern appeared in the *H NMR spectrum for bis(phenylcarbamate)- 
bis-N-oxide (133) at approximately the same shifts. This bis-N-oxide is highly insoluble, 
barely dissolving in DMSO unless it is heated.
1,4-Bis(2-p-nitrophenylaminocarbonyloxyethyl)piperazine bis-N-oxide (134) 
could not be prepared using mCPBA with acetone as solvent due to the insolubility of the 
starting material. Therefore another method was required. Trifluoroacetic acid is well 
known as an excellent solvent, so it seemed obvious to use this in combination with 
hydrogen peroxide to produce trifluoroperacetic acid in situ. Fortunately, the 
bis(nitrophenyl carbamate) did dissolve in the acid and the bis-N-oxide was produced in 
this manner. Like the bis(phenyl carbamate), this compound is highly insoluble, 
dissolving only in DMSO. The Af-oxide stretch band appeared at 920 cm-1 in the IR 
spectrum along with the expected bands for the aromatic region. The JH NMR spectrum 
was run in d6-DMSO, and all the N-CYii methylene protons appeared in a multiplet 
ranging from 8 4.40 to 4.52. In this case these protons appeared further downfield than 
the methylenes next to the carbamate, which appeared at their normal shift of 8 4.10. 
Solvent effects due to the 'wet' d^-DMSO are a possible explanation for this large shift of
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ca 1 ppm. No such effects were seen in the 13C NMR spectrum, with the signals 
appearing at comparable shifts as before.
The dichloro bis-N-oxide (135) was made as usual, but care was taken to form 
the free base in completely dry conditions, using distilled acetone and distilled 
triethylamine, before the addition of mCPBA. This gave the product as white crystals 
which were highly soluble in most organic solvents.
(135)
The IR spectrum showed bands at 950 c m 1 for the N-oxide stretch and 670 cm*1 for the 
C-Cl stretch. The !H NMR spectrum was different from the spectrum of the 
dihydrochloride salt, with the ring protons appearing between 6 2.73 and 3.36. The 
acyclic methylene groups appeared as two triplets at 6 3.64 and 3.90, corresponding to 
the N-CH2 and the CI-CH2 respectively. The 13C NMR spectrum indicated the presence 
of one diastereoisomer. A suprisingly large molecular ion m/z 244 was found in the mass 
spectrum, with the main peak at m/z 163, corresponding to loss of an oxygen and a 
chloroethyl group.
5.4 Conclusions
Crystalline solids of a range of 1,4-disubstituted piperazines and their 
corresponding bis-N-oxides have been synthesised and fully characterised and the 
biological testing results can be found in Chapter 8.
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Chapter 6
Synthesis of N,Nf-bridged bis(2-substituted piperidines)
6.1 Bis-piperidine Alkaloids
This type of structure with two piperidines joined by an alkyl chain, is relatively 
uncommon in nature, and natural compounds joined through both nitrogens are rare. Of 
those that do exist, many have toxic properties. Haliclamines A and B (136) are two 
cytotoxic alkaloids occurring in an unnamed marine sponge of the genus Haliclona. Their 
structures and configurations are based on extensive NMR spectroscopy.137
(136)
Haliclamine A 
Haliclamine B( ^ !4, cis)
Other alkaloids with a two carbon chain linking the two nitrogens include 
thermopsidine,138 convolvidine,139 and salsamine.140
6.2 N ,N'-AIkylbispiperidines
Neurotoxicity has been reported141 to exist in the simplest backbone structure of 
N,Af'-l,2-ethanediyl-bis-piperidine (137). This is not a cumulative poison and
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neurotoxicity is absent in derivatives with different ring systems or with different 
connecting chains.
(137)
N,7V,-aG)-Dialkylbis-piperidine dihydrochlorides (138) have been prepared by 
alkylation of pyridine derivatives with ao )-d iha lo -C 3 _6 -alkanes followed by 
hydrogenation of the resulting bis-pyridinoalkanes in the presence of Adams' catalyst in 
acetic acid.142 These compounds showed high radioprotectant activities when R = H, 
while the Me-substituted salts were more toxic and displayed no radioprotectant activity.
R1 - R4 = H or Me .2HC1
(138)
n = 3-6
Substituted amides of (139) have been found to possess cardiovascular activity, 
in particular calcium antagonistic activity, which indicates that they have potential use in 
the treatment of angina.143 This type of compound is well absorbed and shows high 
metabolic stability with no toxic effects.
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MeO
MeO
MeO
(139)
6 .3  S y n th es is  o f  N ,N '-( l,2 -B ise th a n e d iy l)b is (2 -h y d r o x y m e th y l-  
piperidine)
Literature precedence144 had suggested that pipecolinic acid derivatives (140) 
could be linked with 1,2-dibromoethane. However, when we repeated this reaction, 
mostly starting material was isolated after using a variety of conditions.
(140)
We then tried to use the reductive alkylation procedure which had worked well in 
the iV-methylation of ris-piperidine systems. It had been reported145 that aqueous glyoxal 
reacts with piperidine (141) to give a bis-piperidine system (142).
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(CHO)
(141) (142)
We considered that it should be possible to condense two pipecolinic acids with 
glyoxal and reduce the resultant product to the aliphatic two carbon chain in situ with 
hydrogen and palladium-carbon, as done previously (Chapter 3). However, this was 
unsuccessful and only starting material was isolated.
Vicinal diamination of ethene using a palladium promoted sequence146 followed 
by oxidation was considered but not attempted due to the complexity of the process.
We chose oxalyl chloride as our coupling agent for ease of use and ready 
availability of the reagent, even if it did add a couple of steps on to our route (Scheme 
23).
Methyl DL-pipecolinate hydrochloride (144) was prepared from pipecolinic acid 
(143) using 2,2-dimethoxypropane and conc. hydrochloric acid. This is an excellent 
method of esterification when the starting acid is highly insoluble. Because the molecule 
is chiral, the protons are diastereotopic and the 2H NMR spectrum was quite complex. 
Five protons appeared as a broad multiplet at 8 1.42-1.77 which corresponds to C-4 and 
C-5 methylenes and one proton of C-3. The other proton of C-3 appeared as a multiplet at 
8 2.16, as these protons are diastereotopic. The methylene protons of C-6 were split into 
two multiplets, one at 8 2.91 and the other at 8 3.31. The methine signal appeared further 
downfield at a shift of 8 3.88 as a doublet of doublets. The 13C NMR spectrum showed 
methylene signals at 8 22.0 and 22.1 corresponding to C-4 and C-5, while C-3 appeared 
at 8 26.5. The other methylene carbon, C-6 had its signal at 8 44.9, quite far downfield 
due to the positive charge on the adjacent nitrogen. The methyl carbon of the ester was at 
8 54.4, close to the methine C-6 carbon at 8 57.6. The one quaternary carbon of the ester 
appeared at 8 171.0. A molecular ion of m/z 143 was observed in the mass spectrum,
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with the largest fragment belonging to m/z 84 which corresponds to loss of the ester 
group.
The key reaction was now to couple two of these molecules together using oxalyl 
chloride. This was achieved in chloroform with two equivalents of triethylamine as a base 
to form the piperidine base in situ and to mop up the hydrochloric acid formed in the 
reaction to minimise ester hydrolysis.
(144)(143) (145)
Scheme 23
The dimer (145) was obtained as a clear oil after purification. The IR spectrum 
showed two carbonyl stretch bands, one at 1739 cm’1 for the ester carbonyl, and one at 
1659 c m 1 for the amide carbonyl. The ^  NMR spectrum revealed a broad multiplet 
between 8 1.20 and 1.82 with an intensity of 10 H, corresponding to the methylene 
protons in the rings not attached to nitrogen. A multiplet at 8 2.25 with intensity 2H was 
attributed to one proton of the methylene (C3) adjacent to the chiral centre as in methyl 
DL-pipecolinate. There were two different signals for the axial and equatorial protons 
next to the nitrogen (C6), one multiplet at 8 2.90 and the other at 8 3.30. The methyl 
protons of the esters occurred as a singlet at 8 3.77. A multiplet at 8 5.26 was assigned to 
the methine protons. This compound is a mixture of a racemate and a meso form, and 
two sets of signals were seen in the 13C NMR spectrum. Four methylene carbons were 
observed in duplicate at ca. 8 21, 25, 26 and 44. These were assigned to C-4, C-5, C-3 
and C-6 respectively. There was only one signal at 8 52.3 due to the methine proton at C- 
2. Two quaternary carbons in duplicate at 8 164.9 and 170.8 correspond to the amide 
carbonyl carbon and the ester carbonyl carbon respectively. In the mass
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spectrum, a small molecular ion was observed at m/z 340. The largest ion was at m/z 142 
which is due to cleavage of an amide bond to leave the pipecolinate ester fragment.
Reduction was now required to produce the desired diol intermediate. It was 
envisaged that we might be able to reduce both the amide and ester in one step with 
Li AIH4 . When this was attempted, instead of reducing the amide to the amine, the amide 
bond was cleaved to produce the original starting material. This happens with some 
secondary amides depending on the reaction conditions. 147 The solution was to reduce 
each functional group in turn, starting with the amide, which could be reduced easily with 
borane, followed by reduction of the ester using LiAIR*.
O
(146)(145)
LiAlH,
Scheme 24 (147)
Reduction of the diamide went smoothly and the free base (146) was obtained in 
good yield as a clear oil. As expected, there was only one carbonyl band in the IR 
spectrum at 1737 cm-1 which corresponded to the ester group. The !H NMR spectrum 
can be seen in Figure 8 . The two methine protons appeared together as one multiplet at 8  
2.16. Multiplets at 8  2.42 and 2.57 of equal intensity was attributed to the axial and 
equatorial protons of C-6 .The slightly less complex signal at 5 3.00 was assigned to the
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linear bridging methylenes protons. Assignment was consistent with literature 
precedence. 167
The 13C NMR spectrum was similar to that of the diamide (145) with the signals in 
duplicate. Again, the iV-methylene signals were distinguishable, with one set apparent at 
8  50.7 and 50.9 while the other set was at 8  53.8 and 54.0. These were assigned for the 
same reasons as above to the cyclic and linear carbons respectively. The methine signals 
had shifted 10 ppm downfield to new positions of 8  65.1 and 65.4, whilst the single 
quaternary carbon appeared at 8  174.1 and 174.2. The parent ion m/z 312 was found as a 
small percentage with the major ion being that of exactly half the molecule with m/z of 
156.
The second reduction, this time with UAIH4 went in high yield to give the diol 
(147) as a thick clear oil. There were no bands in the carbonyl region of the IR spectrum; 
instead, new bands at 3329 and 1284 cm-1 corresponding to OH stretch and OH bend 
had appeared. The major difference in the !H NMR spectrum was the emergence of the 
hydroxymethylene protons, which appeared as two doublet of doublets at 8  3.17 and 
3.85. A broad singlet at 8  4.26 was attributed to the OH proton. The 13C NMR spectrum 
showed no duplication of signals. However the rest of the spectrum was similar to that 
above with the exception of the quaternary carbon of the ester and the addition of the 
hydroxymethylene signal which appeared at 8  63.1. The molecular ion minus one 
hydrogen was found at m/z 255, but again, the major ion was that of half the molecule at 
m/z 128.
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6.4 Synthesis of  N , /V ' - ( l ,2 -E th a n ed iy l )b i s (a m in o ca rb o n y lo x y m eth y I-
piperidines)
After synthesising our key intermediate, we prepared a series of bis-carbamates 
and a dihalogen derivative.
NHR
CHoOH
(147)
RHN
R = 'Pr (148) 
= Et (149) 
= Ph (150)
The bis(isopropylcarbamate) (148) was made in the standard way and was 
obtained as white crystals. Bands at 1684 and 1364 cm-1 were evident in the IR spectrum 
and were due to the carbonyl and isopropyl methyl groups respectively. In the !H NMR 
spectrum the ring methylenes C-3, C-4 and C-5 were grouped together in a complex 
multiplet at 8 1.36-1.74, whilst the methine protons and the C-6 protons were also found 
together as a broad multiplet between 5 2.12 and 2.72. The methylene protons between 
the rings appeared at 8 2.89 as a multiplet and the remaining methylene protons next to 
the carbamate groups came at 8 4.15, also as a multiplet. The peaks corresponding to the
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isopropyl component were found at 8 1.15 and 3.80 as a doublet and multiplet 
respectively. In the mass spectrum, the molecular ion was found at m/z 426 as a small 
percentage with the major ion being the peak at m/z 213 corresponding to half of the 
molecule.
Preparation of the bis(ethylcarbamate) (149) yielded the product as a thick clear 
oil which would not crystallise. Similar spectra to that described for the bis(isopropyl 
carbamate) were obtained, and full characterisation was achieved.
In preparing the bis(phenylcarbamate) (150) problems were encountered with the 
crude phenyl isocyanate and this required distillation before use. This derivative was 
insoluble in dichloromethane and came out of solution during the reaction as a white 
precipitate. After purification, white crystals of the product were obtained. The IR 
spectrum showed the carbonyl stretch to be at 1730 c n r1 with the predictable aromatic 
bands appearing at 1600 and 1538 cm-1. The NMR spectrum, run in d6-acetone, was 
very complex, showing complex multiplets for each group of signals. The 13C NMR 
spectrum was as expected with methylene signals at 8 23.7, 26.0 and 29.4 corresponding 
to the ring methylenes C-3, C-4 and C-5. The methylene carbons next to the nitrogens 
came at 8 52.1 and 53.1 and were assigned to the endocyclic and exocyclic methylenes 
respectively. The signal for the methine protons was obvious at 8 60.3 and the remaining 
methylene carbons next to the carbamates came at 8 66.2. The aromatic methines and 
quaternary carbons appeared at the shifts expected for these groups. No parent ion was 
found in the mass spectrum.
The bis(p-nitrophenyl carbamate) (151) was obtained as yellow crystals after 
column chromatography. The spectra followed a similar pattern to those described for the 
bis(phenylcarbamate).
The dichloro derivative (152) was also synthesised. This compound has been 
made before143 as a precursor to the corresponding primary diamine.
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NH
NH
2 Cl
(152)
The compound was made in the usual manner from the diol with thionyl chloride 
and kept as the dihydrochloride salt for analysis. The IR spectrum showed a band at 746 
cm-1 which was attributed to the C-CI stretch. The NMR spectra were run in D2O and the 
*H NMR spectrum is shown in Figure 9. It shows the usual broad multiplet at 8 1.58- 
1.90 for the ring protons. The methylene and methine protons adjacent to the nitrogen 
also appear as a complex multiplet between 8 3.51-3.81. To either side of this multiplet, 
there are two more smaller multiplets corresponding to the chloromethylene protons 
appearing as they had in the diol. This time, however, it was not possible to distinguish 
the doublets. The 13C NMR spectrum showed a new methylene signal at 8 43.8 
belonging to the carbon adjacent to the chlorine. The highest ion found in the mass 
spectrum was due to loss of one chlorine at m/z 257, while the largest fragment of m/z 
146 corresponded to half the molecule.
The dibromo-derivative was not made because of the problems encountered in 
previous syntheses and the generally poor yielding reactions.
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6.5 Synthesis of A f,iV -(l,2 -E th a n ed iy l)b is(a m in o ca rb o n y lo x y m eth y l-
piperidines) bis-iV-Oxides
The synthesis of the bis-TV-oxides was undertaken as before.
NHRNHR
mCPBA
RHNRHN
R = !Pr (153) 
= Et (154) 
= Ph (155)
The bis(isopropylcarbamate) bis-iV-oxide (153) was produced in this manner to 
afford white crystals after purification. The characteristic band of the A-oxide was at 960 
cm-1 in the IR spectrum. The lH NMR spectrum showed that the signal for the methine 
protons had moved downfield to 8  3.06 as was also true of the methylenes adjacent to the 
nitrogens. Multiplets at 8  3.4 and 3.75 were assigned to the endocyclic and exocyclic 
methylene protons respectively.
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The 13C NMR spectrum also revealed the downfield shift of the methylene groups to 8  
61.4 and 63.2, with the signal for the methine protons at a shift of 8  75.1. No parent ion 
was found in the mass spectrum.
The bis(ethylcarbamate) bis-N-oxide (154) was obtained as white crystals. The 
IR spectrum showed the N-O bond at 964 cm' 1 along with the other expected bands. The 
NMR spectra was similar to that of the bis(isopropyl carbamate). Again, no parent ion 
was found in the mass spectrum.
Both of these compounds take water into their lattices when crystallising and this 
is a feature which has been reported before148 for this type of compound.
The bis(2-phenylcarbamate) bis-N-oxide (155) was also obtained as white 
crystals after purification. A band at 1070 c m 1 in the IR spectrum was attributed to the 
N-O bond. The expected chemical shifts were found in the NMR spectra, following the 
same pattern as before and no parent ion was found in the mass spectrum.
The bis(p-nitrophenylcabamate) bis-N-oxide (156) was recovered as a pale 
yellow solid which could not be crystallised. In the IR spectrum, a band at 1064 cm-1 
was assigned to the N-oxide bond. The NMR data were also consistent with the 
structure.
The bis(chloro) bis-A-oxide (157) was prepared in a similar manner and obtained 
as a yellow oil.
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(157)
The IR spectrum showed the N-O band at 932 cm-1 while the C-Cl band was at 
732 cm*1. In the !H NMR spectrum, the endocyclic methylenes adjacent to the nitrogen 
appeared as a multiplet at 5 3.11 while the exocyclic methylenes, methine protons and 
chloro methylene protons appeared together as one large complex multiplet between 8  
3.28 and 5 4.16. A small molecular ion was found at m/z 324 in the mass spectrum.
6.6 Homologous Analogues
It has been reported that varying the linker length between pyrrolobenzodiazepine 
dimers (158) affects DNA binding affinity, cross-linking efficiency and cytotoxicity. 149
OMe MeO
Compounds with an odd number of methylenes (n = 3 or 5) in the linker showed 
a higher affinity for DNA, enhanced cross-linking efficiency and were more cytotoxic 
compared with compounds with either n = 4 or 6 . These data were consistent with the 
differences in ability of the compounds to stabilise DNA helix-coil transitions.
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This led us to investigate the effect of toxicity of the carbon chain length of our 
bis-piperidine derivatives and it was decided to synthesise compounds with 3 and 4 
carbons between the piperidines. This could be easily achieved using malonyl chloride 
and succinyl chloride respectively in the same manner as before (Scheme 25).
6.7 Synthesis of iV ,A f'-(l,3-Propanediyl)bispiperidines
Starting with methyl DL-pipecolinate hydrochloride (144), the diamide (159) was 
prepared using malonyl dichloride to leave the product as a thick clear oil after column 
chromatography. Again, two carbonyl bands were found in the IR spectrum at 1746 cm-1 
and 1645 cm*1. The NMR spectra were similar to the analogue with a two carbon bridge, 
with the extra methylene group appearing at 8  3.50 and 3.54 as two singlets in the *11 
NMR spectrum. This is due to the presence of a racemate and a mseo form as discussed 
previously. One signal was seen at 8  41.2 in the 13C NMR spectrum. The molecular ion 
m/z 354 was present in the mass spectrum as a small percentage.
This diamide was reduced in turn with borane to give the tertiary amine (160) 
which was isolated as a clear oil. The !H NMR spectrum showed the axial and equatorial 
protons of C- 6  at 8  2.34-2.73 as a broad multiplet, with the exocyclic methylene protons 
next to the nitrogen appearing between 8  2.90 and 3.10. As before there were two sets of 
signals in the 13C NMR spectrum corresponding to the presence of the racemate and 
meso forms. Reduction of the diester with LiAHTj. produced the diol (161) as a clear oil. 
The hydroxymethylene protons were apparent at 8  3.70 in the !H NMR spectrum, and 
the corresponding signal in the 13C NMR spectrum appeared at 8  63.0.
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YYNH
(144)
n = 1 (159) 
= 2 (168)
BH
n = 1 (161) 
= 2 (170)
n = 1 (160) 
= 2 (169)Scheme 25
This time, only two bis-carbamates, the phenyl and p-nitrophenyl were 
synthesised as it was felt that only two were necessary to compare toxicities. The 
bis(phenyl carbamate) (162) was isolated as a white solid and had bands in the IR 
spectrum at 1600, 1538, 753 and 693 c m 1 which are all indicative of a phenyl ring. A 
signal at 6  4.22 in the NMR spectrum corresponded to the methylene protons adjacent 
to the newly formed carbamate. Similar spectra was observed for the bis(p-nitrophenyl 
carbamate) (163) compound. Signals at 6  118.4 and 125.5 in the 13C NMR spectrum 
corresponded to the aromatic methine carbons. Quaternary signals at 6  143.1, 146.3 and
154.0 were attributed to CNH, CNO2 and C=0 respectively. The dichloro derivative 
(164) was also made and was obtained as a clear oil. The spectra of this compound were 
similar to those of the diol (161), with the exception of the 13C NMR spectrum in which 
the chloromethylene carbon appeared at 6  43.3.
Formation of the bis-A-oxides proceeded in an analogous manner as before using 
mCPBA. The bis(phenyl carbamate) bis-A-oxide (165) was obtained as a white solid. 
The IR spectrum showed the N-O stretch band at 694 cm-1 and the signals corresponding
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to the methylenes next to the A-oxides were all shifted downfield as expected. Formation 
of the bis(p-nitrophenyl carbamate) bis-A-oxide (166) went smoothly in reasonable yield. 
The NMR spectrum was rather complex consisting of large multiplets. The 13C NMR 
spectrum was clearer and showed signals at 6  64.9 and 65.2 for the methylene carbons 
adjacent to the A-oxides. The bis-chloro bis-A-oxide (167) was isolated as a yellow oil 
and showed a signal at 5 41.1 for the chloromethylene carbon. The methine carbons 
appeared at 6  72.5 which is consistent with the series of compounds.
6.8 Synthesis of AT,W -(1,4-Butanediyl)bispiperidines
Succinyl chloride was reacted with methyl DL-picolinate to produce the system 
with a four carbon bridge. This diamide (168) was isolated as white crystals after 
purification and full characterisation was obtained. The exocyclic methylenes occurred as 
a broad multiplet at 6  2.55-2.90 in the NMR spectrum, while in the 13C NMR 
spectrum the corresponding signal came at a higher shift than before at 6  28.2 which is 
consistent with the theoretical calculated value.
Reduction of the diamide with borane furnished the diamine (169). Unlike the 
corresponding C2 and C3 bridged compounds there was only one set of signals in the 
13C NMR spectrum. Reduction of this amine diester with LiAlfit furnished the diol 
(170) as a white solid. Characteristic OH bands were found in the IR spectrum at 3126 
and 1374 cm-1. The !H NMR spectrum showed a large multiplet at 6  1.07-1.56 
corresponding to the alkyl methylenes of the piperidine rings and the central protons in 
the bridge. The endocyclic N-CH2 protons and methine protons came together as a 
multiplet between 8  2.02 and 2.32, whereas the exocyclic N-CH2 protons appeared 
further downfield as a multiplet at 8  2.65. The hydroxymethyl protons were also a 
multiplet and appeared at 8  3.27-3.53. A broad singlet at 8  3.67 was attributed to the OH 
signal. Signals at 8  23.3, 23.5, 24.6 and 27.8 in the 13C NMR spectrum corresponding 
to the methylenes not connected to nitrogen were not assigned specifically.
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Again, the two aromatic bis-carbamates and the dichloro compound were the only 
derivatives to be synthesised. The bis(phenylcarbamate) (171) was obtained as a white 
solid which had all the expected bands in its IR spectrum, such as the carbonyl stretch at 
1702 cm ' 1 and the strong mono-substituted aromatic bands at 751 and 6 8 8  c m 1. The *H 
NMR spectrum was again quite complex with a multiplet between 8  1.25 and 1.66 
corresponding to the methylene protons not attached to nitrogen. The methine protons 
appeared at 8  2.20 with the endocyclic N-CH2 groups at 8  2.45 and the exocyclic N-CH2 
protons at 8  2.80, all of which were complex multiplets. The aromatic protons were 
distinguishable from each other, with the para-protons appearing at 8  7.06, the ortho­
protons at 8  7.27 and the meta-protons at 8  7.38, again, all of which were multiplets. The 
13C NMR spectrum is shown in Figure 10 and shows methylene carbons at 8  52.1 and 
53.6 corresponding to the endocyclic and exocyclic N-CH2 carbons respectively. The 
methine signal appears at 8  59.4 and the methylenes next to the carbamates occur at 8  
65.9. The two quaternary carbons at 8  137.9 and 153.7 correspond to the phenyl carbons 
and the carbamate carbons respectively. The mass spectrum showed no parent ion but 
many fragments.
RNCO
/ = °
RHN
NHRn = 1 (161) 
= 2 (170)
n = 2
R = Ph (171)R = Ph (162)
NO
(163)
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The bis(p-nitrophenylcarbamate) (172) was obtained as a yellow solid and gave 
spectra similar to that of the phenyl derivative. Bands at 1737, 1552, 1509 and 852 cm-1 
in the IR spectrum were all indicative of the compound. Once more, a large mutiplet in 
the ,H NMR spectrum at 8  1.17-1.46 contained the signals of the methylenes not 
attached to the nitrogens. This spectrum is shown in Figure 11. The endo- and exo­
cyclic N -methylene protons appeared at 8  2.40 and 2.75 respectively. The 13C NMR 
spectrum showed the methine signal at 8  60.0 and the methylene next to the carbamate at 
8  6 6 .6 . The aromatic methine carbons came at 8  118.4 and 125.6 while the three 
quaternary carbons had signals at 8  143.1, 146.4 and 154.1, belonging to CNH, CNO2 
and C =0 respectively.
The dichloro derivative (173) was made using thionyl chloride and was obtained 
as a clear oil. The spectra obtained were all consistent with the structure, with the C-Cl 
stretch appearing at 738 cm-1 in the IR spectrum and the methylenes adjacent to the 
chlorines appearing at 8  45.2 in the 13C NMR spectrum.
SOC1
n = 1 (164) 
= 2 (173)
n = 1 (161) 
= 2 (170)
Bis-W-oxide formation was achieved in the same manner as before and full 
characterisation was obtained for each of the compounds.
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mCPBA
RHN RHNNHR NHR
n = 2
R = Ph (174)R = Ph (165)
NONO
(175)
The bis(p-nitrophenyl carbamate) bis-N-oxide (175) was obtained as a pale 
yellow solid. In the IR spectrum, the band at 1070 cm*1 was attributed to the N-oxide. 
The JH NMR spectrum showed the expected shifts of the methylenes adjacent to the 
nitrogen and these appeared together as a broad multiplet at 8  3.42-3.85. The methine 
protons had shifted downfield to 8  4.15 as a complex multiplet, with the methylene 
protons next to the carbamate appearing at 8  4.60, also as a complex multiplet. Signals in 
the 13C NMR spectrum at 8  63.8 and 64.8 were assigned to the endo- and exo-cyclic 
methylenes adjacent to the nitrogen respectively. The methine signal had also shifted to 8  
72.3 as expected.
The bis-chloro bis-N-oxide (176) was obtained as a yellow oil after 
chromatography.
I l l
n = 1 (164) 
= 2 (173) n = 1 (167) = 2 (176)
The IR spectrum showed bands at 977 and 718 c m 1 which were attributed to the 
AMD and C-Cl stretch. In the NMR spectrum, a large multiplet from 8  1.63 to 2.10 
corresponded to the exocyclic and endocyclic protons not attached to nitrogen. A 
multiplet at 8  2.71 of intensity integrating for two protons corresponded to the methine 
protons adjacent to the Af-oxides. The methylene groups next to the positive nitrogens 
appeared at 8  3.74 to 4.20 as a broad multiplet, with the methylenes next to the chlorines 
occurring at 8  4.43-4.84, also as a multiplet. The 13C NMR followed the same pattern as 
seen before. M + (m/z 353), was not found in the mass spectrum, the heaviest fragment 
being loss of a chloromethylene group and an oxygen.
6.9 Conclusions
A new series of disubstituted bis-piperidine derivatives with corresponding bis- 
A-ox ides have been prepared and characterised from a general route. These compounds 
are a 1:1 mixture of a racemate and meso form as shown by the 13C NMR spectra. The 
biological testing results for these compounds are presented in Chapter 8 .
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Chapter 7
Synthesis of Cobalt (III) Complexes containing Amines
7.1 Introduction
Complexes of many transition metals have demonstrated cytotoxicity in cell 
culture and/or antitumour activity in tumour-bearing animals. 150 Only complexes of 
platinum, however, are currently in routine clinical use. 151 A wide variety of metal 
complexes have also been shown to be radiation-sensitisers of mammalian and/or 
bacterial cells. These include complexes of Ag(I), Cu(I), Cu(II), Zn(II), Rh(II), Pt(II), 
Co(in) and Fe(III) . 152
Co(in) forms kinetically inert octahedral coordination complexes. This inertness 
is due to the d6 low spin electron configuration of trivalent cobalt. 153 Kinetically inert 
transition metal complexes (e.g. Rh(III) and Cr(III)) undergo the water exchange reaction 
relatively slowly, with half-lives of about 1 day. 154 By contrast, complexes of kinetically 
labile metal ions (e.g. Mn(II), Cr(II)) undergo this reaction with half-lives of less than 1 
second . 154 The biological consequence of kinetic inertness is that many Co(III) 
complexes will remain intact when added to a culture medium or injected into animals and 
should arrive at their cellular targets with their ligand configuration intact.
Cobalt is known to form stable octahedral Co(III) complexes with a range of 
electron-donating ligands (L), including both aromatic and aliphatic amines. The 
reduction potentials of the Co(III)/Co(II) couple in these amine complexes fall within an 
appropriate range (-650 to +280 mV) 155 so that one-electron bioreduction to the Co(II) 
species Co(II)L6 is possible. This reduction labilises the ligands enormously, and in 
aqueous conditions they are normally rapidly lost by water displacement to give the 
Co(II)(H20 ) 6 ion (Scheme 26).
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While this overall process is essentially irreversible, kinetically rapid oxidation of 
the transient Co(II)L6 intermediate by molecular oxygen can occur156 to regenerate the 
parent Co(III) complex.
One-electron reduction of Co(III) complexes could therefore, in principle, be used 
to trigger the oxygen-inhibited release of attached amine ligands. If these ligands were 
aliphatic nitrogen mustards, the resulting complexes would be potential bioreducible 
drugs. Donation of the nitrogen lone pair to the metal on complexation greatly lowers the 
nucleophilic character, and so stabilises the mustard. Following one electron reduction, 
the potent aliphatic nitrogen mustards would be released.
A number of Co(III) complexes of the monodentate monoalkylating agent 
aziridine are known, containing up to four aziridines.71 The strained, three-membered 
heterocycle is a highly reactive molecule that readily undergoes ring-opening reactions, 
particularly under acid conditions. However, once coordinated to an inert metal such as 
Co(III), the reactivity of aziridine toward nucleophiles is much diminished and the 
heterocycle is stabilised with respect to ring-opening reactions. Free aziridine is a potent 
alkylating agent and is active towards substrates such as DNA and aziridine groups are 
present in a number of anticancer agents.157 A Co(III) complex of the monodentate 
bisalkylating agent bis(2-chloroethyl)amine (177) has also recently been prepared but, 
like the aziridine complexes (53), is not selective for hypoxic cells as a cytotoxin.158 The 
reason for this is probably that the corresponding Co(II) complexes are not sufficiently 
stable to allow reoxidation by molecular oxygen to compete with ligand release. This
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means that the toxicity towards normal cells is increased and so selectivity between oxic 
and hypoxic cells is decreased.
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Since the kinetic stability of metal complexes is greatly increased if chelating 
ligands are used, 159 a series of Co(III) complexes containing the bidentate bisalkylating 
nitrogen mustards (178) and (179) have been prepared. 14
H
N .Cl
c r  n
(178) H
h 2n   ^ci
(179) Cl
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T
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Complexes of the unsymmetrical mustard (180) have reduction potentials in the 
range of -300 to -450 mV and show hypoxic selectivity in a range of cell lines. The 
complex (180) has 20- to 30-fold selectivity for hypoxic cells and is currently undergoing
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investigation in vivo as the lead compound of this class. The reduction potentials of metal 
complexes are modulated by the nature of the ligands; thus complexes of the symmetrical 
mustard have potentials ca . 125 mV lower than the corresponding complexes of the 
unsymmetrical mustard. The use of 3-alkylpentane-2,4-dionato auxiliary ligands also 
allows some variation in reduction potentials. 160
The work done to date suggests that use of deactivated mustards in a cobalt 
complex is a viable design for bioreducible drugs. Advantages include the fact that 
reductive activation is necessarily a one-electron process and that the pharmacology of the 
released nitrogen mustard is well understood. It was therefore decided that a range of 
diamines, triamines and tetraamines would be synthesised and their complexation to 
Co(HI) would be attempted.
7.2 Synthesis o f N , A - B i s ( 2 - c h I o r o e t h y I ) e t h a n e - 1 , 2 - d i a m i n e  
Dihydrochloride (185)
In order to provide a reference compound for our own complexes, it was decided 
to remake the cobalt complex which Ware et a / . 160 reported had significant hypoxic 
selectivity. This ligand has been reported before161 and the synthesis can be seen in 
Scheme 27. A-Acetylethylenediamine (182) was prepared by selective monoacetylation 
using pig pancreatic lipase, ethylenediamine (181) and ethyl acetate in a shaking bath at 
37 °C for three days. This oil was then treated with excess ethylene oxide in distilled 
methanol to produce the diol (183)162 as a thick oil. This was deacetylated with 
concentrated HC1 after five hours at reflux to give the salt (184). However, this 
compound was isolated as a dark brown oil which could not be crystallised or purified. 
Even after making the free base using sodium bicarbonate, it was impossible to rid the 
compound of its colour. Activated charcoal had little effect and column chromatography 
was impossible due to the polar nature of the compound. As the NMR spectra indicated 
that it was the right compound, it was decided to try the next step of chlorination but the 
free base would not dissolve in thionyl chloride so no reaction could take place.
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Deacetylation was tried using sodium hydroxide to see if a cleaner diamine could be 
obtained, but even after 72 hours heating at reflux, the reaction had not gone to 
completion. This method was therefore abandoned. What was needed was a different 
type of protecting group which could be removed easily and cleanly.
NHCOCHNH NHCOCH3 O 
NH, Me° H
PPL
OHEtOAcNH
(181) (182)
(183)
OH
c.HCl
NaHCO
NH NH
SOC1
OH
.2HC1
(184)(185)
Scheme 27 OH
It was decided to use a BOC protecting group as these usually give crystalline 
solids and are easily removed under mild acidic conditions. The second synthesis can be 
seen in Scheme 28. We chose to use [2 -(r-b u to x y carb o n y lo x y im in o )-2 - 
phenylacetonitrile] (commonly referred to as BOC-ON) as this is specially meant for use 
with amino acids, since our starting material was to be glycine (186). The BOC 
protection went easily in high yield and the product (187) was obtained as white crystals. 
The amide (188) was prepared by means of a mixed anhydride using /-butyl 
chloroformate followed by excess ammonia gas.
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NH;
Et3N
CO H Dioxane/H2 0
BOC-ON
(186)
c h 3c n
Et3N ,
i-Butyl chloroformate 
NH,
NH
1. 3M HC1
NH NH2. NaHCO
(189)
(188)
OH OH
BH,-THF
OH OH
NH (192)
TBDMSiCl
Imidazole
DMF
SOC1BH,-THF
OTBDMS
OTBDMS NH
NH
(191)
Scheme 28
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Deprotection of the amine using aqueous acid went in high yield but it was 
difficult to obtain the free base as the polarity of this compound made it impossible to 
extract into organic solvents. Eventually, addition of sodium bicarbonate followed by 
extracting repeatedly with methanol furnished the amine (189) as a clear oil. Treatment of 
this with ethylene oxide as before gave the diol (190) as a very thick oil, which, again, 
was totally insoluble in all organic solvents except methanol. This led to problems in the 
next step which was supposed to be reduction of the amide with borane, as the oil would 
not dissolve in THF. An extra protection step was necessary in order to render the 
compound more soluble in THF. A TBDMS group was chosen to decrease the polarity 
caused by the hydroxyl groups, as these were the main problem with solubility. TBDMS 
was also a good choice as it could be removed in the acid work-up of the borane 
reduction. This protected diol (191) was obtained in reasonable yield and only the final 
step was required. However, as before, the diol (192) was obtained as a thick oil which 
would not dissolve in thionyl chloride even with heat over long periods of time. It was 
apparent that replacement of the hydroxyls with chlorines in order to improve the polarity 
was of vital importance in making these compounds. As the above route was getting 
rather long and arduous with its own share of problems, a third route was sought. The 
one we eventually chose involved avoiding the diol completely. Based on the above 
method, it involved simply using the nitrogen mustard (193) itself in the mixed anhydride 
reaction instead of ammonia. This meant we had shortened the route considerably and 
removed purification problems encountered with the polar diols. The synthesis can be 
seen in Scheme 29.
The BOC-protected amino acid (187) had characteristic acid bands at 1749 and 
1669 cm*1 with the amide band at 1540 cm-1. ]H NMR spectroscopy showed a large 
singlet at 6  1.45 corresponding to the tertiary butyl methyl protons. The methylene 
protons appeared as a doublet at 8  3.91 with the amide proton as a triplet at 8  5.40. A 
broad singlet at 8  11.08 was attributed to the carboxylic acid proton. The 13C NMR 
spectrum had the methyl carbons at 8  28.2 and the methylene carbon at 8  42.1. The three 
quaternary carbons were spread out, with the tertiary butyl carbon appearing at 8  80.3,
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the carbamate carbonyl carbon at 8 156.1 and the acid carbonyl carbon at 8 173.9. No 
molecular ion was found in the mass spectrum, as the tertiary butyl group did not survive 
the bombardment.
NH
Et3N
CO H Dioxane/H^O
BOC-ON
n = 1 (187) 
= 2 (199)n = 1 (186) 
= 2 (198)
CH3CN
Et3N ,
i-Butyl chloroformate
NH.
(193)
TFA
NH
NH3 C F 3C O
n = 1 (195) 
=  2 (201) BH.-THF n = 1 (194) 
=  2 (200)
NH
n =1 (185) 
=  2 (202)2C1
NH
Scheme 29
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The reaction between the mixed anhydride and bis(2-chloroethyl)amine 
hydrochloride (193) was an unpredictable one as it was necessary to ensure that all the 
chloroformate had reacted with the acid. If the amine was added too quickly to the 
mixture, the chloroformate would react with that instead. Alternatively, if the 
chloroformate was left to react for too long, it would give a brown mess. The addition of 
triethylamine was also found to be important for the success of the reactions. Two 
equivalents are required, one for the removal of the acid proton and the other to form the 
free base of the amine. It was found that if all the base was added initially to the acid 
(187) before addition of the chloroformate, the chloroformate did not react as well with 
the acid, presumably due to the competing reaction of the tertiary amine. So addition of 
one equivalent before addition of the chlorofomate and addition of the other after the 
amine hydrochloride so that the free base could react immediately with the mixed 
anhydride led to suppression of the side products and the amide (194) could be isolated in 
a pure state as a thick clear oil in good yield. Carbamate carbonyl stretch for the amide 
(194) was apparent in the IR spectrum at 1751 c m 1 and the amide carbonyl band came at 
1702 c m 1. A medium band at 700 c n r1 was attributed to the C-Cl stretch. In the 
NMR spectrum (Figure 12) the methylenes of the chloroethyl mustard all appeared 
together as a triplet at 8 3.69 with the glycine methylene coming at 8 4.05. The carbamate 
proton was apparent as a triplet at 8 5.61. The 13C NMR spectrum had three methylene 
carbon signals, at 8 41.1, 43.6 and 49.5, which were attributed to CH2-CI, NRCH2 and 
COCH2 respectively. The newly formed amide carbonyl signal appeared at 8 169.3. The 
molecular ion minus one chlorine was found at m/z 263 in the mass spectrum.
Deprotection of the BOC-protected amide (194) was attempted using aqueous 
acid. This went easily within an hour but difficulties were encountered in isolating the 
free base. So, alternatively, trifluoroacetic acid in dichloromethane was used to remove 
the BOC group and the product was obtained as the salt after triturating with diethyl 
ether. This gave the trifluroacetate salt (195) as white crystals. The amide carbonyl stretch 
band appeared at 1685 cn r1 with a signal at 722 cm*1 attributed to the C-Cl bond. The ^  
NMR spectrum showed three multiplets of intensity 4 : 4 : 2 at 8 3.39, 3.74 and 4.44.
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Figure 12
These signals were assigned to RNCH2 , CH2CI and COCH2 respectively. The 13C 
NMR spectrum showed signals for each carbon present, two signals at 8 39.9 and 40.9 
for the methylenes adjacent to the chlorine and two signals at 8 46.8 and 49.8 for the 
methylenes next to the amide. It was assumed that this was because the n  bonding 
between the nitrogen atom and the carbonyl carbon slows the rotation about this bond, as 
is seen in spectra of dimethylformamide (discussed previously in Chapter 3). The 
molecular ion was found at m/z 198 in the mass spectrum.
The final step involved reduction of the amide bond with borane. The 
trifluoroacetate salt (195) was used directly so excess borane was required as the acetate 
group would be reduced in preference to the amide group. This was indeed the case as 
the salt could be seen to dissolve in the THF minutes after addition of the borane. After 
acidic work-up, 7V,N-bis(2-chIoroethyl)ethane- 1,2-diamine (185) was obtained as the 
dihydrochloride salt in a crystalline form. The NMR spectrum again showed three 
multiplets, this time with intensities 2 : 6 : 4 .  This corresponded to the methylene next to 
the primary amine at 8 3.40, the three methylenes adjacent to the tertiary nitrogen at 8 
3.62 and the remaining methylenes next to the chlorines appearing at 8 3.88. This is 
consistent with the values reported previously.160 The 13C NMR spectrum had four 
signals in it, one at 8 36.0 corresponding to the methylene adjacent to the primary amine 
and one at 8 39.7 corresponding to the chloromethylenes. The signal at 8 52.4 was 
assigned to the single methylene CH2NR2 whilst the one at 8 57.4 was attributed to the 
remaining two methylenes of the tertiary nitrogen, as indicated by the intensities of the 
signals. No molecular ion was found in the mass spectrum, but the largest fragment at 
m/z 154 belonged to an ion with loss of CH2NH2.
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7.3 Synthesis o f N,  N ' - b i s ( 2 - c h I o r o e t h y l ) e t h a n e - l , 2 - d i a m i n e
Dihydrochloride (197)
This ligand had also been reported by Ware et al. and was made by us for 
comparison. This was very easily made163 by direct chlorination of the commercially 
available N,Af-bis(2-hydroxyethyl)ethane- 1,2-diamine) (196) using thionyl chloride.
OH
SOCl2 2 Cl
OH
(196) (197)
The IR spectrum of the dihydrochloride (197) showed bands at 2924 and 2770 
c n r1 corresponding to CH stretch and N-CH stretch. A band at 773 cm-1 was attributed 
to the C-Cl stretch. In the *H NMR spectrum, a singlet at 6 3.49 was surrounded by two 
multiplets at 8 3.23 and 3.80, all of equal intensity. The chloromethylenes were assigned 
the shift at 8 3.80 and the p-chloromethylenes the signal at 8 3.23 as it was obvious that 
these signals were coupled to each other. This left the singlet at 8 3.49 to which the 
remaining methylenes were assigned. The 13C NMR spectrum showed three signals. The 
signal at 8 43.9 was assigned to the chloromethylene carbons, with the signal at 8 50.6 
corresponding to the CH2NHR methylenes. The remaining signal at 8 57.4 was 
attributed to the p-chloromethylene carbons. The highest peak in the mass spectrum at 
m/z 149 was due to loss of a chlorine atom from the parent compound.
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7.4 Synthesis of A , A - B i s ( 2 - c h l o r o e t h y l ) p r o p a n e - l , 3 - d i a m i n e
Dihydrochloride (202)
This higher homologue was also made in an attempt to see if a five or six 
membered ring would be more stable in the complex with cobalt, which would then have 
implications for the release of the ligand and therefore selectivity.
NHNH
2C1
(202)
This ligand was made in exactly the same way as before (Scheme 29), but starting 
with (3-alanine (198). BOC protection to give (199) was achieved as before and this was 
followed by amide (200) formation via the mixed anhydride. Deprotection using TFA 
afforded the salt (201) and this time the free base was isolated as a clear oil. The amide 
carbonyl band appeared at 1682 cn r1 with the C-Cl band appearing at 722 cm-1. The *H 
NMR spectrum showed a large multiplet at 8 3.70 which corresponded to all the 
methylenes except for the methylene adjacent to the carbonyl, which appeared as a triplet 
at 5 4.37. The 13C NMR spectrum showed signals at 8 41.7, 45.2 and 45.9 which 
corresponded to the chloromethylenes, the methylene next to the primary amine and the 
methylenes adjacent to the tertiary amine, respectively. Another methylene signal at 8
62.0 was assigned to the carbon next to the carbonyl and the quaternary carbon of the 
carbonyl itself appeared at 8 158.3. No parent ion was found in the mass spectrum, but 
there was a signal at m/z 178 which corresponded to loss of one chlorine atom.
Reduction of the amide with borane gave the diamine (202) as the dihydrochloride 
salt. The *H NMR spectrum had a multiplet at 8 1.80 which corresponded to the 
methylene protons not attached to either nitrogen. Four multiplets at 5 3.07, 3.25, 3.53 
and 3.67 corresponded to those methylenes which were attached to the nitrogens. It was
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assumed that the protons p to the chlorines would appear further downfield than those 
further away from their influence. The chloromethylenes appeared at 8 3.93, also as a 
multiplet.
7.5 Synthesis of a Triamine Ligand
It seemed reasonable to expect that a triamine would have a different binding 
ability in comparison to a diamine and as this is of fundamental importance in achieving 
selectivity, a triamine was chosen to test this hypothesis.
The synthesis is shown in Scheme 30. We started with the commercially available 
iminodiacetic acid (203) and protected the amine with BOC-ON. The yield of this reaction 
was very poor for a BOC protection, because isolation of the product was difficult due to 
the poor solubility of this compound (204) in organic solvents.
Reaction with the mixed anhydride gave the diamide (205) as a thick clear oil. 
Bands at 1755 and 1698 cm-1 in the IR spectrum corresponded to the carbamate carbonyl 
and the amide carbonyl respectively, with the signal at 733 c n r1 attributed to the C-Cl 
stretch. In the NMR spectrum, the singlet at 8 1.36 corresponded to the tertiary butyl 
protons. Multiplets at 8 3.43 and 3.83 of equal intensity were assigned to the P 
chloromethylene protons and the chloromethylene protons respectively. The methylenes 
adjacent to the carbonyls appeared at 8 4.23 as a singlet.
Treatment with TFA followed by basification yielded the diamide (206) as a thick 
clear oil. The 1H NMR spectrum simply had a multiplet for the mustard methylene 
protons at 8 3.72 and the methylenes adjacent to the carbonyls appeared as a doublet at 8 
4.34. A broad singlet at 8 9.87 was attributed to the secondary amine proton. In the 13C 
NMR spectrum, signals due to the chloromethylene carbons came at 8 41.2 and 41.4. 
There were four signals due to the methylenes p to the chlorines at shifts of 8 48.8, 48.9, 
49.8 and 49.9. The methylene carbon adjacent to the secondary amine was further 
downfield at 8 72.3. Two signals were seen for the carbonyl carbons, one at 8 169.0 and 
the other at 8 169.5.
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(205)
Borane
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3C1 (207)
Scheme 30
Reduction of the diamide (206) to the triamine (207) using borane went smoothly 
to leave the trihydrochloride salt as white crystals. The *H NMR spectrum consisted of 
three multiplets of relative intensity 1 : 3 : 2 .  This corresponded to the methylenes 
adjacent to the secondary amine at 8 3.05, with the methylene protons next to the tertiary
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amines coming in a large multiplet at 8  3.33-3.54. The chloromethylene protons appeared 
at a shift of 8  3.68. The ,3C NMR spectrum was similar to those of the diamines. A 
molecular ion was observed at m/z 354 but the compound was too involatile for an 
accurate mass measurement to be obtained.
7.6 Synthesis of a Tetraamine Ligand
Polyamines have been used to target anticancer agents to DNA164 because of two 
special features: 165 (i) the nature of their interaction with DNA, and (ii) the existence of 
an active uptake system for polyamines in a variety of cell types. Conjugation of a drug to 
a polyammonium cation will confer a high DNA affinity with mobility to allow drugs 
with high specificity to locate appropriate sites on DNA. If a polyamine could be 
combined with a cytotoxic part, then these compounds would be expected to target DNA. 
If these compounds could be further complexed to cobalt, then more selectivity could be 
achieved. It has been reported that the tetraamine, spermine has been complexed 
successfully to cobalt, 166 so we considered it desirable to make a tetraamine with 
nitrogen mustards incorporated that could be complexed to cobalt.
The most simple tetraamine to synthesise was a dimer of the diamine. Two of 
these molecules can be coupled together using oxalyl chloride and the amide (195) to give 
a symmetrical tetraamide (208), with each nitrogen linked by a two carbon chain. It was 
decided to use the trifluoroacetate of (195) as the precursor as then only one reduction of 
the compound (208) would be necessary (Scheme 31).
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The tetraamide (208) was made from the trifluoroacetate salt (195) and the free 
base was made in situ with triethylamine. Oxalyl chloride was added to form the 
tetraamide which was isolated as a clear oil. Three carbonyl stretches were observed in 
the IR spectrum, at 1732 c n r 1 for the tertiary amides and at 1682 and 1514 cm*1 for the 
secondary amides. The lH NMR spectrum was relatively simple with a large multiplet at 
8  3.76 for the mustard methylene protons and a smaller multiplet at 8  4.27 for the 
methylenes next to the secondary amines. A broad singlet was observed at 8  7.69 which 
was assigned to the NH protons. Duplicate signals were seen in the 13C NMR spectrum 
for the methylene carbons adjacent to the chlorines with signals at 8  41.0, 41.1,41.2 and 
41.4. Only two signals were seen for the corresponding p-methylenes but with twice the 
intensity at 8  48.5 and 49.5. The methylene carbons adjacent to the carbonyls appeared as 
one signal at 8  63.4. Again, four signals were seen for the quaternary carbons, two at 8
156.6 and 159.7 which were assigned to the tertiary amides, and two at 8  167.4 and
167.9 which were attributed to the secondary amides. A large fragment corresponding to 
half the molecule at m/z 227 was found in the mass spectrum but there was no peak at 
m/z 454.
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This tetraamide (208) was then subjected to reduction by borane which after 
acidic work up yielded the tetrahydrochloride salt (209). In the NMR spectrum, 
multiplets were observed for each set of signals. The methylene protons at C-3 and C-4 
appeared at 8  3.04, while the protons on C-2 and C-5 were observed at 8  3.27. The 
methylene protons adjacent to the tertiary nitrogens all came together in a multiplet at 8  
3.65 and the chloromethylenes were furthest downfield at a shift of 8  3.86. No parent ion 
was found in the mass spectrum, but a signal at m/z 322 corresponded to loss of two 
chlorine atoms.
7.7 Miscellaneous Diamines
It has been reported167 that N,N1'-linked pipecolinic acids (210) can be chelated to 
nickel(II) to give stable complexes.
(210)
These ligands contain four potential coordinating centres. The system with a C2 bridge 
produces a highly stable complex. This is attributed to its ability to form a planar chelate 
with three fused rings. Extension of the N,Af'-bridge by one methylene group causes a 
sharp decrease in the ability to form a chelate, presumably reflecting the lower stability of 
a six-membered chelate ring. However, the longer the methylene bridge, the more 
tolerable the steric interference.
This led us to think it might be possible to complex our bis-piperidine systems to 
cobalt(III). The dichloro derivative was chosen to minimise steric interference and
130
attempts were made to prepare all three cobalt complexes containing (152), (164) and 
(173).
(152) n=l 
(164) n=2 
(173) n=3
7.8 Synthesis of the Cobalt(III) Precursor Complex
Most Co(ni) complexes undergo very slow substitution at the inert metal centre, 
rendering the synthesis of complexes containing very reactive ligands difficult. The 
preparation of the Co(III) complexes of the bidentate mustards required a cobalt-1 igand 
system which undergoes relatively rapid substitution at Co(III), since the nitrogen 
mustards are unstable when in the required free base form. A suitable cobalt(III) 
precursor is fra/i.s-Na[Co(3-Meacac)2(N02)2] (213) (acac = pentane-2,4-dionato anion) 
which can be prepared by treatment of Na3[Co(NC>2)6] (212) with Na[Meacac] (Scheme 
32).
NO NO
NO
NO
(211) NO NO
(213)(212)
Scheme 32
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Sodium hexanitrocobaltate (III) (212) was made from cobalt nitrate (211) by a 
literature preparation, 168 by reacting cobalt(III) nitrate with sodium nitrite in aqueous 
acidic conditions with a stream of air passing through the solution. This compound was 
obtained as a yellow powder in good yield. This was converted into sodium dinitro- 
bis(3-methyl-acetylacetonato) cobaltate (213) by treating with 3-methylacetylacetone in 
base following a general procedure by Boucher and Bailar. 169 This compound was 
obtained as fine red-brown crystals which are slightly paramagnetic and are soluble in 
water and methanol. In the IR spectrum, signals at 1359 and 1298 cm -1 indicated the 
presence of nitro groups, whilst the carbonyl stretch band appeared at 1562 cm-1. The 
signals in the !H NMR spectrum were present as singlets at 8  1.90 and 2.22 
corresponding to the p methyl group and a  methyl groups respectively. In the 13C NMR 
spectrum, the signals appeared at 8  15.4 and 26.3 and were attributed to CCH3 and 
COCH3 as before. Quaternary signals at 8  100.0 and 187.4 corresponded to the CCH3 
and COCH3 carbons and this is in accordance with literature precedence. 160
7.9 Complexation of the Ligands to Cobalt
Procedures for the synthesis of the known complexes were taken from the 
literature. 160 The basic method involves dissolving the cobalt precursor in a 1:1 mixture 
of water and methanol, followed by addition of activated charcoal. An equimolar amount 
of diamine salt was then added with the careful addition of a slight excess of base next. 
The mixture was stirred for one hour before isolation of the complex by addition of 
ammonium hexafluorophosphate was permitted. In this manner, isolation of a number of 
complexes was accomplished although the yields were very poor after recrystallisation. 
The best yield came from the symmetrical mustard (197) and this is thought to be due to 
the greater stability of this ligand in comparison to the unsymmetrical mustards. 160
Bis(3-methyl-2,4-pentanedionato)[AT,Af-bis(2-chloroethyl)ethane-l,2-diamine]- 
cobalt(III) hexafluorophosphate (214) was isolated as green crystals in poor yield. Bands 
at 2926 and 1569 c n r 1 indicated the presence of aliphatic chains and carbonyl groups
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respectively. The band at 843 c n r1 was assigned to P-F stretch and the band at 737 cm*1 
to C-Cl stretch. In the *H NMR spectrum, there were four singlets present for the four 
CH 3CO methyl groups at 5 1.86, 1.92, 1.96 and 2.07. The remaining CCH3 methyl 
groups appeared as two singlets slightly further downfield at 8  2.23 and 2.32. The 
multiplet at 8  2.70 of intensity two was assigned to the CH2NR2 methylene protons, 
whilst the adjacent CH2NH2 protons appeared at 8  3.84. This is in line with literature 
reports . 160 The remaining (3-chloromethylene protons appeared at 8  2.97 with the 
chloromethylene protons themselves showing at 8  3.62. A broad singlet at 8  4.06 was 
assigned to the amino protons. The 13C NMR spectrum had two signals for the CCH3 
methyl carbons at 8  14.6 and 14.9. For the COCH3 methyl carbons there were again four 
signals ranging from 8  25.6 to 26.4. Two signals were also apparent for the 
chloromethylene carbons, appearing at 8  36.0 and 38.2, as was true of the 0- 
chloromethylene carbons which came at 8  53.5 and 55.7. One signal was present for the 
CH2NH2 carbon at 8  41.7 and one for the CH2NR2 which appeared at 8  61.0. Signals at 
8  102.1 and 103.9 were assigned to the quaternary carbon CCH3 . Four signals from 8
187.7 to 189.5 corresponded to the remaining carbonyl carbons.
Bis(3-methyl-2,4-pentanedionato)[/?S-N,N’-bis(2-chloroethyl)ethane-l,2- 
diamine]-cobalt-(III) hexafluorophosphate (215) was prepared in a similar manner and 
the product was obtained as purple needles after slow recrystallisation. It is possible to
+
(214) p f6
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form three diastereoisomers when the ligand is complexed to cobalt as on coordination, 
each nitrogen atom becomes chiral. This can produce the RR, SS racemate and meso-RS 
compounds but the more stable form (RS) was enriched during crystallisation. This is 
more clearly seen in the NMR spectra. In the NMR spectrum (Figure 13), the Meacac 
signals were similar to that of the above compound (214). The P-chloromethylene 
protons appeared as a multiplet between 8  2.53 and 2.90 with the chloromethylene 
protons appearing as a multiplet at 8  3.66. The CH2NH protons were split and appeared 
as multiplets at 8  3.03 and 3.94, each of intensity 2. A broad singlet at 8  4.61 accounted 
for the NH protons. The 13C NMR spectrum was similar to the previous complex, except 
only one signal was apparent for each of the methyl carbon and the quaternary carbon of 
CCH3 . The IR spectrum was almost identical to that of the previous compound (214).
Co
NH
NH
(215)
Bis(3-methy 1-2,4-pentanedionato)[7V,yV-bis(2-chloroethyl)propane-1,3-diamine]- 
cobalt(III) hexafluorophosphate (216) was prepared in poor yield in the same fashion to 
afford the product as red-brown crystals. The NMR spectra were similar to that of the 
analogous compound as expected with the extra methylene group appearing as a multiplet 
at 8  1.19 in the *H NMR spectrum and at 8  31.3 in the I3C NMR spectrum.
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(216)
Bis(3-methyl-2,4-pentanedionato)[A^,Ar-(l,4-butanediyl)bis(2-chloromethyl- 
piperidine)] cobalt(III) hexafluorophosphate (217) was made by direct reaction between 
the free base of the diamine and the cobalt precursor complex. This resulted in the 
formation of red-brown crystals after slow recrystalliation. The NMR spectrum 
showed a broad multiplet between 8  1.55 and 2.05 corresponding to all the methylenes 
not attached to nitrogen. Four singlets at 8  1.86, 1.92, 2.12 and 2.16 were assigned to 
the CH3CO methyl protons while the two singlets at 8  2.21 and 2.26 corresponded to the 
CCH3 protons. A multiplet at 8  2.90-3.10 with intensity 8  was attributed to both the exo- 
and endo-cyclic methylenes adjacent to the nitrogens. Another mutiplet at 8  3.38 of 
intensity 4 was assigned to the chloromethylene protons with a small multiplet at 8  3.64 
attributed to the CHN methine protons. No 13C NMR spectrum could be obtained due to 
poor resolution with the small amount of material available.
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Co
(217)
Bis(3-methyl-2,4-pentanedionato)[A^AT-(l,3-propanediyl)bis(2-chloromethyl-
piperidine)]cobalt(III) hexafluorophosphate (218) was prepared in a sim ilar manner to 
that above and was obtained as red-brown crystals, although in poor yield. The *H NMR 
spectrum was alm ost identical to that o f its higher homologue, and as before, no 13C 
NMR spectrum could be obtained.
Co
(218)
Although com plexation of the N -C 2-N bis(chlorom ethylpiperidine) com pound 
(152) to cobalt was attempted repeatedly, no product could be isolated. This could be due 
to the steric hindrance caused by the side chains making it difficult for the nitrogens to 
complex to the cobalt.
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Attempts to complex the triamine (207) and tetraamine (209) to cobalt were 
hampered by the lack of a suitable precursor. Ideally, we would like a complex (219) 
with one Meacac and four nitro groups for both the triamine and tetraamine, so we could 
displace three or four nitro groups and still have the Meacac group in place as this group 
seems to be important for achieving the right reduction potential.
NO
NO
(219)
A search of the literature was unsuccessful in finding such a compound so it was 
decided to complex each polyamine to a cobalt precursor to obtain a complex containing 
nitro groups.
A method was found in the literature to complex a triamine to cobaltous nitrate 
h e x a h y d r a t e . 170  This involved a method similar to that used for sodium 
hexanitrocobaltate in which a mixture of cobaltous nitrate, sodium nitrite and the triamine 
were aerated in acidic aqueous solution for one hour.
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2Co(N03)2.6H20  H20
+ NaN02 + H+
+ triamine
Cl
NH
Cl
Cl
Unfortunately, no complex could be isolated from the reaction mixture and it was 
not certain that the triamine had complexed at all. Material isolated from the solution had a 
!H NMR spectrum which was consistent with the structure of the triamine However, it 
could not be ascertained whether the triamine was part of a cobalt complex or was in the 
salt form due to lack of other protons present in the desired complex. No further analysis 
was undertaken.
Complexation of the tetraamine was carried out following a general method171 in 
a similar manner. A mixture of cobalt chloride, lithium hydroxide, sodium nitrite and the 
tetraamine in water was aerated for a period of eight hours before the counter ion of 
hexafluorophosphate was added. Unfortunately, any complex formed could not be 
identified due to the same reasons as above.
7.10 Conclusions
Synthetically useful routes have been devised to diamine ligands which could 
themselves be used as precursors to make polyamine ligands. The two cobalt complexes
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which have been made previously were successfully prepared and all spectral data were 
consistent with those reported before. Three new complexes have been isolated and 
characterised and it should be possible to improve the yields achieved. A suitable cobalt 
precursor needs to be made before complexation of the poly amines can be accomplished. 
This may be a promising area to enter as there is plenty of scope for design of complexes 
which may be useful in the area of bioreducible drugs.
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Chapter 8
Biological Testing Results
8.1 Introduction
The compounds were tested in the Department of Medical Oncology, University 
of Glasgow. The cis- and fraws-2,6-disubstituted piperidine derivatives were tested by 
Dr. Jane Plumb while the rest of the compounds were tested by myself under her 
supervision.
Aerobic toxicity was assessed using a microtitration assay called the MTT based 
cytotoxicity assay, from which IC50 values were calculated after drug exposure for 24 
hours. The selective toxicity of the compounds toward hypoxic cells was determined by 
comparing the toxicity in aerobic and hypoxic conditions after drug exposure for 3 hours. 
The prodrug (A-oxide or cobalt complex) requires a reduction potential within the normal 
range of cellular reductants (about -0.20 to -0.40 V vs normal hydrogen electrode) in 
order to be reduced to the toxic free base.
8.2 Cell Lines
The role of the obligate two-electron-reducing enzyme DT-diaphorase in the 
bioactivation of mitomycin C, E09 and other bioreducible agents has received a lot of 
attention in recent years. 76 This enzyme is of significant interest because DT-diaphorase 
is often found in high concentrations in tumours compared with normal tissue.76 Two 
human colon carcinoma cell lines were employed in these studies which could determine 
the role of DT-diaphorase in the bioreductive activation of our prodrugs. HT 29 cells 
produce high levels of DT-diaphorase and so the mechanism of activation for prodrugs 
may proceed through a 2e' reduction pathway. It should be noted that reduction by DT- 
diaphorase is dependent on the compound and some prodrugs are activated better than
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others. For example quinones and CB 1954 are especially good substrates for DT- 
diaphorase. BE cells contain a mutation in the NQ1 gene and express a mutant form with 
essentially no enzyme activity172 and so a le ' reduction pathway may be expected to 
predominate. The combined results from these two cell lines should provide evidence for 
the mode of action for individual compounds and it should be clear if any compound has 
a preference for activation by DT-diaphorase
8.3 MTT Based Cytotoxicity Assay
Cytotoxicity tests are widely used to evaluate the effects of anticancer drugs on 
cells. Clonogenic assays use plating efficiency, either on plastic or in agar, as an end 
point such that the number of colonies relative to the control indicates the number of cells 
that survived the treatment. Furthermore, the size of the colony can indicate whether the 
treatment was cytotoxic, cytostatic or mitogenic. These assays are slow and the 
development of microtitration assays has been an enormous benefit to those who screen 
new compounds for cytotoxic activity. The end point of a microtitration assay is an 
estimate of cell number. This can be achieved directly by cell counts or by indirect 
methods such as isotope incorporation. Use of MTT as a cell viability measure173 can be 
chosen as the optimal end point.174 MTT is a yellow water soluble tetrazolium dye that is 
reduced by live, but not dead cells, to a purple formazan product that is insoluble in 
aqueous solutions. It should be noted that a number of factors can influence the reduction 
of MTT.175 However, in the assay used, the same result has been achieved as with a 
standard clonogenic assay.176
Cells in exponential phase of growth were exposed to the cytotoxic drug of 
interest. The duration of exposure is usually determined as the time required for maximal 
damage to occur but is also influenced by the stability of the drug. After removal of the 
drug the cells were allowed to proliferate for two to three doubling times in order to 
distinguish between cells which remain viable and are capable of proliferation and those 
which remain viable but cannot proliferate. Surviving cell numbers were then determined
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indirectly by MTT dye reduction. The amount of MTT-formazan produced can be 
determined spectrophotometrically once solubilised in a suitable solvent. It is important to 
note that the following conditions are met.
1) MTT colour is shown to be in the linear range of dependence on the cell number.
2) The colour produced is proportional to the time of MTT exposure.
8.4 Hypoxic Cytotoxicity
Plastic multiwell plates are not suitable for carrying out cytotoxicity experiments 
with drugs that are activated under hypoxic conditions. This is because oxygen is soluble 
in tissue culture plastic and is released slowly into the surrounding environment when 
external oxygen tension decreases.177 To overcome this problem, glass petri dishes were 
used for the drug exposure under nitrogen. The exposure was limited to three hours as 
cells will die without drug exposure if the absence of oxygen is prolonged beyond this 
time. The medium containing the drug was then removed and replaced with fresh 
medium. After two days, surviving cell numbers were then counted directly using a 
Coulter counter, and this number was taken as a percentage of the controls.
8.5 cis- and Ira/is-Disubstituted Piperidines
The results of the testing of these compounds can be seen in Tables 1 and 2. The 
compounds in the shaded areas are the corresponding Af-oxides which are required to be 
non-toxic in oxic conditions but toxic in hypoxic conditions.
The N-oxides were inactive, indicating that using the lone pair of the nitrogen to 
form a bond reduces the toxicity substantially. This is consistent with the mechanism of 
aziridine formation of conventional nitrogen mustards. There appears to be little 
difference in the oxic and hypoxic toxicities for individual N-oxides, so we can assume 
that the reduction potentials of these types of compound are not in the correct range for 
cellular reductants.
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In general, there is little difference between the two cell lines and what difference 
there is can probably be attributed to experimental error. We can therefore conclude that 
none of the compounds are activated appreciably by reductase enzymes including DT- 
diaphorase. Both cis- and rraflj-dibromo-compounds are more toxic than the dichloro- 
compounds and this is consistent with the theory that the incorporation of better leaving 
groups increases alkylating potency. It is interesting to note that the trans- aromatic 
carbamates are up to 100-fold more toxic than the c/5-series, indicating that spatial 
arrangements are important for toxicity. This was unexpected as it was assumed that the 
equatorial groups would be more susceptible to attack by the nitrogen lone pair.
Me
Me
8.6 Piperazine Derivatives
The results of the testing of the piperazine derivatives are shown in Table 3. 
Again we see little hypoxic selectivity from the N-oxides, but a dramatic decrease in 
toxicity is observed in comparison to the free bases, where the N-oxides are basically 
non-toxic. This would appear to mean that the lone pair on the nitrogens is essential for 
toxic activity, as for the 2,6-disubstituted piperidines and is consistent with aziridine 
formation and attack by biological nucleophiles.
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The toxicities of the free bases are similar to those of the piperidine derivatives, 
with the aromatic carbamates being the most active.
There is a significant difference in the toxicities of the N-oxides towards the two 
cell lines. It appears in this case that most of the compounds are selectively more toxic 
towards the BE cells than the HT 29 cells.Compound 131 does not show this selectivity 
as it seems to be completley non-toxic. On the other extreme, compound 135 has an 
increase of around 10-fold in toxicity. This is probably due to straight 2e- reduction. 
However, it may mean that instead of activating our N-oxides, DT-diaphorase may be 
acting as a protective enzyme which is detoxifying a reactive intermediate in our 
compounds. This is the case for SR 4233 where a 2e- reduction protects against toxicity. 
We could therefore expect greater toxicity in BE cells if this is the case for this type of N- 
oxide. This is an interesting result which may have implications for enzyme profiling, if a 
reductase enzyme can be found which does activate these prodrugs.
8.7 Bis-piperidine Derivatives
Tables 4, 5 and 6 show the results of testing the bis-piperidine series with the 2, 3 
and 4 bridging carbons, respectively. All three sets of compounds show a greater toxicity 
for the free bases in comparison to their N-oxides. Again, the N-oxides appear to have 
little selectivity for cells under hypoxic conditions in preference to those under oxic 
conditions.
Compounds with two carbons between the nitrogens (Table 4) show greatest 
toxicity in the aromatic carbamates. There appears to be little difference between the two 
cell lines except for the dichloro (152) and bis(phenyl carbamate) (150) derivatives. 
These compounds in the free base form are ca. 10-fold more toxic to HT 29 cells than BE 
cells. It may be that these derivatives are genuinely being activated in some way by the 
high levels of DT-diaphorase present in this cell line.
Compounds with three carbons between the nitrogens (Table 5) seem generally to 
show the same magnitude of toxicity as the N-C2-N set with the possible exception of the
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dichloro derivative (164) which has a slightly greater toxicity, especially for the BE cells, 
where it shows a 65-fold increase in toxicity over the corresponding N-C2-N compound.
It does appear that when the bridge length is increased to four carbons (Table 6 ), 
the toxicity of the carbamates is increased substantially, by around 100-fold for the HT 
29 cells. This is an interesting observation and it may be that the optimum chain length 
for toxicity has still to be reached. It would be desirable to synthesise some aromatic bis- 
carbamates with a bridging length of greater than four to see if this is the case. The bis(p- 
nitrophenyl carbamate) (172) is the most toxic compound made in this project with IC50 
value of 12 nanomolar against both cell lines. Surprisingly, the dichloro derivative does 
not show the same increase in toxicity, with values comparable to those of the N-C3-N 
series.
8.8 C obalt Complexes
This set of compounds was tested for oxic/hypoxic selectivity, with IC50 values 
measured for the mustard hydrochloride salts. Table 7 shows IC50 values for the 
polyamine salts and some of the cobalt complexes, along with oxic/hypoxic selectivity at 
the lower concentration of 0 .1  mmol. The IC50 values cover a wide range. The salts seem 
to show a preferential toxicity towards BE cells but, surprisingly, the triamine (207) and 
the tetraamine (209) do not show the higher toxicity that was expected because of the four 
potential alkylating chloroethyl groups. It may be that this is due to steric effects of the 
extra chloroethyl groups. The two diamines (185) and (197) that have been made 
before160 do not show as high toxicity as reported but this is probably due to the different 
cell lines used. The cobalt complexes show varying toxicities. The values of (214) and 
(215) (which had been made before) correlate very well with those reported, 160 with the 
unsymmetrical diamine complex (214) showing the highest toxicity of those made. Of the 
two bis-piperidine complexes, the compound with N-C4-N (217) shows less toxicity 
than the free diamine indicating that the complex is quite stable in these conditions. On the 
other hand, the complex containing N-C3-N (218) is 10-fold more toxic than the N-C4-N
152
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complex, and its IC50 values correlate quite well with the free base values (Table 5). This 
would indicate that this complex is less stable and quickly breaks down to give the free 
diamine. There is a slightly higher toxicity towards the HT 29 cells than the BE cell line, 
but not much is known about the enzymology of cobalt complexes. We therefore felt it 
was worth conducting a more detailed oxic/hypoxic screen on the cobalt complexes. 
These results are shown in graph form.
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SR 4233 (44) was also tested as a standard to see if the test system was working 
in a satisfactory manner. The complexes were tested at three different concentrations, 
starting at 1 mmol with a five-fold dilution each time, under oxic and hypoxic conditions 
with a three hour drug exposure.
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SR 4233 (44) can be seen to be more toxic under hypoxic than oxic conditions for 
both cell lines at the concentration of 40 mM, This is consistent with results obtained by 
others using the same system.28
Of all the cobalt complexes tested, the greatest selectivity was seen with that 
complex (214) which had been proven before to be selective.160 It had been reported to 
have 20-fold selectivity for hypoxic cells but our own results showed a selectivity of ca. 
6-fold. This result can easily be explained by the different cell lines used.
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The diamine complex (215) did not show any activity at all towards either cell line 
and this is in line with the results of Ware et a/.160 The higher homologue (216) did not 
show any selectivity at all with the BE cells, with very similar toxicity under both oxic 
and hypoxic conditions, but some selectivity was observed with the HT 29 cells at a 
concentration of 200 mM.
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The bis-piperidine complexes showed very similar behaviour. The N-C3-N 
derivative (218) had some selectivity, with the compound being more toxic towards BE 
cells under hypoxic conditions at a concentration of 200 mM. The compound was actually 
more toxic towards oxic HT 29 cells than hypoxic HT 29 cells at all concentrations. The 
derivative with N-C4 -N (217) showed similar results except that it was more toxic to BE 
cells under hypoxic conditions at concentration of 1 mmol only. Again, greater toxicity 
was observed for the HT 29 cells under oxic conditions.
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8.9 Conclusions
It would appear that under the conditions used, none of the N-oxides are suitable 
for use as bioreducible drugs. This is either due to these compounds not having 
appropriate reduction potentials or due to lack of activation by the reductase enzymes 
present in the HT 29 cell line. Many of the free bases are highly toxic species. These are 
probably acting as alkylating agents by forming aziridinium rings which can then be 
attacked by DNA. It is probable that on release from the molecule the aromatic carbamates 
are exerting their own toxic actions which are contributing to the high toxicity of these 
compounds. It would be desirable if more detailed testing on a selection of these 
compounds could establish the nature of their toxic actions. More work is required on the 
cobalt complexes to see if these compounds could be counted as a viable class of 
bioreducible drug. There are some encouraging results presented here which indicate that 
this could be worthwhile.
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Experimental
General
All melting points were measured on a Gallenkamp melting point apparatus and are 
uncorrected. Infra red spectra were obtained on a Perkin Elmer 580 spectrophotometer in 
the form of KBr discs for solids and thin films for oils and liquids unless otherwise 
stated. Nuclear magnetic resonance spectra were recorded with a Bruker WP200-SY 
spectrometer operating at 200 MHz (6h ) and 50 MHz (6 c). The multiplicities of the 13C 
NMR spectra were determined using DEPT spectra with pulse angles of <j> = 90 ° and,^ = 
135 °. Spectra were recorded for solutions in deuteriochloroform unless otherwise stated, 
with tetramethylsilane as internal standard. Mass spectra were obtained with A.E.I. MS 
12 or 902 spectrometers. Elemental analyses were obtained with a Carlo-Erba 1106 
elemental analyser.
TLC was carried out on neutral aluminium oxide 60 F254 plates of 0.2 mm thickness 
obtained from Merck and were detected using UV light, Dragendorff reagent178 (tertiary 
amines) and vanillin (carbonyl compounds).
Tetrahydrofuran was dried by distillation from sodium-benzophenone under nitrogen 
prior to use. Dichloromethane was dried by distillation from calcium hydride. Methanol 
was dried by distillation from clean, dry magnesium turnings and iodine. Acetone was 
dried with anhydrous potassium carbonate followed by distillation. DMF was dried by 
distillation from magnesium sulfate. Solvents were evaporated off under reduced 
pressure below 50 °C.
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General Procedures
General Procedure A
A mixture of the diol, isocyanate (quantities are given under individual compounds) and 
3 drops of dibutyl tin diacetate were stirred together at room temperature in 
dichloromethane (20 ml) until TLC indicated that the reaction was complete. The solution 
was then concentrated to leave a residue which was purified as described.
General Procedure B
mCPBA was dissolved in dry acetone and the amine (quantities are given under 
individual compounds) in acetone (5 ml) was added dropwise. After TLC had indicated 
the reaction had gone to completion, the solution was carefully concentrated. Flash 
chromatography on alumina with methanol (50 ml) removed the acid residues and 
evaporation of the methanol left a residue which was purified as described.
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Experimental to Chapter 3
cis-2,6-Piperidinedicarboxylic Acid Hydrochloride96 (76)
Dipicolinic acid (1.50 g, 8.7 mmol) in glacial acetic acid (50 ml) was hydrogenated at 
atmospheric pressure and room temperature for 30 h using platinum (IV) oxide (0.15 g) 
as catalyst. The catalyst was removed by filtration through Celite and the filtrate was 
acidified by conc. HC1 to precipitate the hydrochloride as a white solid. Crystallisation 
from water gave cis-2,6-piperidinedicarboxylic acid hydrochloride (1.4 g, 89%), m.p. 
284-286 °C, vmax 3400, 3000 and 1750 c m 1; 8 H (90 MHz) (D20 ) 1.5-2.2 (6 H, m, ring 
CH2) and 4.35 (2H, m, CtfN); m/z 173 (M+ 0.1 %), 128 and 82 (100%).
V -M ethyl-cis-2,6-Piperidinedicarboxylic A cid115 (77)
A mixture of cij-2,6 -piperidinedicarboxylic acid hydrochloride (1.00 g, 5.8 mmol), 37 % 
formaldehyde solution (0.96 g), 90 % formic acid (1.2 ml) and sodium bicarbonate (0.5 
g, 5.8 mmol) was heated at reflux for 19 h. Precipitated sodium chloride was filtered off 
and the filtrate concentrated to an oil. Crystallisation from methanol gave N-methyl-cis-
2,6-piperidinedicarboxylic acid as white crystals (0.68 g, 6 8 %), m.p. 212-216 °C, 8 h 
(90 MHz) (D20 ) 1.5-2.3 (m, 6 H, ring CH 2), 2.83 (3H, s, N C//3) and 3.9 (2H, m, 
CHN); m/z 187 (M+ 0.2 %), 142, 114, 96, 82 and 70.
Diethyl 2,6-pyridinedicarboxylate97 (78)
Dipicolinic acid (5.0 g, 30 mmol) was refluxed for 42 h with thionyl chloride (15 ml). 
The excess thionyl chloride was removed in vacuo and the residue was taken up in CCI4 
and treated with ethanol at 50-60 °C. The crude diester precipitated on cooling and was 
recrystallised with methanol to leave white crystals (5.65 g, 97%), Rp 0.58 (EtOAc) m.p. 
38 °C, vmax 1745, 1576, 1532, 1482, 1385, 1242 and 764 cm*1; 8H 1.46 (6 H, t, 7 7 Hz,
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C //3), 4.49 (4H, q, J  1 Hz, CH2), 8.07 ( 1H, dd J  8  Hz, and J  8  Hz, CHCHN), and
8.30 (2H, d, /  8  Hz, C //N ); 8 C 14.1 (q), 62.2 (t), 127.7 (d, CHC), 138.1 (d, 
C//CHC), 148.4 (s, CN) and 164.4 (s, C=0); m/z 223 (Af+, 0.3%), 178 (9%) and 150 
(19%) (Found: C, 59.33; H, 6.02; N, 6.21. C iiH 13N 0 4  requires C, 59.19; H, 5.83; N, 
6.28%).
Diethyl AMMethyl cw-2,6-piperidinedicarboxylate (79)
Diethyl 2 ,6 -pyridinedicarboxylate (2.0 g, 8.9 mmol) was suspended in glacial acetic acid 
(50 ml) and hydrogenated at atmospheric pressure and room temperature for 30 h using 
PtC>2 (0.20 g) as catalyst. The catalyst was removed by filtration through Celite and the 
filtrate was returned to the hydrogenator with 36% formaldehyde solution and 10% 
palladium on charcoal catalyst (0.20 g). Absorption of H2 proceeded in 18 h at 
atmospheric pressure and room temperature. The catalyst was removed by filtration 
through Celite and the clear filtrate was covered with ether and cooled to 5 °C. The 
solution was made basic slowly with 35% NaOH solution. The ether layer containing the 
liberated ester was separated and, after the aqueous layer was completely extracted with 
the same solvent, the combined extracts were dried over magnesium sulfate, filtered and 
concentrated to leave diethyl N-methyl cis-2,6 -piperidinedicarboxylate as white crystals 
(1.09 g, 50%), m.p. 85-86 °C, Rp 0.55 (EtOAc: pet ether, 1:1), vmax (2940, 2861, 1730 
and 1376 cm’1; 8 h 1.21 (6 H, t, J 1 Hz, CH2C //3), 1.52-1.68 (6 H, m, ring CH2), 2.13 
(3H, s, N C //3), 2.65-2.72 (2H, dd, J 2 Hz and J  11 Hz, NCH) and 4.13 (4H, q, J 1 
Hz, CH2CH 3); 8 C 13.9 (q, CH2CH3), 22.7 (t, CH2CH 2CH), 29.1 (t, CH2CH), 41.8 
(q, NCH3), 60.4 (t, CH20), 67.9 (d, CHN) and 172.5 (s, C=0); m/z 243 (Af+ 0.6%), 
170 (100%), 156, 142 and 96 (Found: M+, 243.1470. C 12H21NO4  requires 243.1458).
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AM Vfethyl-c«-2,6-bis(hydroxymethyl)piperidine (74)
Diethyl A^-methyl-cw-2,6-piperidinedicarboxylate (2.0 g, 8.2 mmol) in dry THF (20 ml) 
was added to UAIH4 (16 ml, 16 mmol) under nitrogen and heated at reflux for 3 h. Water 
was added at 0 °C to decompose the LiAlUt and the resulting slurry was concentrated to 
leave a white residue. This was washed with pyridine and filtered. The filtrate was 
concentrated to leave N-methyl cis-2 ,6 -bis(hydroxymethyl)piperidine as a clear oil ( 1 .4 5  
g, 97%), RF 0.35 (EtOAc), vmax 3373, 2934, 2860, 2793, 1235, 1064 and 1025 c m 1; 
5h 1.37-1.77 (6 H, m, ring Ctf2), 2.21 (3H, s, N C//3), 2.26 (2H, m, NCH), 3.39 (2H, 
dd, 7 4 Hz and /  11 Hz, CH2O), 3.70 (2H, dd, J 4 Hz, J  11 Hz, CH20 )  and 3.98 (2H, 
bs, OH)\ 6 C 23.7 (t, CH 2CH 2CHN), 26.7 (t, CH2CHN), 34.9 (q, NCH3), 63.5 (t, 
CH20 ) and 64.1 (d, CHN); m/z 159 (M+ 0.1%), 142, 125, 128 (100%), 110, 96 and 82 
(Found: A/+ 159.1241. C8H i7N 0 2 requires M+ 159.1259).
iV-M ethyl-cis-2,6-bis(isopropylam inocarbonyloxym ethyl)piperidine (80)
N-Methyl-ci.s-2,6-bis(hydroxymethyl)piperidine (0.46 g, 2.9 mmol) and isopropyl 
isocyanate (0.74 g, 8.7 mmol) were reacted according to procedure A for 24 h. The 
product was obtained as white crystals after recrystallisation from EtOAc/hexane (0.82 g, 
8 6 %), m.p. 95-97 °C, Rp 0.46 (EtOAc: hexane, 1:1), vmax 3400, 2990, 2800, 1690 and 
1370 cm-1; 6 H 1.14 (12H, d, J 1 Hz, C //3CH), 1.35-1.81 (6 H, m, ring C //2), 2.28 (2H, 
m, C//N CH 3), 2.33 (3H, s, N C//3), 3.81 (2H, m, CHCH3), 4.10 (4H, m, CH20 )  and 
4.75 (2H, bs, NH)\ 6 C 23.0 and 23.5 (q, CH3CH), 23.7 (t, CH2CH 2CH), 28.66 (t, 
CH2CH), 37.7 (q, NCH3), 43.1 (d, CHNH), 63.3 (d, CHNCH3), 66.9 (t, CH20 )  and 
155.7 (s, C=0); m/z 314 , 227, 213 (100%), 128, 110 and 96 (Found: C, 58.17; H, 
9.77; N; 12.59. C ]6U3lN30 4 requires C, 58.36; H, 9.42; N, 12.77%).
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/V-M ethyl-ci5-2,6-bis(ethylaminocarbonyIoxymethyl)piperidine (81)
/V-Methyl-c/^^-bisOiydroxymethyOpiperidine (0.46 g, 2.9 mmol) and ethyl isocyanate 
(0.62 g, 8.7 mmol) were reacted according to procedure A for 24 h. The product was 
obtained as a clear oil after flash chromatography on alumina with ethyl acetate as eluant. 
The oil solidified after a week in the freezer but could not be crystallised (0.83 g, 95%), 
m.p. 58-60 °C, RF 0.33 (EtOAc:hexane, 1:1), vmax 3400, 2800 and 1690 c m 1; 8 h 1.14 
(6 H, t, J  7 Hz, C //3CH 2), 1.36-1.81 (6 H, m, ring C //2), 2.28 (2H, m, C //N C H 3),
2.34 (3H, s, N Ctf3), 3.20 (4H, q, J  1 Hz, CH2CH3), 4.13 (4H, m, CH2O) and 5.24 
(2H, bs, NH)\ 5C 15.3 (q, CH3CH2), 23.6 (t, CH2CH2CH), 28.3 (t, CH2CHN), 35.2 
(t, CH2CH3), 37.4 (q, NCH3), 63.1 (d, CHN), 66.7 (t, CH20 ) and 156.4 (s, C =0); 
m/z 302 (M+, 0.1%), 287, 213, 199 (100%), 128, 110 and 96 (Found: M+, 302.2076. 
C i4H28N30 4  requires 302.2080).
/V-M ethyl*c{5-2,6-bis(phenylaminocarbonyloxymethyl)piperidine (82)
A^-Methyl-c/5 -2 ,6 -bis(hydroxymethyl)piperidine (0.46 g, 2.9 mmol) and phenyl 
isocyanate (1.03 g, 8.7 mmol) were reacted according to procedure A for 24 h. The 
product was obtained as a yellow oil and was purified by flash chromatography on 
alumina with ethyl acetate. After concentration the residue was recrystallised with 
EtOAc/hexane to leave white crystals (0.82 g, 71%), m.p. 145-147 °C, Rp 0.7 
(EtOAc:hexane, 1:1), vmax 3380, 2800, 1700, 1600, 1525, 750 and 690 cm-1; 8 H 1.27- 
1.91 (6 H, m, ring CH2), 2.43 (3H, s, N C//3), 2.54 (2H, m, CtfNCH3), 4.26 (4H, m, 
CH2O), 7.07 (2H, m, p-CH), 7.27-7.37 (8 H, m, m- and o-CH) and 9.35 (2H, s, NH); 
8 C 23.4 (t, CH2CH2CHN), 27.5 (t, CH2CHN), 36.4 (q, NCH3), 63.2 (d, CHNCH3),
66.2 (t, CH20 ), 118.6 (d, o-CH), 123.3 (d, p-CH), 128.9 (d, m-CH), 137.8 (s, CNH) 
and 153.3 (s, C=0); m/z 247, 213, 128, 119 (100%) and 110.
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/V-M ethyl-cis-2,6-bis(/?-nitrophenylaminocarbonyloxymethyl)piperidine
(83)
A-Methyl-cw-2,6-bis(hydroxymethyl)piperidine (0.46 g, 2.9 mmol) and p-nitrophenyl 
isocyanate (1.43 g, 8.7 mmol) were reacted according to procedure A for 24 h. After 
removal of the solvent, a yellow powder was left which was purified using a gravity 
alumina column, eluting with tolueneiether (2 :1) to produce yellow crystals (0.82 g, 
58%), m.p. 78-80 °C, Rp 0.40, (EtOAc:hexane, 1:4), vmax 3420, 2920, 2760, 1725, 
1600, 1545, 1505, 1330 and 850 cm '1; 8 h (d6 -acetone) 1.29-1.78 (6 H, m, ring C //2),
2.35 (3H, s, N C //3), 2.40 (2H, m, C //N C H 3), 4.21 (4H, m, C/720 ), 7.75 and 8.17 
(8 H, d, 7 ca. 9 Hz, AA'BB' system) and 9.40 (2H, s, NTT); 8 C 24.1 (t, CH2CH2CHN),
28.9 (t, CH2CHN), 38.0 (q, NCH3), 63.42 (d, CHNCH3), 68.3 (t, CH20), 118.6 (d, 
CHCNH), 125.7 (d, C H C N 0 2), 143.3 (s, CNH), 146.4 (s, C N 0 2) and 154.0 (s, 
C=0); m/z 334, 292 (19%), 260 and 110 (24%) (Found: C, 54.06; H, 5.17; N, 14.40. 
C22H25N50 8 requires C, 54.21; H, 5.13; N, 14.37%).
N -M ethyl cis-2,6-bis(chlorom ethyl)piperidine92 (66)
N-Methyl-cij-2,6-bis(hydroxymethyl)piperidine (0.46 g, 3.2 mmol) was dissolved in 
dichloromethane and added slowly to thionyl chloride at 0 °C. The mixture was heated at 
reflux for 3 h, then water was added carefully and the solution was saturated with sodium 
bicarbonate. Separation of the two phases was followed by washing of the organic phase 
with NaHCC>3 solution (2 x 20 ml), drying, filtration and evaporation to yield N-methyl- 
cw-2,6-bis(chloromethyl)piperidine as a brown oil. Flash chromatography on alumina 
using ethyl acetate as eluant gave the product as a clear oil (0.46 g, 80%), Rp 0.66 
(EtOAc:hexane, 1:8), vmax 2939, 2860, 2737 and 674 cm-1; 8 h 1.38-1.83 (6 H, m, ring 
C H 2), 2.32 (3H, s, N C //3), 2.42 (2H, m, NC //), 3.53 (2H, dd, J  6  Hz and J  11 Hz, 
CH2C1) and 3.63 (2H, dd, 7 6  Hz and 7 11 Hz, CJT2C1); 5C 22.9 (t, CH2CH2CHN),
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28.6 (t, CH2 CHN), 37.0 (q, NCH3), 47.3 (t, CH2 C1) and 64.2 (d, CHN); m/z 160, 110
and 96 (Found: M+ (-C1) 160.0906. C8 Hi5 NC1 requires 160.0893).
A T-M ethyl-c/5-2,6-bis(brom om ethyl)piperidine (84)
A-Methyl cw-2,6-bis(hydroxymethyl)piperidine (0.46 g, 3.2 mmol) was dissolved in 
dichloromethane and added slowly to phosphorus tribromide (1.92 g, 7.1 mmol) at 0 °C. 
The mixture was heated at reflux for 3 h, then water was added carefully and the solution 
was saturated with sodium bicarbonate. Separation of the two phases was followed by 
washing of the organic phase with NaHC03 solution (2 x 20ml), drying, filtration and 
evaporation to yield N-methyl-c/s-2,6-bis(bromomethyl)piperidine as a clear oil (0.2 g, 
23%) Rf  0.66 (EtOAc:hexane, 1:8), vmax 2937, 2860, 2781 1301and 570 cm-1; 8H 1.42- 
1.82 (6H, m, ring CH2), 2.31 (3H, s, N C//3), 2.42 (2H, m, NCtf), 3.41 (2H, dd, 7 6 
Hz and J  11 Hz, CH2Br) and 3.50 (2H, dd, J  6 Hz and J  11 Hz, C //2Br); 5C 22.6 (t, 
CH2CH 2CHN), 29.1 (t, CH2CHN), 36.5 (t, CH2Br), 36.7 (q, NCH3) and 63.5 (d, 
CHN); m/z 285 (M+ 1.2%), 204, 190 (100%), 110 and 96 (Found M+  284.9552. 
C8Hi5NBr2 requires M + 284.9552).
iV -M ethyl-cis-2 ,6-b is(isopropylam inocarbonyloxym ethyl)p iperid ine N-  
oxide (86)
N-Methyl-ci5-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine (0.2 g, 0.6 mmol) 
and mCPBA (0.14 g, 0.64 mmol) were reacted according to procedure B for 24 h. The 
remaining white powder was recrystallised from ethyl acetate to leave the product, (0.18 
g, 87%), m.p. 180 °C, RF 0.68 (EtOAc), v max 3420, 2990, 1680 and 920 cm-1; 8H 
(CD3OD) 1.12 (12H, d, 7 7 Hz, CH3CH), 1.45-1.93 (6H, m, ring C //2), 3.18 (3H, s, 
N +C//3), 3.52 (2H, m, C//N+), 3.70 (2H, m, CHCH3), 4.05 (2H, d, 7 13 Hz, CH2O) 
and 4.61 (2H, dd, 7 6 Hz and 7 13 Hz, C /f20); 8C 22.9 (q, CH3CH), 25.4 (t, ring 
CH 2), 44.1 (d, CH CH3), 55.8 (q, N+CH3), 64.3 (t, CH20), 76.2 (d, CHN+) and
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157.3 (s, C=0); m/z , 314, 213, 126, 110 (65%) and 96 (Found: C, 55.95; H, 9.01; N,
11.91. C 1 6H3 1 N 3 O5 requires C, 55.65; H, 8.99; N, 12.17%).
/V-M ethyl-r(.s-2,6-bis(ethylaminocarhonyloxymethyI)piperidine A -oxide
(87)
A-Methyl-c/.s-2,6-bis(ethylaminocarbonyloxymethyI)piperidine (0.20 g, 0.6 mmol) and 
mCPBA (0.14 g, 0.64 mmol) were reacted according to procedure B for 24 h. The 
remaining white powder was recrystallised from ethyl acetate to give the product (0.17 g, 
81%), m.p. 158-159 °C, RF 0.60 (MeOH), vraax 3420, 2990, 1730 and 920 c m 1; 8H 
(D20 ) 0.99 (6H, t, J  7 Hz, CH3CH2), 1.51-1.83 (6H, m, ring CH2), 2.94-3.09 (7H, 
m, CH2CH3 and N+CH3). 3.75 (2H, d, J  13 Hz, C//N+) and 4.45 (4H, m, CH20)\  8c
14.9 (q, CH3CH2), 22.1 (t, CH2CH2CHN+), 24.8 (t, CH2CHN+), 36.3 (t, CH2CH3),
55.4 (q, N +CH3), 64.4 (t, CH 20 ), 75.6 (d, CHN+) and 158.5 (s, C =0); m/z  317 
(0.2%), 199, 144, 128 (100%), 126, 110 (100%) and 96 (Found: M+ 317.2005. 
C l4H27N3<I>5 requires 317.1950).
yV-M ethyl-cis-2,6-bis(phenylaminocarbonyloxymethyl)piperidine A -oxide
(8 8 )
A?-Methyl-c«-2,6-bis(phenylaminocarbonyloxymethyl)piperidine (0.15 g, 0.4 mmol) and 
mCPBA (0.10 g, 0.45 mmol) were reacted according to procedure B for 18 h. The 
remaining pale yellow powder was recrystallised from methanol to give the product as a 
white solid (0.10 g, 67%), m.p. 170-172 °C, RF0.50 (EtOAc), vmax 3400, 2950, 1700, 
1600, 1530, 920, 760 and 690 c m 1; 8H (CD3OD) 1.50-1.94 (6H, m, ring CH2), 2.87 
(3H, s, N+C /f3), 3.43 (2H, m, C//N+), 4.00 and 4.52 (4H, m, CH2O), 6.82 (2H, m, 
p-CH), 7.02 (4H, m, m-CH) and 7.29 (4H, m, o-CH); 8C 25.5 (t, CH2C H 2CHN+),
26.4 (t, CH2CHN+), 55.9 (q, CH3N+), 62.0 and 64.5 (t, CH20 ), 76.2 and 79.7 (d, 
CHN+), 119.8 (d, o-CH), 124.0 (d, p-CH), 129.8 (d, m-CH), 140.0 (s, CNH) and
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155.1 (s, C=0); m/z 247, 213, 144, 126, 110 and 96 (Found: C, 64.27; H, 6.55; N,
10.17. C2 2 H 2 7 N3 O 5 requires C, 63.92; H, 6.53; N, 10.17%)-
A -M ethyl-cis-2,6-bis(chlorom ethyl)piperidine /V-oxide (89).
N-Methyl-cis-2,6-bis(chloromethyl)piperidine (0.10 g, 0.5 mmol) and mCPBA (0.13 g, 
60 mmol) were reacted according to procedure B for 24 h. This left A-methyl cis-2,6- 
bis(chloromethyl)piperidine A-oxide as a yellow oil (0.04 g, 44%), Rp 0.47 (MeOH), 8 h 
(CD 3OD) 1.53-1.88 (4H, m, CA2CHN+), 1.98-2.16 (2H, m, CA2R), 2.80 (3H, s, 
C //3N+), 3.21 (2H, m, C//N+), 3.88 (2H, dd, J  4 Hz and 11 Hz, CH2Cl) and 4.17 
(2H, dd, 7 4 Hz and 11 Hz, C f/2CI); 8 C 23.1 (t, CH2R), 27.2 (t, CH2CHN+), 42.0 (t, 
CH2C1), 44.6 (q, CH3N+) and 80.9 (d, CHN+); m/z 211 (M+ 9.4%), 196, 176, 162, 
146 (100%), 110 and 94 (Found: M+ 211.0525. C8H i5NOCI2 requires M+ 211.1530).
A -M ethyl-crs-2,6-bis(brom om ethyl)piperidine A-oxide (90).
N-Methyl-c/s-2,6-bis(bromomethyl)piperidine (0.1 g, 0.37 mmol) and mCPBA (0.08 g, 
45 mmol) were reacted according to procedure B for 24 h. This left A-methyl-ci.v-2 ,6 - 
bis(bromomethyl)piperidine A-oxide as a yellow oil (0.04 g, 41%), Rp 0.55 (MeOH), 
Vmax 2943, 2829, 916 and 541 cm-'; 8H (CD3OD) 1.33-1.69 (4H, m, CA2CHN+), 2.04 
(2H, m, C //2R), 2.87 (3H, s, CA3N+), 3.18 (2H, m, CAN+), 3.66 (2H, m, CA2Br) 
and 4 . 0 2  (2H, m, CA2Br); 8 C 2 2 .1  (t, CH2R), 28.6 (t, CH2CHN+), 36.0 (t, CH2Br),
45.8 (q, CH3N+) and 75.2 (d, CHN+); m/z 285, 204, 190 (100%), and 96.
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Experimental to Chapter 4
Diethyl a ,a ’-D ibrom opim elate116 (99)
Pimelic acid (10.80 g, 68 mmol) in thionyl chloride (12.2 ml) was heated at 40 °C for 18 
h. Iodine (0.2 g) and bromine (8.04 ml, 150 mmol) were added and the mixture was 
heated at 80 °C for 6 h. After cooling, the solution was added to ethanol (60 ml). Water 
(150 ml) was added and the aqueous solution was extracted with diethyl ether (3 x 25 
ml). The combined ether extracts were washed with 10% sodium thiosulfate solution (5 x 
20 ml). The ether layer was dried, filtered and concentrated to leave a pale yellow oil. 
Vacuum distillation gave the product as a clear oil (19.50 g, 77%), Rp 0.68 (hexane), 
b.p. 165-170 (4 mmHg), vmax 2980, 1740, 1425, 1230 and 1100 cm-1; 8H 1.30 (6H, t, 
J  1 Hz, CH3CH2), 1.62 (2H, m, CH2CH2CHBr), 2.10 (4H, m, CH2CHBr), 4.00 (2H, 
m, CH B t) and 4.20 (4H, q, J 1 Hz, CH2C H 3); 8C 13.9 (q, C H 3C H 2), 25.0 (t, 
CH2CH2CHBr), 33.9 (t, CH2CHBr), 45.3 (d, CHBr), 62.1 (t, CH3CH20 )  and 169.6 
(s, C=O); m/z 249, 222, 166 and 73 (100%).
cis- and fra/is-2,6-P iperidinedicarboxam ide117 (100) and (101)
Diethyl aa'-dibromopimelate (13.1 g, 36 mmol) in liquid ammonia in a sealed tube was 
left standing at room temperature for 3 d. The tube was opened at -78 °C and allowed to 
warm to room temperature. Ice water (10 ml) was added to the solid residue. The 
remaining solid residue was filtered off and dried to give c/s-piperidinedicarboxamide 
(2.50 g, 41 %), m.p. 226-228 °C, v max 3300, 2980, 1680, 1630 and 1400 cm-1; 8H 
(90MHz) (D20 ) 1.3-2.15 (6H, m, ring CH2) and 3.45 (2H, m, CHN); m/z 172 (Af+ 0.3 
%), 127 and 82 (100%). Concentration of the filtrate gave crystals of trans- 
piperidinedicarboxamide (2.10 g, 34%), m.p. 264-268 °C, vmax 3300, 2980, 1680, 1630 
and 1400 cm-1; 8H (90 MHz) (D20 ) 1.5-2.35 (6H, m, ring CH2) and 4.4 (2H, m, 
CHN); m/z 172 (Af+ 0.3%), 127 and 82 (100%).
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cis-2,6-Piperidinedicarboxylic Acid96 (76)
cw-2,6-Piperidinedicarboxamide (1.58 g, 9.1 mmol) in 10% barium hydroxide solution 
was heated at reflux for 2 h. Carbon dioxide was added to the solution and the solid 
barium carbonate was filtered off. The filtrate was acidified with conc. HC1 and 
concentrated to leave cis-piperidinedicarboxylic acid hydrochloride as a white solid (0.79 
g, 50%), m.p. 286-288 °C, vmax 3400, 3000 and 1750; 8H (90 MHz) (D20 )  1.5-2.25 
(6H, m, ring CH2) and 3.85 (2H, m, CHN); m/z 173 (M+ 0.1 %), 128 and 82 (100%).
lra/ts-2,6-Piperidinedicarboxylic Acid117 (102)
frans-2,6-Piperidinedicarboxamide (1.58 g, 9.1 mmol) in 10% barium hydroxide 
solution was heated at reflux for 2 h. Carbon dioxide was added to the solution and the 
solid barium carbonate was filtered off. The filtrate was acidified with conc. HC1 and 
concentrated to leave cis-piperidinedicarboxylic acid hydrochloride as white crystals 
(0.65 g, 41%), m.p. 264-266 °C, 5H (90 MHz) (D20 ) 1.5-2.15 (6H, m, ring CH2) and 
4.25 (2H, m, CHN); m/z 173 (A#+ 1%), 139, 111, 95 and 82.
Diethyl A -m ethyl 2,6-piperidinedicarboxylate119 (79) and (103)
Methylamine (33% in methylated spirits, 10.23 g, 111 mmol) was added carefully to 
diethyl a,a'-dibromopimelate (13.30 g, 36 mmol) at 0 °C and was left standing for 30 
min. Potassium iodide (0.20 g) was added and the solution was heated at 75 °C for 24 h. 
After cooling, the solution was added to water (30 ml) and extracted with diethyl ether (3 
x 30 ml). The ether extracts were then shaken with 3M H2SC>4 (5 x 10 ml) and the 
combined aqueous extracts were made slightly alkaline with 5M NaOH at 0 °C. The 
resulting free base was extracted from the aqueous layer with diethyl ether (4 x 25 ml). 
The combined ether extracts were then dried, filtered and concentrated to leave a pale 
yellow oil. This was purified using flash chromatography, eluting with ethyl acetate to
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give a 1:1 mixture of the cis- and t rans -isomers (6.58 g, 76%), Rp (0.60) 
(EtOAc:hexane, 1:3), v max 2942, 2864 1731cm-1; 6H 1.29 (6H, t, J  7 Hz, C //3CH2), 
1.48-1.95 (6H, m, ring C //2), 2.21 and 2.40 (3H, s, N C //3), 2.80 (1H, m, C //N ), 
3.78 (1H, m, C //N ) and 4.19 (4H, q, J  7 Hz, C //2C H 3); 6C 14.2 and 14.3 (q, 
CH3CH2), 18.9 and 23.0 (t, CH2CH2CHN), 28.8 and 29.7 (t, CH2CHN), 40.6 and
42.1 (q, CH3N), 60.3 and 60.7 (t, CH20), 61.6 and 68.2 (d, CHN) and 172.8 and
173.4 (s, C=0); m/z 243 (M+ 0.5%), 170, 142 (100%) and 96 (Found: M+ 243.1470. 
C i2H21N 0 4 requires Af+ 243.1474).
^V-Methyl-/ra/u-2,6-piperidinedicarboxylic Acid Hydrochloride (106)
Diethyl N-methyl-2,6-piperidinedicarboxylate (4.0 g, 16 mmol) was dissolved in 10 M 
HC1 (20 ml) and left for 2 h at room temperature. The solution was then heated at 100 °C 
for 24 h in a sealed tube, then cooled and evaporated to dryness. The residue was washed 
with acetone and filtered to leave the hydrochloride salt as white crystals (3.4 g, 94 %), 
m.p. 228-230 °C, vmax 3440, 2945, 1745, 1459, 1369 and 718 cm-1; 8H (D20 ) 1.41-
1.77 and 2.03 (6H, m, ring CH2\  2.75 (3H, s, NCH3) and 3.77 (2H, d, J  9 Hz, CHN); 
6C (D20 ) 21.8 (t, CH2CH2CH), 28.0 (t, CH2CHN), 42.7 (q, NCH3), 67.9 (d, CHN) 
and 171.1 (s, C=0); m/z 187 (M+ 0.1%), 142 (100%), 96 and 70 (Found: M+, 
187.0845; C, 42.75; H, 6.05; N, 6.10. C8H i3N 0 4 requires M  +187.0804; C, 42.95; H, 
5.82; N, 6.26%).
N-M ethyl-fr«jis-2,6-bis(hydroxym ethyl)piperidine (97)
Af-Methyl-fra/is-2,6-piperidinedicarboxylic acid hydrochloride (2.0 g, 9 mmol) was 
placed in a dry flask under nitrogen. Dry THF (10 ml) was added to form a slurry and the 
mixture was cooled to 0 °C. 1 M Borane-THF solution (60 ml, 60 mmol) was added over 
a period of 10 min after which the solution was heated at reflux for 48 h. The solution 
was cooled to 0 °C and the reaction was quenched with THF:water (1:1). The THF was
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then removed in vacuo to leave the aqueous solution which was basified with 5M NaOH. 
This was then extracted with dichloromethane (3 x 30 ml) and the organic extracts were 
dried, filtered and concentrated to give the product as a clear oil (1.2 g, 84%), Rp 0.69 
(EtOAc), v max 3741, 2874 and 1308 c n r 1; 5h 1.15-1.85 (6 H, m, ring C //2), 2.32 (3H, 
s, N C //3), 2.43 (2H, m, C tfN ), 3.45 and 3.91 (4H, dd, J  4 Hz and J  11 Hz, CH2O ) 
and 3.56 (2H, bs, OH); 6 C 23.5 (t, C H 2C H 2CH N ), 26.5 (t, C H 2CH N), 34.5 (q, 
C H 3N), 63.3 (t, C H 20 )  and 64.0 (d, CHN); m/z  158 (M+ (-1H) 0.5% ), 142, 128 
(100% ), 126, 110, 96 and 82 (Found: A/+ -H 158.1181. C sH i6 N 0 2 requires M +-H  
158.1181).
AM Vlethyl-fra/>s2,6-bis(isopropylaiiiinocarboiiyloxymethyl)piperidine 
(107)
N -M ethyl-m m .y-2,6-bis(hydroxym ethyl)piperidine (0.46 g, 2.9 mm ol) and isopropyl 
isocyanate (0.74 g, 8.7 mmol) were reacted according to procedure A for 24 h. The 
product was obtained as an oil which was subjected to flash chromatography on alumina 
with ethyl acetate. After evaporation, the remaining white powder was crystallised from 
dichloromethane/hexane to leave the product as flakey white crystals (0.82 g, 8 6 %), Rp 
0.67 (EtOAc), m.p. 138-140 °C, v max 3400, 2980, 2800, 1690 and 1370 c n r 1; 8 H 1.15 
(12H, d, J 1 Hz, C / /3CH), 1.40 (2H, m, C / /2C H 2CH N), 1.68 (4H, m, C / /2C H N ),
2.30 (2H, m, C //N C H 3), 2.33 (3H, s, N C ff3), 3.81 (2H, m, C tfC H 3), 4.10 (4H, m, 
CH2O) and 4.71 (2H, bs, NH); 8 C 23.0 (q, C H 3CH), 25.6 (t, C H 2C H 2CH), 28.5 (t, 
C H 2CH), 37.5 (q, N C H 3), 42.9 (d, CHNH), 63.2 (d, C H N C H 3), 66.7 (t, C H 20 )  and
155.8 (s, C = 0 ); m/z 314 , 227, 213, 227,128, 110 (100%) and 96 (Found: C, 58.11; H, 
9.49; N; 12.98. C 16H 31N 3O4 requires C, 58.36; H, 9.42; N, 12.77%).
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A-M ethyl-fra/is-2,6-bis(ethylam inocarbonyloxym ethyl)piperidine (108)
Ar-Methyl-fra/z.y-2,6-bis(hydroxymethyl)piperidine (0.46 g, 2.9 mmol) and ethyl 
isocyanate (0.62 g, 8.7 mmol) were reacted according to procedure A for 24 h. The 
product was obtained as a thick clear oil after flash chromatography on alumina using 
ethyl acetate as eluant (0.83 g, 95%), Rp 0.43 (EtOAc:hexane, 1:1), vmax 3460, 2980, 
2800 and 1700 c m 1; 6H 1.13 (6H, t, J 1 Hz, CH3CH2), 1.40 (2H, m, CH2CH2CHN), 
1.81 (4H, m, CH2CHN), 2.31 (3H, s, N C //3), 3.09-3.27 (6H, m, C tf2CH3 & CHN),
4.10 (4H, m, C H 2O), 5.30 (2H, bs, NH); 8C 14.9 (q, C H 3C H 2), 23.5 (t, 
C H 2C H 2CH), 28.2 (t, C H 2CHN), 35.7 (t, C H 2C H 3), 37.1 (q, N CH 3), 63.1 (d, 
CHN), 66.5 (t, CH20 ), 156.6 (s, C=0); m/z 302 (M+, 0.2%), 286, 257, 213, 199 
(100%), 128, 110 (100%), 96 and 82 (Found: A/+, 302.2072. Ci4H28N30 4 requires 
A/+302.2079).
AMVlethyl-lra/is-2,6-bis(phenylaminocarbonyIoxymethyl)piperidine (109)
N-Methyl-frans-2,6-bis(hydroxymethyl)piperidine (0.50 g, 3.1 mmol) and phenyl 
isocyanate (1.12 g, 9.3 mmol) were reacted according to procedure A for 24 h. The 
product was obtained as an oil which was purified using a flash chromatography column 
on alumina with ethyl acetate as eluant. The resulting white powder after evaporation was 
crystallised from dichloromethane/hexane (1.10 g, 88%), m.p. 130-132 °C, Rp 0.58 
(EtOAc:hexane, 1:1), vmax 3390, 2800, 1700, 1590, 1525, 750 and 690 cm-1; 8H (d6- 
DMSO) 1.20-1.93 (6H, m, ring CH2), 2.32 (3H, s, NCH3), 2.35 (2H, m, CHNCH3),
4.11 (4H, m, C //20), 6.99 (2H,m, p-CH), 7.28 (4H, m, m-CH) 7.53 (4H, m, o-CH) 
and 9.55 (2H, s, NH)\ 8C 23.3 (t, CH 2C H 2CHN), 27.5 (t, C H 2CHN), 36.8 (q, 
NCH3), 63.4 (d, CHNCH3), 66.4 (t, CH20), 118.3 (d, o-CH), 122.4 (d, p-CH), 128.8 
(d, m-CH), 139.3 (s, CNH), 153.6 (s, C=0); m/z 247, 213, 128, 119, 110, and 93 
(100%) (Found: C, 66.32; H, 6.99; N, 10.29. C22H27N30 4 requires C, 66.50; H, 6.80; 
N, 10.57%).
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A-M ethyl-toz/i£-2,6-bis(p-nitrophenylam inocarbonyloxym ethyl)piperidine
(110)
Af-Methyl-rrart.s-2,6-bis(hydroxymethyl)piperidine (0.50 g, 3.1 mmol) and/?-nitrophenyl 
isocyanate (1.55 g, 9.4 mmol) were reacted according to procedure A  for 24 h. A fter 
removal o f  the solvent, a yellow pow der was left w hich was purified using a gravity 
alum ina colum n, eluting with toluene.ether (2 : 1) to produce yellow crystals (0.65 g, 
42% ), Rp 0.40 (toluenerether, 2:1) m.p. 49-50 °C, v max 3360, 2920, 2800, 1720, 1600, 
1550, 1500, 1330 and 850 cm -1; 5h (CD 3OD) 1.34-1.90 (6 H, m, ring CH 2), 2.40 (3H, 
s, N C H 3), 2.42 (2H, m, CH NCH 3), 4.17 (4H, m, CH 20 ) ,  7.52 and 8.04 (8 H, d, J  9 
Hz, AA'BB' arom atic system); 8c 24.4 (t, CH 2C H 2CHN), 29.0 (t, CH2CHN), 38.1 (q, 
N C H 3), 64.6 (d, C H N C H 3), 67.9 (t, CH 20 ) ,  118.8 (d, C H C N H ), 125.8 (d, 
C H C N O 2), 143.8 (s, CNH), 146.6 (s, C N 0 2) and 154.9 (s, C = 0); m/z 350, 322, 242,
110 and 96 (Found: C, 54.58; H, 5.53; N, 14.42. C 22H 25N 5O 8 requires C, 54.21; H, 
5.13; N, 14.37%).
A-M ethyl-/ra/i5-2,6-bis(chlorom ethyl)piperidine (111)
Af-Methyl-fra«.s-2,6-bis(hydroxymethyl)piperidine (0.46 g, 3.2 mmol) was dissolved in 
dichloromethane and added slowly to thionyl chloride at 0 °C. The mixture was heated at 
reflux for 3 h, then water was added carefully and the solution was saturated with sodium 
bicarbonate. Separation of the two phases was followed by washing of the organic phase 
with NaHCC>3 solution (2 x 20 ml), drying, filtration and evaporation to yield N-methyl- 
fran.y-2,6-bis(chloromethyl)piperidine as a brown oil. Flash chromatography using ethyl 
acetate as eluant gave the product as a clear oil (0.45 g, 72%), Rp 0.70 (EtOAc:hexane, 
1:8), v max 2939, 2860, 2786 and 674 c m 1; 6 H 1.61-1.91 (6 H, m, ring CH2\  2.32 (3H, 
s, N C //3), 2.40 (2H, m, NCH) and 3.58 (4H, m, CH2C1); 6 C 23.0 (t, C H 2C H 2C H N ),
27.3 (t, CH 2CHN), 36.0 (q, N CH 3), 47.5 (t, CH 2C1) and 63.6 (d, CHN); m/z 197 (M+ 
0.7%), 160, 110 and 96 (Found: M + 197.0561. C 8H 15NCI2 requires M +197.0552).
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yV-Methyl-lra/i5-2,6-bis(bromomethyl)piperidine (112)
Af-MethyI-rraw.s-2,6-bis(hydroxymethyl)piperidine (0.46 g, 3.2 mmol) was dissolved in 
dichloromethane and added slowly to phosphorus tribromide (1.92 g, 7.1 mmol) at 0 °C. 
The mixture was heated at reflux for 3 h, then water was added carefully and the solution 
was saturated with sodium bicarbonate. Separation of the two phases was followed by 
washing of the organic phase with NaHCC>3 solution (2 x 20 ml), drying, filtration and 
evaporation to yield ALmethyl-fran.y-2,6-bis(bromomethyl)piperidine as a clear oil (0.31 
g, 34%), Rp 0.70 (EtOAc:hexane, 1:8), v max 2945, 1313 and 568 cm-1; 8h 1.41-1.85 
(6H, m, ring CH 2), 2.32 (3H, s, NCH3), 2.44 (2H, m, NCH), 3.42 (2H, dd, J  6 Hz 
and J  11 Hz, C //2Br) and 3.56 (2H, dd, J  6 Hz and J  11 Hz, CH2Br); 5C 22.5 (t, 
CH2CH2CHN), 28.9 (t, CH2CHN), 36.4 (t, CH2Br), 36.6 (q, NCH3) and 63.5 (d, 
CHN); m/z 285 (M+ 1.2%), 204, 190 (100%), 110 and 96 (Found M + 284.9542. 
CgHi5NBr2 requires M + 284.9553).
Ar-M ethyl-lra/!£-2,6-bis(isopropyIaminocarbonyloxymethyl)piperidme N-  
oxide. (113)
A^-Methyl-rranls-2,6-bis(isopropylaminocarbonyloxymethyl)piperidine (0.27 g, 0.8 
mmol) and mCPBA (0.20 g, 0.9 mmol) were reacted according to procedure B for 18 h. 
This left a white powder which was recrystallised from ethyl acetate to give the product 
(0.14 g, 42%), m.p. 177-178 °C, RF 0.70 (MeOH), vmax 3330, 2970, 1690 and 920 cnr 
8h 1.16 (12H, d, J 1 Hz, C //3CH), 1.53-2.07 (6H, m, ring C //2), 3.15 (3H, s, 
N+Cff3), 3.30 (2H, m, C/7N+), 3.77 (2H, m, CtfCH3), 4.07 (2H, d, J  13 Hz, C //20 ),
4.77 (2H, dd, J  6 Hz and J  13 Hz, CH20)  and 5.93 (2H, bd, J 1 Hz, NH)\ 8C 22.1 (t, 
CH2CH2CHN+), 22.8 (q, CH3CH), 24.2 (t, CH2CHN+), 43.1 (d, CHNH), 55.6 (q, 
N+CH3), 63.6 (t, CH20), 75.2 (d, CHN+) and 155.5 (s, C=0); m/z 327, 314, 213, 
158, 126, 110 (100%) and 96 (Found: C, 55.41; H, 8.76; N, 11.81. C i6H 3iN 30 5 
requires C, 55.65; H, 8.99; N, 12.17%).
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Ai-Methyl-lr<z/is-2,6-bis(ethylaminocarbonyloxyinethyl)piperidine N-
oxide. (114)
Ar-Methyl-rran.s-2,6-bis(cthylaminocarbonyloxymethyl)piperidine (0.50 g, 1.6 mmol) 
and mCPBA (0.36 g, 1.68 mmol) were reacted according to procedure B for 4 h. This 
left a yellow oil which was crystallised from acetone to leave the product as a white solid 
(0.26 g, 52%), m.p. 178-179 °C, RF 0.63 (MeOH), vmax 3420, 2990,1720 and 920 cnr 
8h (D20 )  0.98 (6H, t, 7 7 Hz, CH3CH2), 1.44-1.80 (6H, m, ring CH2), 2.95-3.12 
(7H, m, CH3N+ and CH2CH3), 3.38 (2H, m, CHN+), 3.93 (2H, d, 7 13 Hz, CH20 )  
and 4.44 (2H dd, 7 6 Hz and 7 13 Hz, C //20); 8C 14.9 (q, C H 3CH), 22.1 (t, 
CH2C H 2CHN), 24.8 (t, CH2CHN), 36.3 (t, CH 2C H 3), 55.4 (q, CH 3N), 64.4 (t, 
CH20), 75.6 (d, CHNO) and 158.5 (s, C=0); m/z 317 (M+ 0.5%), 246, 215 199, 126, 
110 and 96 (Found: M+ 317.1973. C 14H27N30 5  requires Af+317. 1951).
N  -M ethyl-rrans-2 ,6-b is(phenylanrinocarbonyloxym ethyl)p iperid ine N-  
oxide. (115)
/V-Methyl-frans-2,6-bis(phenylaminocarbonyloxymethyl)piperidine (0.30 g, 0.75 mmol) 
and mCPBA (0.20 g, 0.9 mmol) were reacted according to procedure B for 4 h. This left 
a white powder which was recrystallised with methanol and the mother liquors were 
crystallised from ethyl acetate (0.14 g, 45%), m.p. 178-180 °C, Rp 0.67 (EtOAc), vmax 
3400, 2990, 1700, 1600, 1525, 920, 760 and 690 c m 1; 8H (d,;-DMSO) 1.56-1.88 (6H, 
m, ring CH2), 3.15 (3H, s, N+CH3), 3.59 (2H, m, C7/N+), 4.07 (2H, d, 7 11 Hz, 
CH2O), 4.76 (4H, dd, J  6 Hz and J  13 Hz, CH2O), 7.02 (2H, t, J  8 Hz, p-CH),  7.31 
(4H, t, J  8 Hz, m-CH)  and 7.53 (4H, d, J  8 Hz, o-CH)\ 8C 21.5 (t, CH2CH2CHN+),
24.2 (t, CH2CHN+), 55.2 (q, CH3N+), 63.4 (t, CH20 ), 73.0 (d, CHN+), 118.3 (d, o- 
CH), 122.5 (d, p-CH), 128.7 (d, m-CH), 139.1 (s, CNH) and 153.3 (s, C=0); m/z  
247, 213, 144, 126, 110 and 96 (Found: C, 60.42; H, 5.89; N, 9.10. 
C22H27N30 5.1.5H20  requires C, 60.00; H, 6.13; N, 9.54%).
177
A-M ethyl-fra/is-2,6-bis(chlorom ethyl)piperidine A-oxide. (116)
A-Methyl-rra«.s-2,6-bis(chloromethyl)piperidine (0.10 g, 0.5 mmol) and mCPBA (0.14 
g, 64 mmol) were reacted according to procedure B for 18 h. This left N-methy\-trans-
2.6-bis(chloromethyl)piperidine A-oxide as a yellow oil (0.06 g, 58%), Rp 0.40 
(MeOH), vmax 2947, 915 and 667 c n r1; 6H (CD3OD) 1.60-1.91 (4H, m, C //2CHN+), 
2.09-2.16 (2H, m, CH2R), 2.81 (3H, s, CH3N+), 3.18 (2H, m, C//N +), 3.87 (2H, 
dd, J  4 Hz and 11 Hz, CH2C1) and 4.18 (2H, dd, J  3 Hz and 11 Hz, CH2C1); 5C 23.1 (t, 
CH2R), 27.2 (t, CH2CHN+), 41.0 (t, CH2C1), 44.4 (q, CH3N+) and 80.7 (d, CHN+); 
m/z 211 (Af+ 4.7%), 196, 176, 146 (100%), 110 and 94 (Found: C, 45.10; H, 7.24; N, 
6.56. C8H i5NOC12 requires C, 45.28; H, 7.08; N, 6.60%).
A-M ethyl-frans-2,6-bis(brom om ethyl)piperidine A-oxide. (117)
A-Methyl-frartj-2,6-bis(bromomethyl)piperidine (0.10 g, 0.4 mmol) and mCPBA (0.08 
g, 45 mmol) were reacted according to procedure B for 18 h. This left A-methyl-fra/w-
2.6-bis(bromomethyl)piperidine A-oxide as a yellow oil (0.06 g, 50%), v max 2948, 
2870, 923 and 574 c n r1; 6H (CD3OD) 1.37-1.76 (4H, m, CH2CHN+), 2.12 (2H, m, 
CH2R), 2.94 (3H, s, CA3N+), 3.13 (2H, m, C//N+), 3.64 (2H, m, CH2B t) and 3.95 
(2H, m, CA2Br); 8C 21.7 (t, CH2R), 28.3 (t, CH2CHN+), 36.6 (t, CH2Br), 46.4 (q, 
CH3N+) and 75.1 (d, CHN+); m/z 285, 204, 190 (100%), and 96.
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Experimental to Chapter 5
1.4-Bis(2-isopropylam inocarbonyIoxyethyI)piperazine (128)
1.4-Bis(2-hydroxyethyl)piperazine (1.0 g , 5.75 mmol) and isopropyl isocyanate (1.47 
g, 17.2 mmol) were reacted according to procedure A for 3 h until a clear solution was 
obtained. The solvent was then removed in vacuo to leave a white powder. This was 
recrystallised from dichloromethane/hexane to produce a white solid (1.91 g, 100%), 
m.p. 127-128 °C, RF 0.70 (EtOAc), vmax 3330, 2780, 2810, 1690, 1365 c m 1; 6H 1.15 
(12H, d, J 1 Hz, C //3CH), 2.55-2.64 (12H, m, NCH2), 3.78 (2H, m, C/JCH3), 4.16 
(4H, t, J  6 Hz, CH20 )  and 4.83 (2H, bs,Ntf); Sc 23.4 (q, CH3CH), 43.0 (d, CHCH3),
53.1 (t, ring CH2), 57.1 (t, NCH2), 61.5 (t, CH20), and 155 7 (s, O O ); m/z 334 (M+, 
0.1%), 242 (8.6%), 228 (35.2%), 156 (82.0%), 125 (100%) (Found: Af+, 344.2423, 
C, 55.87; H, 9.51; N, 16.47. C i6H32N40 4 requires M+ 344.2407, C, 55.80; H, 9.30; 
N, 16.27%).
1.4-Bis(2-ethylam inocarbonyIoxyethyl)piperazine (127)
1.4-Bis(2-hydroxyethyl)piperazine (1.0 g, 5.75 mmol) and ethyl isocyanate (1.25 g,
17.2 mmol) were reacted according to procedure A for 3 h until a clear solution was 
obtained. The solvent was then removed in vacuo to leave an oil. This was then 
crystallised from dichloromethane/hexane to produce a white solid (1.73 g, 95%), m.p. 
102 °C, RF 0.70 (EtOAc); v max 3330, 2830, 1710 c n r 1; 6H 1.13 (6H, t, /  7 Hz, 
CH3CH2), 2.54-2.64 (12H, m, NCH2), 3.20 (4H, q, J  7 Hz, C tf2CH3), 4.17 (4H, t, J 
5.5 Hz, CH2O) 5.20 (2H, bs, NH)\ 5C 15.1 (q, CH3CH), 35 6 (t, CH2CH3), 53.1 (t, 
ring CH2), 57.0 (t, NCH2), 61.6 (t, CH20), and 156.3 (s, C=O); m/z 316 (A/+, 0.1%) 
227 (14.4%), 214 (36.3%), 156 (32.5%), and 125 (100%); (Found: M+, 316.2110, C, 
52.80; H, 8.64; N, 18.08. C ,4H28N40 4 requires A/+ 316.2108, C, 53.16; H, 8.86; N, 
17.72%).
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l,4-Bis(2-phenylam inocarbonyloxyethyl)piperazine (129)
l,4-Bis(2-hydroxyethyl)piperazine (1.0 g, 5.75 mmol) and phenyl isocyanate (2.05 g,
17.2 mmol) were reacted according to procedure A for 6 h and a white precipitate was 
obtained. The solvent was then removed in vacuo to leave a white powder. This was 
recrystallised from methanol to produce a white solid (1.91 g, 100%), m.p. 158-159 °C, 
Rp 0.75 (EtOAc); v max 3330, 2810, 2780, 1700, 1600, 1530, 750, 690 cm-1; 6H (c^- 
DMSO) 2.52 (8H, s, ring CH2), 2.63 (4H, t, J  6 Hz, N C //2), 4.22 (4H, t, J  6 Hz, 
CH20 ), 6.96 (2H, t, J 1 Hz, p-CH), 7.25 (4H, t, J 1 Hz, m-CH), and 7.46 (4H, d, J 1 
Hz, o-CH)\ 8C (d6-DMSO) 53.1 (t, ring CH2), 56.7 (t, NCH2), 61.5 (t, CH20), 118.4 
(d, o-CH), 122.3 (d, p-CH), 128.5 (d, m-CH), 139.0 (s, CNH) and 153.7 (s, C=0); 
m/z 262 (20.6%), 156 (40.0%) and 125 (65.5%) (Found: C, 64.37; H, 6.60; N, 13.52. 
C22H28N40 4 requires C, 64.10; H, 6.97; N, 13.59%).
1.4-Bis(2-p-nitrophenylaminocarbonyIoxyethyl)piperazine (130)
1.4-Bis(2-hydroxyethyl) piperazine (1.0 g , 5.75 mmol) and p-nitrophenyl isocyanate 
(2.83 g, 17.2 mmol) were reacted according to procedure A for 18 h. Undissolved 
starting material was filtered off and the solvent was removed in vacuo to leave a yellow 
powder. This was then washed repeatedly with methanol to produce a yellow solid (1.62 
g, 56%), m.p. 215-217 °C, vmax 3340, 2820, 1730, 1600, 1550, 1500, 1330 and 850 
cm-1; 8H (d6-DMSO) 2.39-2.55 (8H, m, ring C //2N), 2.62 (4H, t, J  5 Hz, NCH2), 4.27 
(4H, t, 7 5  Hz, CH20),  7.74 and 8.30 (8H, d, J ca. 9 Hz, AA'BB' system) and 10.46 
(2H, bs, NH); 8C 52.9 (t, ring CH 2), 56.5 (t, CH 2N), 62.0 (t, CH 20), 117.8 (d, 
CHCNH), 125.2 (d, CH CN 02), 141.7 (s, CNH), 145.9 (s, C N 02) and 153.4 (C=0); 
m/z 307, 164, 143, 125 and 70 (Found: C, 52.41; H, 5.14; N, 16.80. C22H26N60 8 
requires C, 52.59; H, 5.18; N, 16.73%).
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l,4-bis(2-chloroethyl)piperazine dihydrochloride136 (125)
1.4-Bis(2-hydroxyethyl)piperazine (1.0 g, 5.74 mmol) was dissolved in dichloromethane 
and added slowly to thionyl chloride (10 ml) at 0 °C. The reaction was left to stir for 8 h 
at room temperature after which the solvent was removed to leave a yellow solid. This 
was recrystallised from methanol to leave white crystals (1.20 g, 74%), m.p. 215-216 
°C, vmax 2820, 2790 and 670 c m 1; 6H (D20 ) 3.70 (4H, t, J 4 Hz, CH2N+), 3.77 (8H, 
s, ring CH2) and 3.94 (4H, t, J  4 Hz, CH2C1); 8C 37.6 (t, CH2C1), 49.2 (t, ring CH2) 
and 58.4 (t, CH2N+); m/z 212 (A/+ 2.1%), 177, 174, 161 (100%), 125, 118 and 70 
(100%) (Found: Af+ 212.0662. C8H i6N2C12 requires M+212.0664).
1 .4 -B is(2-isopropylam inocarbonyloxyethy l)p iperazine A-oxide (132)
mCPBA (0.43 g, 2 mmol) and l,4-bis(2-isopropylaminocarbonyloxyethyl)piperazine 
(0.30 g, 0.90 mmol) were reacted according to procedure B for 3 h. This left a white 
powder which was recrystallised from methanol to leave the product (0.22 g, 64%), Rp 
0.50 (EtOAc) m.p. 157-158 °C, vmax 3430, 2870, 1690, 1466, 1367, 1257 and 960 Cm" 
»; 6h (d6-DMSO) 1.10 (12H, d, J  7 Hz, C //3CH), 3.63 (6H, m, ring C/72N+ax and 
C //C H 3), 3.98 (4H, bs, C //2N+), 4.33 (4H, d, J  9 Hz, ring CH2N+eq ) and 4.58 (4H, 
bs, C //20); 5C 22.6 (q, CH3CH), 42.6 (d, CHCH3), 57.3 (t, CH2N+), 58.6 (t, ring 
CH2), 67.8 (t, CH20 ) and 154.7 (s, C=0); m/z 172, 156, 143, 126, 115 and 70 (100%) 
(Found: C, 44.47; H, 8.53; N, 12.95. C i6H32N40 6.3H20  requires C, 44.65; H, 8.83: 
N, 13.02%).
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l,4-Bis(2-ethylam inocarbonyloxyethyl)piperazine A-oxide (131)
mCPBA (0.57 g, 2.65 mmol) and l,4-bis(2-ethylaminocarbonyloxyethyl)piperazine 
(0.40 g, 1.27 mmol) were reacted according to procedure B for 4 h. This left a white 
powder which was recrystallised from methanol to give the product (0.35 g, 79%), m.p. 
205-207 °C, RF 0.56 (MeOH), vmax 3330, 1690 and 960 c m 1; 5H (D20) 0.95 (6 H, t, 7 7  
Hz, C //3CH2), 2.96 (4H, q, 7 7 Hz, C //2CH3), 3.24 (4H, d, 7 9 Hz, ring C/72N+ax), 
3.50 (4H, bs, CA2N+), 4.12 (4H, d, 7 9 Hz, ring C //2N+eq) and 4.44 (4H, bs CH2O); 
8 C 14.9 (q, CH3), 36.3 (t, CH2CH3), 58.9 (t, CH2N+), 59.9 (t, ring CH2), 69.8 (t, 
CH20 ) and 158.1 (s, C=0); m/z 243, 188, 175, 157, 143 and 70 (Found: C, 43.53; H, 
8.06; N, 14.35. C i4H28N40 6 .2H20  requires C, 43.75; H, 8.33; N, 14.58).
l,4-Bis(2-phenyIam inocarbonyloxyethyl)piperazine A-oxide (133)
mCPBA (0.45 g, 2.1 mmol) and l,4-bis(2-phenylaminocarbonyloxyethyl)piperazine 
(0.40 g, 0.97 mmol) were reacted according to procedure B for 4 h. This left a white 
powder which was recrystallised from methanol (0.36 g, 84%), m.p. 151-152 °C, Rp 
0.70 (EtOAc), vmax 3400, 1720, 1074 c m 1; 8 H (d6-DMSO) 3.82 (4H d, 7 9 Hz, ring 
C tf2N+ax), 4.15 (4H, bs, C //2N+), 4.40 (4H, d, 7 9 Hz, ring C //2N+eq), 4.76 (4H, 
bs, CH2O), 7.02 (2H, t, 7 7 Hz, p-CH), 7.31 (4H, t, 7 7 Hz, m-CH), 7.48 (4H, d, 7 7 
Hz, o-CH) and 9.82 (2H, bs, NH); 8 C 57.9 (t, CH2N), 58.5 (t, ring CH2N), 67.2 (t, 
CH20 ), 118.5 (d, o-CH), 122.7 (d, p-CH), 128.8 (d, m-CH), 139.0 (s, NHCH) and
152.9 (s, C=0); m/z 262, 188, 175, 157, 143, 119 (100%) and 70 (Found: C, 54.79; H, 
6.71; N, 11.63. C22H28N40 6 .2H20  requires C, 55.00; H, 6 .6 6 ; N, 11.66%).
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l,4-Bis(2-/?-nitrophenylam inocarbonyloxyethyl)piperazine A-oxide (134)
1.4-Bis(2-p-nitrophenylaminocarbonyloxyethyl)piperazine (0.30 g, 0.60 mmol) was 
dissolved in TFA (15 ml). H2O2 (0.27 g, 2.4 mmol) was added and the solution was 
stirred for 18 h at room temperature. The solution was then filtered to remove 
undissolved starting material and the filtrate was added to ether upon which a precipitate 
appeared. This was filtered to leave a pale yellow solid which was washed with methanol 
(0.27 g, 84%), m.p. 173-175 °C (dec), vmax 3340, 1740, 1600, 1550, 1500, 1330, 920 
and 850 c m 1; 8 H (d6-DMSO) 4.05-4.22 (4H, m, CH2O), 4.40-4.52 (12 H, m, 
CH2N+), 7.75 and 8.26 (8H, d, J  ca. 9 Hz, AA'BB' system) and 10.59 (2H, bs, Ntf); 
8C 57.2 (t, ring CH2), 57.6 (t, CH2N), 66.6 (t, CH20), 117.9 (d, CHCNH), 125.2 (d, 
CHCNO2), 141.9 (s, CNH), 145.3 (s, C N 02) and 152.4 (s, C=0); m/z 534, 234, 208, 
188, 172, 164 (84%), 157, 90 (100%) and 70; (Found: C, 46.74; H, 5.88; N, 14.77. 
C22H26N6O10.2H2O requires C, 46.32; H, 5.26; N, 14.74%).
1.4-bis(2-chloroethyl)piperazine A -ox id e136 (135)
1.4-bis(2-chloroethyl)piperazine hydrochloride (0.2 g, 0.71 mmol) and triethylamine 
(0.11 g, 1.48 mmol) were dissolved in acetone and stirred for 4 h to form the free base. 
mCPBA (0.32 g, 1.5 mmol) was then added and the solution was stirred for another 2.5 
h. The solvent was removed in vacuo and the residue taken up in methanol. This solution 
was then subjected to alumina flash column chromatography with methanol after which 
the solvent was removed to leave a white solid which was recrystallised from 
dichloromethane/hexane (0.13 g, 76%), Rp 0.70 (EtOAc:hexane, 1:3), m.p. 62-64 °C, 
Vmax 670 and 950 c n r1; 6H 2.73-3.36 (8H, m, ring CH2), 3.64 (4H, t, /  6 Hz, CH2N+) 
and 3.90 (4H, t, J  6 Hz, CH2O); 6C 42.1 (t, ring CH2), 54.4 (t, CH2N+) and 71.6 (t, 
CH2C1); m/z 244 (Af+ 8.1%), 165, 163 (100%), 147 and 84 (Found: M+ 244.0558; C, 
39.58; H, 6.28; N, 11.28. C8H 16N20 2Cl2 requires M+ 244.0557; C, 39.51; H, 6.58; 
N, 11.52%).
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Experimental to Chapter 6
Methyl DL-Pipecolinate Hydrochloride (144)
A solution of DL-pipecoIinic acid (10.0 g, 77.5 mmol) in distilled 2,2-dimethoxypropane 
(160 ml) with conc. HC1 ( 8 8  ml) was heated at reflux for 30 min then stirred at room 
temperature for 18 h. The solution was concentrated to leave a red solid. This was 
washed with isopropanol to remove the red colour and leave a white powder ( 1 2 .6  g, 
91%), m.p. 205-207 °C, vmax 2990, 1750, 1250 and 1100 c m 1; 8 H (D20 )  1.42-1.77 
and 2.16 (6 H, m, ring CH2), 2.91 and 3.31 (1H, m, NCH2), 3.68 (3H, s, CO2CH3) 
and 3.88 (1H, m, C//N); 8 C 22.0 and 22.1 (t, ring CH2), 26.5 (t, CH 2CH 2CH 2N),
44.9 (t, CH2N), 54.4 (q, C 0 2CH3), 57.6 (d, CHN) and 171.0 (s, C=0); m/z 143 (A/+
8.4 %), 128, 84 (100%) and 82 (Found: M+ 143.0946. C7H i3N 0 2 requires 143.0944).
Ar,Ar'-(l,2-D ioxo-l,2-ethanediyl)bis(2-m ethoxycarbonylpiperidine) (145)
To a solution of chloroform (30 ml) was added methyl pipecolinate hydrochloride (5.0 g,
27.8 mmol) and triethylamine (6.80 g, 66.7 mmol) under nitrogen. The solution was 
stirred for 10 min before being cooled to -5 °C. Oxalyl chloride (1.65 g, 13.0 mmol) was 
then added dropwise over a period of 10 min. The flask was then allowed to return to 
room temperature and the components were stirred for 2 h. Removal of the solvent in 
vacuo left a brown residue which was taken up in water and extracted with ethyl acetate 
(3 x 30 ml). The combined organic extracts were dried, filtered and evaporated to leave a 
yellow oil. Flash chromatography on alumina using EtOAc followed by concentration 
produced a clear oil (3.60 g, 82%), Rp 0.70 (EtOAc), v max 2948, 2861, 2712, 1739 and 
1659 cm-1; 8 H 1.20-1.82 (10H, m, ring CH2), 2.18-2.35 (2H, m, ring C //2CH 2N), 
2.85 (1H, m, CH2N), 3.31 (1H, m, CH2N), 3.77 (6 H, s, CH3) and 5.26 (2H, m, 
CHN)-  8 C 20.9, 21.1, 24.6 25.0, 26.0 and 26.2 (t, ring CH2), 43.4 and 43.9 (t, 
CH2N), 51.0 (q, COCH3), 52.3 (d, CHN), 164.3 and 164.9 (s, NC=0) and 170.6 and
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170.8 (s, COCH3 ); m/z 340 (M+ 5%), 281, 197, 170, 142 (100%) and 111 (Found: M+
340.1634. C 1 6H2 4 N2 O6  requires M+ 340.1635).
N ,N '-(l,2-Ethanediyl)bis(2-m ethoxycarbonylpiperidine) (146)
N, N'-(l,2-Dioxo-l,2-ethanediyl)bis(2-methoxycarbonylpiperidine) (2.0 g, 5.9 mmol) in 
dry THF (20 ml) was added to a solution of 1M borane-THF (30 ml, 30 mmol) under 
nitrogen at 0 °C. The solution was then heated at reflux for 2 h. 6 M HC1 (5 ml) was 
added dropwise at 0 °C with the formation of hydrogen, followed by the addition of 
water (10 ml). The THF was then removed by distillation to leave an aqueous solution 
which was concentrated in vacuo. Methanol (20 ml) and conc. HC1 (2 drops) were added 
to the residue and the mixture was concentrated in vacuo to remove the methyl borate 
formed. This procedure was repeated twice, after which no more weight loss was 
recorded. The remaining thick clear oil was taken up in chloroform (25 ml) and 
triethylamine (5 ml) was added. The resulting solution was stirred for 30 min before 
being concentrated to leave a white residue. This was taken up in water and extracted 
with ethyl acetate (3 x 30 ml). The combined organic extracts were dried, filtered and 
evaporated to leave a clear oil (1.46 g, 73%), Rp 0.60 (EtOAc), vmax 2935, 2855 and 
1737 cm-1; 6 H 1.32-1.74 (12H, m, ring CH2), 2.16 (2H, m, C//N), 2.42 and 2.57 (4H, 
m, ring C7/2N), 3.05 (4H, m, NCH2CH2N ) and 3.65 (6 H, s, C 0 2CH3)\ 8 C 22.5, 22.6, 
25.3, 29.6 and 29.7 (t, ring CH2), 50.7 and 50.9 (t, ring CH2N), 51.6 (q, CO2CH3),
53.8 and 54.0 (t, NCH 2 CH 2N), 65.1 and 65.4 (d, CHN) and 174.1 and 174.2 (s, 
C 0 2CH3); m/z 312 (M+ 8 %), 253, 170, 156 (100%) and 112 (Found: M+ 312.2049. 
C 16H28N2O4 requires M+ 312.2028).
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A^NXljZ-EthanediyObis^-hydroxymethylpiperidine) (147)
N,Af'-(l,2-Ethanediyl)bis(2-methoxycarbonylpiperidine) (2.0 g, 6.4 mmol) in dry THF 
(20 ml) was added dropwise to a solution of 1M LiAlU* (15 ml, 15 mmol) at 0 °C under 
nitrogen. The solution was warmed to room temperature and stirred for 4 h. The flask 
was then cooled to 0 °C and water : THF (1 : 1, 20 ml) was added dropwise. Both 
solvents were evaporated in vacuo which left a white powder. This was stirred with 
dichloromethane (30 ml) for 30 min then the solution was filtered and the filtrate was 
concentrated in vacuo to leave a clear oil (1.56 g, 95%), Rp 0.34 (MeOH), vmax 3329, 
2926, 2853 and 1284 c m 1; 6 H 1.34-1.71 (12H, m, ring CH2), 199 (2H, d, J  11 Hz, 
CHN), 2.17 (4H, m, ring CH2N), 2.84 (4H, d, J  11 Hz, NCH2CH2N), 3.18 (2H, dd, 
J  1.5 Hz and J  12 Hz, CH2OH), 3.85 (2H, dd, J  3.5 Hz and J  12 Hz, CH2OH) and 
4.26 (2H, b>, OH); 6 C 24.2, 25.0 and 28.7 (t, ring CH2), 49.3 (t, ring CH2N), 54.4 (t, 
NCH2CH2N), 62.1 (d, CHN) and 63.0 (t, CH2OH); m/z 256, 255, 238, 225, 142, 128 
(100%), 110, 98 and 84 (Found: M + -H, 255.2072. C i4 H 2gN2 0 2 requires M + -H 
255.2069).
N,/V’-(l»2-Ethanediyl)-bis(2-isopropylam inocarbonyIoxym ethyI- 
piperidine) (148)
N,N'-( 1,2-Ethanediyl)bis(2-hydroxymethylpiperidine) (0.30 g, 1.2 mmol) and isopropyl 
isocyanate (0.31 g, 3.6 mmol) were reacted according to procedure A for 18 h. This gave 
the product as a yellow oil which was purified by flash chromatography on alumina using 
ethyl acetate as eluant. After concentration the remaining white powder was recrystallised 
using dichloromethane/hexane (0.45 g, 8 8 %), Rp 0.60 (EtOAc), m.p. 162-164 °C, v max 
3331, 2928, 2853, 2795, 1684, 1364 and 1259 cm->; 8 H 1.15 (12H, d, J  11 Hz, 
CH 3CH), 1.36-1.74 (12H m, ring CH2), 2.12-2.72 (4H, m, CHN and ring CH2N),
2.89 (4H, m, NCH2CH2N), 3.80 (2H, m, CHCH3), 4.15 (4H, m, CH20 ) and 5.17 
(2H, bs, NH); 6 C 22.8 (q, C H 3CH), 25.3, 28.8 and 29.4 (t, ring CH 2), 42.8 (d,
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CHCH3), 50.72 (t, ring CH2N), 52.7 (t, NCH2CH2N), 59.5 (d, CHN), 65.7 (t, CH20 )  
and 155.7 (s, C=0); m/z 426 (M+ 0.3%), 310, 227, 213 (100%), 128 and 110 (Found: 
M+ 426.3230. C22H42N40 4 requires M+ 426.3180).
Ar,A^'-(l,2-Ethanediyl)-bis(2>ethylam inocarbonyloxym ethylpiperidine) 
(149)
Af,AT-(l,2-Ethanediyl)bis(2-hydroxymethyIpiperidine) (0.30 g, 1.2 mmol) and ethyl 
isocyanate (0.25 g, 3.6 mmol) were reacted according to procedure A for 18 h. This gave 
the product as a clear oil after flash chromatography on alumina eluting with ethyl acetate 
(0.40 g, 82%), RF 0.40 (EtOAc), vmax 3414, 2982, 2806, 1716, 1450 and 1265 cm-1; 
5h 1.14 (6 H, t, J  1 Hz, CH3C H 2), 1.21-1.80 (12H, m, ring CH2), 2.23 (2H, m, 
CHN),  2.52 (4H, m, CH2N), 2.88 (4H, m, NCH2C H 2N ), 3.20 (4H, q ,7  7 Hz, 
CH2CH3), 4.13 (4H, m, CH2O) and 5.31 (2H, bs, NH)\ 6 C 15.2 (q, CH3CH2), 23.5,
25.4 and 29.1 (t, ring CH2), 35.8 (t, CH2CH3), 50.7 (t, CH2N), 52.9 (t, NCH2 CH2N),
59.7 (d, CHN), 66.1 (t, CH20 ) and 156.7 (s, C=0); m/z 398 (M+ 0.1%) 296, 220, 
213, 199 (100%), 142,128 and 110 (Found: M+ 398.2892. C20H38N4O4  requires M+ 
398.2885).
A ,A '-(l,2-Ethanediyl)-bis(2-phenylam inocarbonyIoxym ethyIpiperidine) 
(150)
A^,A-(l,2-Ethanediyl)bis(2-hydroxymethylpiperidine) (0.30 g, 1.2 mmol) and phenyl 
isocyanate (0.43 g, 3.6 mmol) were reacted according to procedure A for 24 h. This gave 
the product as an oil which was purified on an alumina flash chromatography column 
eluting with ethyl acetate. The resulting white powder was then recrystallised from 
dichloromethane (0.45 g, 77%), Rp 0.75 (EtOAc), m.p. 142-143 °C, vmax 3323, 2856, 
1730, 1600, 1538, 754 and 693 c n r1; 8 h (d6-acetone) 1.26-1.71 ( 1 2 H, m, ring CH2), 
2.31 (2H, m, CHN), 2.56 (4H, m, CH2N), 2.89 (4H, m, NCH2CH2N), 4.23 (4H, m,
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CH2O), 6.90 (2H, m, p-CH), 7.26 (4H, m, m-CH), 7.57 (4H, m, o-C//) and 8.85 (2H, 
bs, N//); 8 C 23.7 26.0 and 29,4 (t, ring CH2), 52.1 (t, CH2N), 53.1 (t, NCH2CH2N),
60.3 (d, CHN), 66.2 (t, CH20), 119.2 (d, o-CH), 123.2 (d, p-CH), 129.4 (d, m-CH),
140.0 (s, CNH) and 154.4 (s, C=0); m/z 212, 194, 119 and 93 (100%) (Found: C, 
67.75; H, 7.75; N, 11.46. C28H38N4 0 4  requires C, 68.02, H, 8.04, N 11.37%).
jV,^V'-(l,2-EthanediyI)-bis(2-/?-nitrophenylaminocarbonyloxyiiiethyl- 
piperidine) (151)
7V,Af-(l,2-Ethanediyl)bis(2-hydroxymethylpiperidine) (0.48 g, 1.87 mmol) and p-  
nitrophenyl isocyanate (0.62 g, 3.8 mmol) were reacted in dichloromethane (25 ml) with 
3 drops of dibutyl tin diacetate for 20 h. The solution was then filtered and the filtrate was 
concentrated to leave a yellow residue. This was purified on a gravity column on alumina 
using ethyl acetate : pet ether 40-60 °C which left the product as yellow crystals after 
concentration (0.53 g, 48%), Rp 0.55 (EtOAcrpet ether, 1:2), m.p. 92-93 °C, vmax 3406, 
2932, 2810, 1736, 1599, 1554, 1508, 1332, 1219 and 852 cm*1; 6 H 1.42-2.00 (12H, 
m, ring C H 2), 2.54 (2H, m, CHN),  2.89 (4H, m, C tf2N), 3.18-3.40(4H, m, 
NCH 2CH2N), 4.23 (4H, m, CH2O), 7.58 and 8.13 (8 H, m, aromatic CH) and 9.35 
(2H, bs, NH)\ 5c  22.6, 24.0 and 27.8 (t, ring C H 2), 50.7 (t, C H 2 N), 53.2 (t, 
N C H 2 C H 2 N), 61.1 (d, CHN), 65.4 (t, C H 20 ), 117.8 (d, CHCNH), 125.0 (d, 
CHCN02), 142.7 (s, CNH), 144.6 (s, C N 02) and 152.8 (s, 0=0); m/z 343, 267, 238, 
225, 223, 164, 142, 128 (100%) and 110.
N ,A ’-(l,2-E thanediyl)b is(2-ch lorom ethylp iperid ine) D ihydrochloride143 
(152)
N,N'-(\  ,2-Ethanediyl)bis(2-hydroxymethylpiperidine) (0.40 g, 1.56 mmol) in 
dichloromethane was added slowly to thionyl chloride (15 ml) at 0°C. The solution was 
stirred at room temperature for 24 h, after which the solvent was removed to leave a
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white residue. This was dissolved in methanol and concentrated again, this time to leave 
white crystals (0.51 g, 89%), m.p. 231-233 °C, v max 2948, 2870 and 746 cm '1; 8 h 
(D 2 0 ) 1.58-1.90 (12H, m, ring CH2), 3.17 (2H, m, CHN ), 3.51-3.81 (8 H, m, 
N C H 2CH2N and CH2N) and 4.07 (4H, m, CH2C\y, 5C 21.6, 23.2 and 28.0 (t, ring 
CH2), 43.8 (t, CH2C1), 46.9 (t, CH2N), 54.3 (t, NCH2CH2N) and 65.5 (d, CHN); m/z 
257, 243, 222, 192, 160, 146 (100%), 110 and 97 (Found M+ -Cl 257.1797. 
C i4H26N2CI requires M+ -Cl 257.1791).
(V,lV'-(l>2-Ethanediyl)-bis(2*isopropylaniinocarbonyloxym ethyl- 
piperidine) bis-N-Oxide (153)
N,N'-( 1,2 -Ethanediyl)-bis(2 -isopropylaminocarbonyloxymethylpiperidine) (0.30 g, 0.7 
mmol) and mCPBA (0.33 g, 1.55 mmol) were reacted according to procedure B for 18 
h. This gave the product as white crystals after recrystallisation from acetone (0.20 g, 
62%), m.p. 152-154 °C, RF 0.66 (MeOH), vmax 3343, 2946, 1686, 1364, 1250 and 960 
c m 1; 8 h 1.14 (12H, d, J  7 Hz, C //3CH), 1.37-2.24 (12H m, ring CH2), 3.06 (2H, m, 
C //N + ), 3.44 (4H, m, CH2N+), 3.76 (4H, m, N + C ff2C tf 2 N+), 3.97 (2H, m, 
CHCH3), 4.13 (4H, m, CH2O) and 4.67 (2H, bs, NH)\ 8 C 23.6 (q, CH3CH), 19.9,
22.8 and 24.8 (t, ring C H 2), 43.1 (d, C H C H 3), 61.4 (t, C H 2 N + ), 63.2 (t, 
N+CH2CH2N+), 65.2 (t, CH20 ), 75.1 (d, CHN+) and 155.2 (s, C=0); m/z 245, 158, 
144, 142 and 102 (Found: C, 53.82; H, 8.91; N, 11.60. C22H42N40 6 .2H20  requires 
C, 53.44; H, 9.31; N, 11.34%).
N,Al’-(l,2-E thanediyl)-b is(2-ethylam inocarbonyloxym ethylpiperidine) 
bis-iY-Oxide (154)
N,N'-( 1,2-Ethanediyl)-bis(2-ethylaminocarbonyloxymethylpiperidine) (0.30 g, 0.75 
mmol) and mCPBA (0.36 g, 1.66 mmol) were reacted according to procedure B for 18 
h. This gave the product as a clear oil which was crystallised from acetone and
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recrystallised from dichloromethane (0.24 g, 74 %), m.p. 132-134 °C, RF 0.66 (MeOH), 
Vmax 3396, 2972, 1730, 1248 and 964 c m 1; 8 H 1.10 (6 H, t, CH3CH2), 1.31-2.16 
(12H, m, ring CH2), 3.15 (6 H, m, CHN+ and CH3C //2), 3.38 (4H, N+C//2C //2N+), 
3.68 (4H, m, C //2 N+), 4.52 (4H, m, CH20 )  and 5.31 (2H, m, NH)\ 8 C 15.0 (q, 
C H 3 C H 2 ), 19.9, 2 2 .1  and 24.4 (t, ring C H 2), 35.7 (t, C H 2 C H 3), 61.3 (t, 
N +CH 2 CH 2N+), 62.9 (t, CH 2N+), 65.8 (t, CH 20 ), 74.7 (d, CHN+) and 156.1 (s, 
C=0); m/z 228, 202, 140, 126, 113, 110 and 100 (100%) (Found: C, 47.69; H, 8.94; 
N, 10.92. C2oH38N40 6.4H20  requires C, 47.81; H, 9.16; N, 11.15%).
(V ,iV '-(l,2-Ethanediyl)-bis(2-phenylam inocarbonyloxym ethylpiperidine) 
bis-N -O xide (155)
N,N'-( 1,2-Ethanediy 1 )-bis(2-pheny lam inocarbonyloxy methyl piperidine) (0.30 g, 0.6 
mmol) and mCPBA (0.29 g, 1.3 mmol) were reacted according to procedure B for 18 h. 
This gave the product as white crystals after recrystallisation from acetone (0.20 g, 63%), 
Rf  0.72 (MeOH), vmax 3431, 1726, 1601, 1500, 1230, 1070, 752 and 694 cm-1; 8 H (d6- 
Acetone) 1.35-2.21 (12H, m, ring CH2), 3.37 (2H, m, CHN+), 3.66 (4H, m, CH2N+),
3.89 (4H, m, N+C /f2C ff2N+), 4.65 (4H, m, CH2O), 6.94 (2H, m, p-CH), 7.25 (4H, 
m-CH)  and 7.43 (4H, m, o-C H ); 8 C 20.6, 22.7 and 25.1 (t, ring C H 2), 61.6 (t, 
CH 2N+), 63.8 (t, N+CH 2 CH 2N+), 66.0 (t, CH20 ), 119.1 (d, o-CH), 123.4 (d, p- 
CH), 129.5 (d, m-CH), 140.6 (s, CNH) and 154.0 (s, C=0); m/z 276, 248, 212, 140, 
126, 119 (100%), 113, 110 and 98 (Found; C, 64.03; H, 6.32; N, 10.60. C28H38N40 6 
requires C, 63.88; H, 7.22; N, 10.66%).
Ar,A1'-(l,2-Ethanediyl)-bis(2-/7-nitrophenylam inocarbonyloxym ethyl- 
piperidine) bis-;V-Oxide (156)
N,N'-(\ ,2-Ethanediyl)-bis(2-p-nitrophenylaminocarbonyloxymethylpiperidine) (0.20 g, 
0.34 mmol) and mCPBA (0.16 g, 0.75 mmol) were reacted together in acetone for 18 h
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at room temperature. After careful concentration of the solution, the residue was purified 
using flash chromatography on alumina, eluting first with ethyl acetate to remove any 
impurities, and then with methanol to remove the product. This gave the product as 
yellow crystals (0.11 g, 51%), m.p. 176-177 °C, vmax 3426, 1736, 1599, 1560, 1508, 
1332, 1224, 1064 and 854 cm '1; 5H 1.25-2.20 (12H, m, ring CH2\  3.15 (2H, m, 
C//N+), 3.50 (4H, m, CH2N+), 3.82 (4H, m, N+CH2CH2N+)y 4.70 (4H, m, CH2O), 
7.58 and 8.13 (8 H, AA'BB' system); 8 c 19.7, 21.7 and 24.1 (t, ring CH2), 61.7 (t, 
C H 2N+), 63.4 (t, N +CH 2 CH 2N+), 65.4 (t, CH 20), 71.6 (d, CHN+), 117.7 (d, 
CHCNH), 124.9 (d, C H C N 0 2), 142.5 (s, CNH), 144.8 (s, C N 0 2) and 153.0 (s, 
C=0); m/z 292, 261, 196, 142, 138 (100%), 128, 113, 112 and 100.
N , A '-(l,2-E thanediyl)bis(2-chlorom ethylpiperidine) bis-N-Oxide (157)
N,AT-(l,2-Ethanediyl)bis(2-chloromethylpiperidine) (0.2 g, 0.68 mmol) and mCPBA 
(0.32 g, 1.5 mmol) were reacted according to procedure B for 18 h. This gave the 
product as a yellow oil (0.14 g, 65%), RF 0.61(MeOH), vmax 2947, 2869, 932 and 732 
cm '1- 8 h (D20 )  1.52-2.14 (T2H, m, ring CH2), 3.11 (4H, m, C //2N+) and 3.28-4.16 
(10H, m, N+CH2CH2N+, CHN+ and CH2Cl); m/z 324, 221, 162, 148, 126, 112, 100 
and 84 (100%) (Found M+ 324.1369. C 14H26N2O2CI2 requires M+ 324.1353).
A>A ,-(l,3-D ioxo-l,3-propaned iyl)b is(2-m ethoxycarbonylp iperid ine)
(159)
To a solution of chloroform (30 ml) was added methyl pipecolinate hydrochloride (5.0 g,
27.8 mmol) and triethylamine (6.80 g, 66.7 mmol) under nitrogen. The solution was 
stirred for 10 min before being cooled to -5 °C. Malonyl dichloride (1.27 ml, 13.0 mmol) 
was then added dropwise over a period of 10 min. The flask was then allowed to warm 
to room temperature and the mixture was stirred for 2 h. Removal of the solvent in vacuo 
left a brown residue which was taken up in water and extracted with ethyl acetate (3 x 30
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ml). The combined organic extracts were dried, filtered and concentrated to leave a 
yellow oil. Flash chromatography on alumina eluting with EtOAc followed by 
concentration produced a clear oil (3.40 g, 74%), Rp 0.67 (EtOAc), vmax 2951, 2864, 
1746, 1645 and 1278 c m 1; 6 H 1.29-1.72 (10H, m, ring CH2), 2.28 (2H, m, 
C //2CH2N) 3.25-3.44 (4H, m, CH2N), 3.50 and 3.54 (2H, s, NCOCtf2CON), 3.73 
(6 H, s, C //3) and 5.38 (2H, m, C//N); 8 C 20.8, 24.8 and 26.1 (t, ring CH2), 43.9 (t, 
CH2N), 51.9 (q, COCH3), 53.8 (d, CHN), 61.2 (t, NCOCH2CON), 167.2 (s, NC=0) 
and 170.9 (s, COCH3); m/z 354 (M+ 5%), 323, 295, 212, 170, 142 and 84 (100%) 
(Found: Af+ 354.1796. C 17H26N20 6 requires M+ 354.1779).
^yV '-(l,3-Propanediyl)bis(2-m ethoxycarbonylpiperidine) (160)
Af,AT-(l,3-Dioxo-l,3-propanediyl)bis(2-methoxycarbonylpiperidine) (3.50 g, 9.8 mmol) 
in dry THF (20 ml) was added to a solution of 1M borane-THF (77 ml, 77 mmol) under 
nitrogen at 0 °C. The solution was then heated at reflux for 2 h. 6 M HC1 (5 ml) was 
added dropwise at 0 °C with the formation of hydrogen, followed by the addition of 
water (10 ml). The THF was removed by distillation to leave an aqueous solution which 
was concentrated in vacuo. Methanol (20 ml) and conc. HC1 (2 drops) were added to the 
residue and the mixture was evaporated in vacuo to remove the methyl borate ester 
formed. This procedure was repeated twice, after which no more weight loss was 
recorded. The remaining thick clear oil was taken up in chloroform (25 ml) and 
triethylamine (5 ml) was added. The resulting solution was stirred for 30 min before 
being evaporated to leave a white residue. This was taken up in water and extracted with 
ethyl acetate (3 x 30 ml). The combined organic extracts were then dried, filtered and 
concentrated to leave a clear oil (2.40 g, 75%), Rp 0.55 (EtOAc), vmax 2936, 2855, 1737 
and 1261 cm’1; 8 H 1.12-1.35 (2H, m, NCH2C //2CH 2N), 1.47-1.85 (12H, m, ring 
C H 2), 1.90-2.22 (2H, m, CHN),  2.34-2.73 (4H, m, CH2N), 2.90-3.10 (4H, m, 
NCH2CH 2C //2N) and 3.62 (6 H, s, C 0 2C //3); 8 C 22.4 (t, NCH2 CH2CH 2N), 24.0, 
24.1, 25.0, 25.3, 29.3 and 29.4 (t, ring CH 2), 50.1 and 50.2 (t, CH 2N), 51.3 (q,
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C 0 2 CH3), 54.1 and 54.3 (t, NCH2 CH2 CH2 N), 64.8 and 65.1 (d, CHN) and 173.9 (s,
C 0 2 CH3); m/z 326 (M+ 17%), 267, 184, 170, 156, 142, 126, 124 and 98 (100%)
(Found: M+ 326.2205. C i7 H3oN2 C>4 requires 326.2197).
A^,A^'-(l,3-Propanediyl)bis(2-hydroxypiperidine) (161)
A,W-(l,3-Propanediyl)bis(2-methoxycarbonylpiperidine) (2.5 g, 7.67 mmol) in dry 
THF (20 ml) was added dropwise to a solution of 1M Li A lik in  THF (32.2 ml, 32.2 
mmol) at 0 °C under nitrogen. The solution was warmed to room temperature and stirred 
for 4 h. The flask was then cooled to 0 °C and water : THF (1 : 1, 20 ml) was added 
dropwise. Both solvents were evaporated in vacuo which left a white powder. This was 
stirred with dichloromethane (30 ml) for 30 min after which the solution was filtered and 
the fitrate concentrated in vacuo to leave a clear oil (1.81 g, 87%), Rp 0.65 (MeOH), 
Vmax 3348, 2934 and 1383 cm-1; 8 h 1.19-1.77 (14H, m, ring CH 2 a n d  
NCH2C //2CH2N), 2.05-2.38 (4H, m, CH2N) 2.45 (2H, m, CHN), 2.90-3.22 (4H, m, 
N C //2CH 2C //2N), 3.55-3.87 (4H, m, C/72OH) and 4.33 (2H, bs, OH); 8 C 22.6 (t, 
N C H 2 C H 2C H 2N), 24.7, 27.8 and 29.6 (t, ring C H 2), 51.9 (t, C H 2N), 56.7 (t, 
NCH2CH2CH2N), 62.4 (d, CHN) and 63.0 (t, CH2OH); m/z 222, 156, 142, 128, 110, 
98 and 84 (100%) (Found: M+ (-H20), 252.2180. C 15H28N20  requires 252.2178).
A ,W -(l,3-Propanediyl)-b is(2-phenylam inocarbonyIoxym ethylpiperidine)
(162)
A,N'-(l,3-Propanediyl)bis(2-hydroxypiperidine) (0.40 g, 1.5 mmol) and phenyl 
isocyanate (0.35 g, 2.9 mmol) were reacted according to procedure A for 18 h. Flash 
chromatography on alumina with ethyl acetate produced a white powder which was 
crystallised with dichloromethane. This gave the product as white crystals (0.35 g, 46%), 
Rf  0.70 (EtOAc), 128-130 °C, vmax 3302, 2857, 1710, 1600, 1538,1224, 753 and 693 
cm*1; 8 h 1.15-1.93 (14H, m, ring CH2 and NCH2C //2CH2N), 2.45 (2H, m, CHN),
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2.66-3.08 (8 H, m, N C //2CH2C //2N and CH2N), 4.22 (4H, m, CH2O), 6.92 (2H, m, 
p-CH), 7.23 (4H, m, m-CH), 7.46 (4H, m, o-CH) and 8.78 (2H, bs, NH); 6 C 20.2 (t, 
N C H 2 C H 2C H 2 N), 22.4 23.6 and 27.6 (t, ring C H 2), 50.9 (t, C H 2N), 51.9 (t, 
NCH2CH2CH2N), 57.9 (d, CHN), 64.2 (t, CH20), 118.8 (d, o-CH), 122.7 (d, p-CH),
128.8 (d, m-CH), 138.8 (s, CNH) and 153.6 (s, C=0); m/z 261, 247, 234, 212, 142, 
128, 119, 98 and 84 (100%) (Found: C, 68.75; H, 8.08, N, 10.95. Q 9H 4 0 N4 O4 
requires C, 68.50; H, 7.87; N, 11.02%).
yV,Aff-(l,3-Propanediyl)-bis(2-p-nitrophenylam inocarbonyloxym ethyl- 
piperidine) (163)
AW-(l,3-PropanediyI)bis(2-hydroxypiperidine) (0.20 g, 0.74 mmol) andp-nitrophenyl 
isocyanate (0.28 g, 1.7 mmol) were reacted according to procedure A for 18 h. The 
residue was dissolved in methanol and was purified by flash column chromatography on 
alumina, eluting first with ethyl acetate to remove starting material impurities and then 
with methanol to remove the product. The methanol was removed to leave the product as 
yellow crystals (0.24 g, 54%) Rp 0.55 (EtOAc:), m.p. 109-111 °C, vmax 3432, 2937, 
2858, 1735, 1598, 1553, 1508, 1332, 1218 and 852 c m 1; 6 H (d6-acetone) 1.20-1.90 
(14H, m, ring CH2 and NCH2C //2CH2N), 2.18 (2H, m, CHN), 2.47 (4H, m, C //2N), 
2.84 (4H, m, NCtf2CH2C //2N), 4.24 (4H, m, CH20),  7.75 and 8.12 (8 H, m, aromatic 
CH) and 9.40 (2H, bs, NH); 8 C 23.8 (t, NCH2CH2CH2N), 26.1, 26.5 and 29.4 (t, ring 
CH2), 50.6 (t, CH 2N), 52.2 (t, NCH2CH2 CH2N), 59.9 (d, CHN), 6 6 .8  (t, CH20 ) ,
118.4 (d, CHCNH), 125.5 (d, C H C N 02), 143.1 (s, CNH), 146.3 (s, C N 0 2) and
154.0 (s, C=0); m/z 292, 261, 142, 138 (100%), 124, 111 and 98.
A ,A '-(l,3-Propanediyl)bis(2-chIoropiperidine) (164)
/V,N-(l,3-Propanediyl)bis(2-hydroxypiperidine) (0.40 g, 1.48 mmol) was dissolved in 
dichloromethane (5 ml) and was slowly added to thionyl chloride (15 ml) at 0 °C. The
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solution was stirred at room temperature for 24 h, after which the solvent was removed. 
The residue was dissolved in dichloromethane (20 ml) and basified with sodium 
bicarbonate solution. The organic layer was removed and the aqueous layer was extracted 
with dichloromethane (2 x 20 ml). The combined extracts were dried, filtered and 
concentrated to leave a brown oil. Flash chromatography on alumina with ethyl acetate 
yielded after evaporation, a clear oil (0.38 g, 83%), Rp 0.60 (EtOAc:hexane, 1:6), vmax 
2936, 2857, 2797 and 733 cm ^ b n  1.36-1.69 (14H, m, ring C H 2 a n d  
N C H 2C // 2C H 2N), 1.92-2.25 (2H, m, CHN),  2.54 (4H, m, CH2N), 2.81 (4H, m, 
N C //2R C //2N) and 3.61 (4H, m, CH2C1); 8 C 22.7 (t, NCH2CH2CH2N), 25.3, 28.8 
and 29.4 (t, ring CH2), 43.3 (t, CH2C1), 45.3 (t, CH2N), 51.5 (t, NCH2CH2 CH2N) 
and 60.4 (d, CHN); m/z 273, 235, 174, 162, 160, 146, 138 (100%), 124, 111 and 98 
(Found M+ -Cl 273.1893. C 15H28N2C1 requires M+ 273.1901).
Ar,W -(l>3-Propanediyl)-bis(2-phenylam inocarbonyloxym ethylpiperidine) 
bis-JV-Oxide (165)
N,AT-(l,3-Propanediyl)-bis(2-phenylaminocarbonyloxymethylpiperidine) (0.17 g, 0.33 
mmol) and mCPBA (0.14 g, 0.83 mmol) were reacted according to procedure B for 24 
h. This gave the product as white crystals after recrystallisation from acetone (0.11 g, 
63%), RF 0.73 (MeOH), vmax 3334, 1729, 1601, 1504, 1231, 1070, 758 and 694 cm-1; 
8 h 1.25-2.06 (14H, m, ring CH2 and N+CH 2C tf2CH 2N+), 3.10 (2H, m, CHN+), 
3.22-3.64 (4H, m, CH2N +), 4.07-4.32 (4H, m, N + C //2 R C //2N+) 4.02 (2H, m, 
C //N +) 4.41-4.76 (4H, m, CH2O), 7.01 (2H, m, p-CH), 7.26 (4H, m, m-CH), 7.52 
(4H, m, o-CH); 5C 20.0 (t, N+CH2 CH2CH 2N+), 21.5 23.5 and 24.6 (t, ring CH2 ),
53.8 (t, CH 2N+), 55.1 (t, N+CH2CH 2CH2N+), 63.1 (t, CH20), 74.5 (d, CHN+), 
118.6 (d, o-CH), 123.1 (d, p-CH), 128.9 (d, m-CH), 138.5 (s, CNH) and 153.0 (s, 
C=0); m/z 322, 250, 216, 127, 119 and 84 (100%).
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iV,./V'-(l,3-Propanediyl)-bis(2-/?-nitrophenylaminocarbonyloxymethyl-
piperidine) bis-A-Oxide (166)
N.N'-i 1,3-Propanediyl)-bis(2-p-nitrophenylaminocarbonyloxymethylpiperidine) (0.20 
g, 0.33 mmol) and mCPBA (0.18 g, 0.83 mmol) were reacted according to procedure B 
for 24 h. This gave the product as yellow crystals after recrystallisation from acetone, 
(0.100 g, 48%), m.p. 142-144 °C, vmax 1729, 1596, 1569, 1505, 1332, 1224, 1062 and 
856 c m 1; SH (CD3OD) 1.67-2.16 (14H, m, ring CH2 and N+CH2CH2CH2N+), 3.22- 
3.62 (8 H, m, N+CH2CH2CH2N+ and N+CH2), 4.17 (2H, m, CHN+), 4.69 (4H, m, 
CH20 ), 7.65 (4H, m, CH) and 8.13 (4H, m, CH); 6 C 21.7 (t, N+CH2 CH2CH 2N+), 
22.9, 25.6 and 26.5 (t, ring CH2), 64.9 (t, CH2N+), 65.2 (t, N+CH2RCH 2N+), 70.4 
(t, CH 20 ), 72.6 (d, CHN+), 118.9 (d, CHCNH), 125.9 (d, C H C N 0 2), 143.9 (s, 
CNH), 146.5 (s, C N 02) and 154.5 (s, C=0); m/z 301, 295, 261, 258, 251, 244, 164, 
156, 139 and 100(100%).
W ,W -(l,3-PropanediyI)bis(2-chloropiperidine) bis-H-Oxide (167)
H,AT-(l,3-Propanediyl)bis(2-chloropiperidine) (0.25 g, 0.8 mmol) and mCPBA (0.45 
g, 2.4 mmol) were reacted according to procedure B for 24 h. This gave the product as a 
yellow oil (0.16 g, 62%), RF 0.53 (MeOH), vmax 2951, 1448, 978 and 687 cm*1; 6 H
I.54-1.80 (14H, m, ring CH2 and N+CH2CH2CH 2N+), 2.75 (2H, m, CHN+), 4.15 
(4H, m, CH2C1) and 4.38-5.03 (8 H, m, N+CH2); 6 C 20.1 (t, N+CH2 CH2CH 2N+), 
21.5 25.96 and 28.7 (t, ring C H 2), 41.1 (t, C H 2 C1), 65.9 (t,C H 2 N +), 72.1 (t, 
N+CH2CH2CH2N+), 72.5 (d, CHN+); m/z 190, 176, 154, 146, 140 and 98.
A ,A ,-(l,4-D ioxo-l,4-butanediyI)b is(2-m ethoxycarbonylpiperid ine) (168)
To a solution of chloroform (30 ml) was added methyl pipecolinate hydrochloride (5.0 g,
27.8 mmol) and triethylamine (6.80 g, 66.7 mmol) under nitrogen. The solution was
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stirred for 10 min before being cooled to -5 °C. Succinyl dichloride (1.44 ml, 13.0 mmol) 
was then added dropwise over a period of 10 min. The flask was then allowed to warm 
to room temperature and the mixture was stirred for 2 h. Removal of the solvent in vacuo 
left a brown residue which was taken up in water and extracted with ethyl acetate (3 x 30 
ml). The combined organic extracts were dried, filtered and concentrated to leave a 
yellow oil. Flash chromatography on alumina eluting with EtOAc followed by 
concentration produced white crystals (4.0 g, 84%), m.p. 92 °C, Rp 0.44 (EtOAc), vmax 
2951, 2858, 1736 and 1634 c m 1; 6 H 1.22-1.74 (10H, m, ring C //2), 2.24 (2H, m, ring 
C //2CH 2N), 2.55-2.90 (4H, m, COCH2CH2CO), 3.22 (2H, m, CH2N) 3.72 (6 H, s, 
C //3), 3.88 (2H, m, CH2N) and 5.37 (2H, m, C//N); 6 C 20.8, 25.0 and 27.0 (t, ring 
CH2), 42.9 (t, CH2N), 52.0 (q, COCH3), 53.8 (d, CHN), 167.2 (s, NC=0) and 171.9 
(s, COCH3); m/z 368 (A/+ 1.3%), 337, 209, 226 (100%), 198, 142 and 84 (Found: C, 
58.85; N, 7.76; N, 7.66; M+ 368.1947. C 17H26N20 6 requires C, 58.69; H, 7.61; N, 
7.61%; M+ 368.1937).
/V,A’-(l,4 -B u tan ed iy l)b is(2 -m eth o x y carb o n y lp ip erid in e) (169)
Af,AP-(l,4-Dioxo-l,4-butanediyl)bis(2-methoxycarbonylpiperidine) (4.40 g, 12 mmol) 
in dry THF (20 ml) was added to a solution of 1M borane-THF (94 ml, 94 mmol) under 
nitrogen at 0 °C. The solution was heated at reflux for 2 h. 6 M HC1 (5 ml) was added 
dropwise at 0 °C with the formation of hydrogen, followed by the addition of water (10 
ml). The THF was then removed by distillation to leave an aqueous solution which was 
then concentrated in vacuo. Methanol (20 ml) and conc. HC1 (2 drops) were added to the 
residue and concentration in vacuo removed the methyl borate ester formed. This 
procedure was repeated twice, after which no more weight loss was recorded. The 
remaining thick clear oil was taken up in chloroform (25 ml) and triethylamine (5 ml) was 
added. The resulting solution was stirred for 30 min before being concentrated to leave a 
white residue. This was taken up in water and extracted with ethyl acetate (3 x 30 ml). 
The combined organic extracts were then dried, filtered and evaporated to leave a clear oil
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(2.80 g, 72%), RF 0.50 (EtOAc), vmax 2937, 2857, 1737 and 1260 cm-1; 8 H 1.24-1.80 
(16H, m, ring CH2 and CH2C //2C //2CH2), 2.04-2.20 (2H, m, C//N), 2.25 (2H, m, 
CH2N), 2.48 (2 H, m, CH2N), 3.06 (4H, m, N C//2CH 2CH 2C //2N) and 3.71 (6 H, s, 
CO2C //3); 8 C 22.5 (t, NCH2CH2CH2CH2N), 24.4, 25.1 and 29.5 (t, ring CH2), 50.4 
(t, CH2N), 51.4 (q, CO2CH3), 56.2 (t, NCH2RCH2N), 65.2 (d, CHN) and 174.1 (s, 
CO2CH3); m/z 340 (M+ 19%), 281, 198 (100%), 182, 170, 156, 111 and 98 (Found: 
M+ 340.2361. C 18H32N2O4 requires 340.2372).
N ,W -(l,4-B utanediyl)b is(2-hydroxypiperid ine) (170)
N,yV’-(l,4-Butanediyl)bis(2-methoxycarbonylpiperidine) (2.8 g, 8.1 mmol) in dry THF 
(20 ml) was added dropwise to a solution of 1M UAIH4  (36 ml, 36 mmol) at 0 °C under 
nitrogen. The solution was warmed to room temperature and stirred for 4 h. The flask 
was then cooled to 0 °C and water : THF (1 : 1, 20 ml) was added dropwise. Both 
solvents were evaporated in vacuo which left a white powder. This was stirred with 
dichloromethane (30 ml) for 30 min after which the solution was filtered and the filtrate 
concentrated in vacuo to leave a white solid (1.90 g, 83%), m.p.117-119 °C, Rp 0.51 
(MeOH), v max 3126, 2934, 2855, 1374 and 1231 cm-1; 8 H 1.07-1.56 (16H, m, ring 
CH2 and NCH2C //2C //2CH2N), 2.02-2.32 (6 H, m, CHN and C //2N), 2.52-2.78 (4H, 
m, N C //2R C //2N), 3.27-3.53 (4H, m, CH2OH) and 3.67 (2H, bs, OH); 8 C 23.3 (t, 
NCH 2 CH 2 CH2CH 2N), 23.5, 24.5 and 27.8 (t, ring CH2), 51.3 (t, CH2N), 53.1 (t, 
NCH 2RCH 2N), 61.0 (d, CHN) and 62.4 (t, CH2OH); m/z 267, 253, 236, 224, 170 
(100%), 156, 140 (100%), 128, 112 and 98 (Found: M+ -4H, 281.2201. C 16H28N20 2  
requires M+ -4H 281.2193)
A ,A ,-(l,4-B utanediyI)-bis(2-phenylam inocarbonyIoxym ethyl-piperidine)
(171)
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yV,Af'-(l,4-Butanediyl)bis(2-hydroxypiperidine) (0 .40 g, 1.4 mmol) and phenyl 
isocyanate (0.42 g, 3.5 mmol) were reacted according to procedure A for 18 h. Flash 
chromatography on alumina with ethyl acetate left a white powder which was 
recrystallised from dichloromethane to afford the product as white crystals (0.63 g, 
8 6 %), m.p. 138-140 °C, Rp 0.63 (EtOAcrpet ether, 1:1), v max 3338, 2852, 1702, 1602, 
1540, 1242, 751 and 6 8 8  c u H j S h  1 .25-1 .66  (16H , m, ring C H 2 a n d  
N C H 2C / / 2 C / / 2 C H 2 N), 2.20 (2H, m, CHN),  2.45 (4H, m, CH 2N), 2 .80  (4H, 
N C //2R C //2N), 4.23 (4H, m, CH2O), 7.06 (2H, m, p-CH),  7.27 (4H, m, m-CH)  and 
7.38 (4H, m, o-CH) ; 6 C 23.3 (t, NCH2CH2 CH2CH2N), 23.6, 25.4 and 29.0 (t, ring 
CH2), 52.1 (t, CH2N), 53.7 (t, NCH2RCH2N), 59.4 (d, CHN), 65.9 (t, CH20 ), 116.5 
(d, o-CH), 123.3 (d, p-CH), 128.9 (d, m-CH), 138.0 (s, CNH) and 153.7 (s, C =0); 
m/z 372, 282, 266, 253, 236, 224, 170, 140, 119 (100%) and 98.
A>A ,-(l,4-B utanediyl)*bis(2-p-nitrophenylam inocarbonyloxym ethyl- 
piperidine) (172)
AW-(l,4-Butanediyl)bis(2-hydroxypiperidine) (0.40 g, 1.41 mmol) and p-nitrophenyl 
isocyanate (0.58 g, 3.5 mmol) were reacted according to procedure A for 18 h. Flash 
chromatography was carried out on alumina, first eluting with ethyl acetate to remove 
starting material and then with methanol to remove the product.This gave the product as 
yellow crystals (0.54 g, 63%) Rp 0.56 (EtOAc), m.p. 91-92 °C, vmax 3355, 2936, 2808, 
1737, 1600, 1552, 1509, 1332, 1216 and 852 cm-1; 8 h (d6~acetone) 1.17-1.46 (16H, m, 
ring CH2 and NCH2C //2C //2CH2N), 2.15 (2H, m, CHN), 2.40 (4H, m, CH2N), 2.75 
(4H, m, NCH2RC H 2N), 4.21 (4H, dd, J  5 Hz and J  11 Hz, CH20),  7.77 and 8.17 
(8 H, d, J  ca. 9 Hz, AA'BB' system) and 9.45 (2H, bs, NH)\  5 C 23.8 (t, 
NCH 2 CH2 CH2CH 2N), 24.6, 26.0 and 29.8 (t, ring CH2), 52.2 (t, CH 2N), 54.4 (t, 
N C H 2R C H 2N), 59.9 (d, CHN), 6 6 . 6  (t, CH 20 ), 118.4 (d, CHCNH), 125.5 (d, 
CHCNO2), 143.1 (s, CNH), 146.4 (s, C N 02) and 154.1 (s, C=0); m/z 261, 253, 236, 
196, 170, 164, 140, 138 (100%) and 98.
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N, A ’-U^-ButanediyO bis^-chloropiperidine) (173)
Ar,AT-(l,4-ButanediyI)bis(2-hydroxypiperidine) (0.60 g, 2.11 mmol) was dissolved in 
dichloromethane (5 ml) and was slowly added to thionyl chloride (15 ml) at 0 °C. The 
solution was stirred at room temperature for 24 h, after which the solvent was removed. 
The residue was dissolved in dichloromethane (20 ml) and basified with sodium 
bicarbonate solution. The organic layer was removed and the aqueous layer was extracted 
with dichloromethane (2 x 20 ml). The combined extracts were dried, filtered and 
concentrated to leave a brown oil. Flash chromatography on alumina eluting with ethyl 
acetate left after evaporation a clear oil (0.52 g, 77%), Rp 0.60 (hexanerEtOAc, 6:1), 
Vmax 2934, 2856, 2792, 1462, 1445 and 738 c m 1; 6H 0.88-1.55 (16H, m, ring CH2 and 
NCH 2C //2C //2 CH 2N), 2.20 (2H, m, CHN), 2.48-2.72 (8 H, m, NCH2RC H 2N and 
CH2N) and 3.58 (4H, m, CH2C1); 6 C 22.7 (t, NCH2 CH2CH2CH2N), 23.1, 25.1 and
28.7 (t, ring CH2), 45.2 (t, CH2C1), 51.1 (t, CH2N), 53.1 (t, NCH2RCH2N) and 60.5 
(d, CHN); m/z 285, 271, 250, 235, 188, 159, 152, 146, 140, 138 and 112 (100%) 
(Found M+ -Cl 285.2095. C 16H3oN2C1 requires M+ -Cl 285.2080).
Ar,iV '-(l,4-Butanediyl)-bis(2-phenylam inocarbonyIoxym ethyl-piperidine) 
bis-N-O xide (174)
Af,Ar-(l,4-Butanediyl)-bis(2-phenylaminocarbonyloxymethylpiperidine) (0.38 g, 0.73 
mmol) and mCPBA (0.30 g, 1.74 mmol) were reacted according to procedure B for 24 
h. This gave the product as white crystals after recrystallisation from acetone (0.30 g, 
73%), m.p. 6 6 - 6 8  °C, RF 0.44 (MeOH), 5H 1.26-2.16 (16H, m, ring CH2 and 
N+CH2C/72C//2CH2N+), 2.20 (2H, m, CHN+), 3.43-3.67 (8 H, m, N+CH2RCH2N+ 
and CH2N+), 4.02 (2H, m, C//N+) 4.21-4.53 (4H, m, CH2O), 7.01 (2H, m, p-CH), 
7.21 (4H, m, m-CH),  7.60 (4H, m, o-CH)  and 9.75 (2H, bs, NH)\ 6 C 21.0 (t,
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N+CH2CH2CH2CH2N+), 22.5, 25.4 and 29.6 (t, ring CH2), 55.3 (t, CH2N+), 62.0 (t, 
N+CH2RCH2N+), 64.3 (t, CH20), 79.4 (d, CHN+), 119.8 (d, o-CH), 124.3 (d, p- 
CH), 129.8 (d, m-CH), 139.6 (s, CNH) and 154.7 (s, C=0); m/z 328, 247, 216, 127, 
119 and 93 (100%) (Found: C, 61.21; H, 7.20; N, 10.10. C3oH42N4 0 6 .2 H20  requires 
C, 61.02; H, 7.79; N, 9.49%).
iV ,lV '-(l,4-butaiiediyl)-bis(2-p-nitrophenylam inocarbonyloxym ethyl- 
piperidine) bis-A-oxide (175)
<V,Ar-( 1,4-Propanediyl)-bis(2-p-nitrophenylaminocarbonyloxymethylpiperidine) (0.30 
g, 0.49 mmol) and mCPBA (0.20 g, 1.18 mmol) were reacted according to procedure B 
for 24 h. This gave the product as yellow crystals after recrystallisation from acetone 
(0.16 g, 55%), m.p. 117-119 °C, v max 3422, 2950, 1734, 1597, 1560, 1508, 1332, 
1222, 1070 and 853 c n r ' ; 5 H (CD3OD) 1.48-2.21 (16H, m, ring C H 2 and 
N+CH2C1T2C//2CH2N+), 3.42-3.85 (8H, m, N +C //2), 4.15 (2H, m, CHN+), 4.67 
(4H, m, C H 20 ) ,  7.64 (4H, m, CH)  and 8.11 (4H, m, CH)-, 8 C 20.9 (t, 
N+CH2CH2CH2CH2N+), 22.0, 23.6 and 25.7 (t, ring CH2), 63.8 (t, CH2N+), 64.8 (t, 
N+CH2RCH2N+), 69.6 (t, CH20), 72.3 (d, CHN), 118.9 (d, CHCNH), 125.8 (d, 
CHCNO2), 143.8 (s, CNH), 146.5 (s, C N 02) and 154.1 (s, C=0); m/z 315, 278, 252, 
186, 156, 164, 138, 114 and 90 (100%) (Found: C, 56.20; H, 6.81; N, 12.97. 
C3oH4oN60 10 requires C, 55.90; H, 6.21; N, 13.04%).
(V,(V'-(l,4-Butanediyl)bis(2-chIoropiperidine) bis-iV-oxide (176)
iV.iV-0,4-Butanediyl)bis(2-chloropiperidine) (0.23 g, 0.74 mmol) and mCPBA (0.43 
g, 1.84 mmol) were reacted according to procedure B for 24 h. This gave the product as 
a yellow oil (0.20g, 76%), RF 0.63 (MeOH), v max 2955, 1448, 978 and 718 cm-1; 8H 
(CD3OD) 1.63-2.10 (16H, m, ring CH2 and N+CH2C //2C tf2CH2N+), 2.71 (2H, m, 
C //N +), 3.74-4.20 (8H, m, N+ C //2) and 4.43-4.84 (4H, m, CH2C1); 8C 20.7 (t,
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N+CH 2 CH2CH2CH 2N+)t 22.7 27.0 and 28.7 (t, ring CH2), 41.1 (t, CH2C1), 66.2 (t, 
CH2N+), 73.3 (t, N+CH2RCH2N+), 75.0 (d, CHN+); m/z 337, 237, 235, 221, 196, 
187, 156, 138, 128 and 1 0 0  (100%) (Found: M + -2C1, -CH2 and -O 251.2079. 
C 15H26N2O requires 251.2085).
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Experimental to Chapter 7
/V-Acetylethane-1,2-diamine (182)
Ethylenediamine (5.0 g, 83 mmol) was dissolved in ethyl acetate (50 ml) and PPL (5.0 g) 
was added. The flask was shaken at 100 rpm in a temperature controlled water bath at 25 
°C. Portions were taken out at intervals to follow the reaction by TLC. After 3 d, the 
reaction solvent was decanted from the flask and retained. Chloroformrmethanol (9:1) (2 
ml) was added to the enzyme which was stirred for 1 h at room temperature. This broke 
up the enzyme (which had clumped together) which was filtered through Celite and the 
combined extracts and solvent was dried over sodium sulfate, filtered and concentrated to 
yield an oil (5.8 g, 6 8 %), 8 H (90 MHz) 2.0 (3H, s, CH3), 2.75 (2H, m, C //2NH2) and 
3.2 (2H, m, C //2NH).
A r'-A ce ty l-A ,A -b is(2 -h y d ro x y e th y l)e th an e -l,2 -d iam in e 162 (183)
Ethylene oxide (2.3 ml, 49 mmol) was collected in a measuring cylinder at -30 °C. This 
was added to a flask containing N-acetylethane- 1,2-diamine (2.0 g, 19.6 mmol) in 
methanol (25 ml) at -30 °C. This solution was stirred for 18 h. at room temperature after 
which the solution was heated at 70 °C for 6  h. The solvent was then removed to leave a 
thick oil which was distilled to leave the product as a clear oil (2.86 g, 72%), 8 h (90 
MHz) (CD3OD) 1.80 (3H, s, CH3), 2.5 (6 H, m, NCH2), 3.1 (2H, m, CH2NH) and 3.5 
(4H, m, CH2OH); m/z 190 (M+ 0.4%), 174, 159, 147, 130, 118 (94%) and 74.
N ,N -B is(2 -h y d ro x y e th y l)e th an e-l,2 -d iam in e  (184)
AT-Acetyl-N,AT-bis(2-hydroxyethyl)ethane-1,2-diamine (2.8 g, 15 mmol) and conc. HC1 
(5 ml) in water (2 ml) were heated together at reflux for 6  h. This solution was added to 
an ethanolic solution of NaOH (0.6 g, 15 mmol). After 30 min. stirring, the solution was
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diluted with acetone to precipitate sodium chloride, filtered and concentrated to leave a 
thick, dark oil (1.76 g, 80%), 8 H (D2 0 ) 2.50 (8 H, m, CH2N) and 3.45 (4H, m, 
CH2OH); 5C 38.5 (t, CH2NH2), 56.4 (t, CH2N) and 59.7 (t, CH2OH).
l-Butoxycarbonylaminoethanoic acid (187)
To a stirred solution of glycine (5.0 g, 6 6  mmol), in distilled triethylamine (8.0 g, 80 
mmol), was added a mixture of BOC-ON (19.7 g, 80 mmol) in 1,4-dioxane (75 ml) and 
water (75 ml). The solution quickly became homogeneous and was left to stir for 2 h at 
room temperature. The solution was then washed with ethyl acetate (5 x 40 ml) followed 
by acidification with 5% citric acid. The aqueous layer was then extracted with ethyl 
acetate (3 x 30 ml) and the organic extracts were dried, filtered and concentrated to leave 
the product as white crystals (11.5 g, 100%), m.p. 8 6  °C (lit, 87-88 °C), Rp 0.25 
(EtOAc), vmax 3408, 940, 2618, 2537, 1749, 1669, 1540, 1450 and 1368 cm"1; 5H 1.45 
(9H, s, C(C//3)3), 3.91 (2H, dd, J  5 Hz and J  13 Hz, NHC//2), 5.40 (1H, t, NH) and
11.08 (1H, bs, OH)\ 5C 28.2 (q, C(CH3)3), 42.1 and 43.3 (t, NHCH2), 80.3 and 81.8 
(s, C(CH3)3), 156.1 and 157.4 (s, NHCO), 173.9 and 174.4 (s, C 0 2H); m/z 170, 120, 
101, 76, 59 and 57 (100%) (Found: C, 48.02; H, 7.64; N, 8.12. C7Hi3N 0 4 requires C, 
48.00; H, 7.43; N, 8.00%).
A'-l-Butoxycarbonylaminoethanamide (188)
r-Butoxycarbonylaminoethanoic acid (5.0 g, 28.6 mmol) and distilled triethylamine (3.46 
g, 34.3 mmol) were cooled to -5 °C in distilled acetonitrile (100 ml). Added dropwise to 
this was /-butylchloroformate (4.70 g, 34.3 mmol) whilst stirring. Ammonia gas was 
bubbled through the solution for 5 min in which time the precipitate turned from yellow 
to white. The solution was then stirred for 2 h at room temperature. The solution was 
then concentrated to leave a solid yellow residue which was taken up in water (30 ml) and 
extracted with ethyl acetate (3 x 30 ml). The combined extracts were then dried, filtered
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and concentrated to leave a white solid which was crystallised from ethyl acetate (4.22 g, 
84%), 8 h 1.44 (9H, s, C(C//3)3), 3.79 (2H, d, J  5 Hz, C //2NH), 5.90 (1H, bs, NH) 
and 6.72 and 6.84 (2H, bs, NH 2)\ 5C 28.2 (q, C(CH3)3), 43.6 (t, CH2NH), 79.9 (s, 
C(CH3)3), 156.2, (s, OCONH) and 173.1 (s, NCOCH2); m/z 130, 101, 59 and 57 
( 100%).
Aminoethanamide Hydrochloride (189)
f-Butoxycarbonylaminoethanamide (4.0 g, 23 mmol) was dissolved in 3M HCl/EtOAc 
(50 ml). After 1 h the solution was concentrated to leave a solid residue. This was 
washed with ethanol and filtered to leave white crystals of the hydrochloride salt (2.40 g, 
95%), m.p. 180 °C, 5h 3.75 (C //2); 8 C 41.1 (t, CH2) and 170.3 (s, C=0); m/z 74 (M+ 
100%) and 57 (Found: A/+ 74.0465, C, 21.79; H, 6.73; N, 25.16. C2H6N 2O.HCl 
requires M+ 74.0479, C, 21.72; H, 6.33; N, 25.34).
N',Af'-bis(2-hydroxyethyl)am inoethanam ide (190)
Aminoethanamide hydrochloride (1.35 g, 12.2 mmol) was dissolved in methanol (10 ml) 
and sodium bicarbonate was added. The solution was stirred for 30 min before the 
solution was filtered. The filtrate was concentrated to leave a solid residue which was 
extracted with ethanol. This solution was filtered and the filtrate was cooled to -30 °C. 
Ethylene oxide (5 ml) was added to the filtrate and the resultant mixture was stirred for 24 
h at room temperature. The solution was concentrated to leave a very thick clear oil (1.62 
g, 82%), 8 h (CD3OD) 2.85 (4H, m, N C //2CH2OH), 3.40 (2H, m, CH2CO) and 3.75 
(4H, m, CH2OH); 8 C 42.8 (t, CH2CO), 59.3 (t, CH2N), 61.5 (t, CH2OH) and 174.6 
(s, C=0).
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I
| A^ ,,^V,-bis(2-f-ButyIdimethylsilyloxyethyI)aminoethanamide (191)
A solution of the diol (1.8 g, 11 mmol), imidazole (3.32 g, 48 mmol) and TBDMSiCl 
(4.2 g, 27.7 mmol) in dry DMF (5 ml) was stirred at room temperature for 18 h under 
nitrogen. Water (20 ml) was added and the aqueous solution was extracted with ether (3 
x 25 ml). The combined organic extracts were washed with brine ( 6  x 25 ml), dried, 
filtered and evaporated to leave the product as a clear oil (4.2 g, 97%), 8 h (90 MHz) 0.0 
(12 H, s, SiCH3), 1.60 (18H, s, C(CH3)3), 2.6 (4H, m, CH2N), 3.0 (2H, m, CH2CO) 
and 3.5 (4H, m, CH20).
N',Af'-Bis(2-hydroxyethyl)ethane-l,2-diam ine Dihydrochloride (192)
N',7V’-bis(2-/-Butyldimethylsilyloxyethyl)aminoethanamide (4.2 g, 10.7 mmol) was 
placed in a dry flask under nitrogen. Dry THF (10 ml) was added to form a slurry which 
was then cooled to 0 °C. 1 M Borane-THF (21 ml, 21 mmol) was added dropwise over 
10 min in which time the solution became clear. The solution was then heated at reflux 
for 2 h. The reaction was then quenched with 6 M HC1 (5 ml) followed by water (10 ml). 
The THF was removed by distillation and the remaining solution was concentrated to 
leave a white residue. This was dissolved in methanol (10 ml) and cone HC1 (2 drops) 
which was subsequently evaporated in vacuo to remove the methyl borate formed. This 
procedure was repeated twice until no more weight loss was recorded. The residue was 
then dissolved in ethanol to which sodium bicarbonate was added. This solution was 
filtered and the filtrate was concentrated to give the product as a thick clear oil ( 1 .0  g, 
64%), 8 h 2.6 (8 H, m, CH2N), and 3.5 (4H, m, CH20); 8 C 38.5 (t, CH2NH2), 56.4 (t, 
CH2N) and 59.8 (t, CH2OH).
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/V'-/-ButoxycarbonylaminoA, A-bis(2-chIoroethyl)ethanamide (194)
f-Butoxycarbonylaminoethanoic acid (2.0 g, 11.4 mmol) and distilled triethylamine (1.70 
g, 17.1 mmol) were cooled to -5 °C in distilled acetonitrile. Added dropwise to this was /- 
butylchloroformate (2.06 g, 15 mmol) whilst stirring. After a white precipitate formed, 
bis-(2chloroethyl)amine hydrochloride (2.0 g, 11.4 mmol) was added. Triethylamine 
(1.7 g, 17.1 mmol) was then added dropwise and the solution was stirred for 2 h at room 
temperature. The solution was then concentrated to leave a solid yellow residue which 
was taken up in water (30 ml) and extracted with ethyl acetate (3 x 30 ml). The combined 
extracts were then dried, filtered and concentrated to leave a yellow oil. After flash 
chromatography on alumina using ethyl acetate the product was left as a clear oil (2 .6  g, 
76%), RF 0.55 (EtOAc:hexane 1:1), vmax 3399, 2966, 1751, 1702, 1368 and 700 cm-1; 
8 h 1.45 (9H, s, C(Ctf3)3), 3.69 (8 H, t, J  5 Hz, NCH2CH2C\), 4.05 (2H, d, /  5 Hz, 
N H C //2) and 5.61 ( 1H, t, NH)\ 8 C 28.2 (q, C(CH3)3), 41.1 (t, C H 2C1), 43.6 (t, 
NCH2CH 2C1), 49.5 (NHCH2), 79.5 (s, C(CH3)3), 155.6 (s, OCONH) and 169.3 (s, 
NCOCH2); m/z 263, 229, 207, 175, 171, 146, 133, 105 and 92 (100%) (Found: M+ -Cl 
263.1155. Ci iH2oN20 3C1 requires 263.1162).
2-Amino-A,Ar-Bis(2-chloroethyl)ethanainide Trifluoroacetate (195)
Af'-f-ButoxycarbonylaminoAf AM)is(2-chloroethyl)ethanamide (2 .0  g, 6.7 mmol) was 
dissolved in dry dichloromethane (25 ml) under nitrogen and trifluoroacetic acid (5 ml) 
was added dropwise at 0 °C. The solution was allowed to return to room temperature and 
left to stir for 1 h. The solution was concentrated to a thick oil and triturated with diethyl 
ether. White crystals precipitated immediately and were filtered and air dried (1.98 g, 
95%), m.p. 117-118 °C, vmax 3155, 1685, 1626, 1527 and 722 cm-1; 5H (D20 )  3.39 
(4H, m, N C//2CH2C1), 3.74 (4H, m, CH2C \) and 4.44 (2H, m, COC//2); 6 C 39.9 and
40.9 (t, CH2C1), 46.8 and 49.8 (t, NCH2CH2C1), 62.1 (t, COCH2) and 166.5 (s, C=0);
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m/z 198 (Af+ 0.3%), 165,163, 147, 126, 106 and 92 (100%) (Found: M+ 198.0340.
C6 Hi2 N2 OCl2 requires M+ 198.0327).
A, Af-Bis(2-chIoroethyl)ethane-l,2-diam ine D ihydrochloride160 (185)
2-Amino-./V,Af-Bis(2-chloroethyl)ethanamide trifluoroacetate (1.5 g, 4.8 mmol) was 
placed in a dry flask under nitrogen. Dry THF (10 ml) was added to form a slurry which 
was then cooled to 0 °C. 1 M Borane-THF (20 ml) was added dropwise over 10 min in 
which time the solution became clear. The solution was then heated at reflux for 2 h. The 
reaction was quenched with 6 M HC1 (5 ml) followed by water (10 ml). The THF was 
removed by distillation and the remaining solution was concentrated to leave a white 
residue. This was dissolved in methanol (10 ml) and cone HC1 (2 drops) which was 
subsequently evaporated in vacuo to remove the methyl borate ester formed. This 
procedure was repeated twice until no more weight loss was recorded. The residue was 
then crystallised from ethanol to give the product (0.9 g, 90%), m.p. 135-137 °C, v.max 
2954, 2514, 1638, 1450 and 763 c m 1; 6 H 3.40 (2H, m, C //2N H 2), 3.62 (6 H, m, 
CH 2N) and 3.88 (4H, m, C //2C1); 6 C 36.0 (t, CH 2N H 2), 39.7 (t, CH 2C1), 52.4 (t, 
CH2NR2) and 57.4 (t, NCH2CH2C1); m/z 158, 154 (100%), 142, 120, 112, 106 and 
92 (Found: C, 27.73; H, 5.27; N, 10.59. C6H 14N 2C12 .2HC1 requires C, 27.90; H, 
5.42; N, 10.85%).
iV ,W -Bis(2-chloroethyl)ethane-l,2-diam ine D ihydrochloride163 (197)
Af,AP-Bis(2-hydroxyethyl)ethane- 1,2-diamine (0.5 g, 3.4 mmol) was added slowly to 
thionyl chloride (10 ml) at 0 °C. The resulting slurry was left to stir for 2 h at room 
temperature. Excess thionyl chloride was removed in vacuo and the residue was washed 
with methanol to obtain white crystals of the dihydrochloride salt (0.65 g, 74%), m.p. 
138-139 °C, v max 2924, 2478, 1638, 1446 and 773 c m - ' ; 5 H 3.24 (4H, m, 
NCH2CH2C1), 3.49 (4H, s, C tf2NHR) and 3.81 (4H, m, Ctf2Cl); 8 C 43.9 (t, CH2C1),
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50.7 (t, CH2 NHR), and 57.4 (t, NCH2 CH 2 C1); m/z 159, 149, 128, 117, 104 and 74
(100%) (Found: C, 27.81; H, 5.52; N, 10.66. C6 H 1 4N2 C12 .2HC1 requires C, 27.90; H,
5.42; N, 10.85%).
/•Butoxycarbonylaminopropanoic acid (199)
To a stirred solution of P-alanine (4.50 g, 50 mmol), in distilled triethylamine (8.0g, 80 
mmol), was added a mixture of BOC-ON (13.7 g, 54 mmol) in 1,4-dioxan (75 ml) and 
water (75 ml). The solution quickly became homogeneous and was left to stir for 2 h at 
room temperature. The solution was then washed with ethyl acetate (5 x 40 ml) followed 
by acidification with 5% citric acid. The aqueous layer was then extracted with ethyl 
acetate (3 x 30 ml) and the organic extracts were dried, filtered and concentrated to leave 
the product as white crystals (8.0 g, 90%), m.p. 72-74 °C, Rp 0.28 (EtOAc), vmax 3443, 
2940, 2633, 2575, 1709, 1649, 1560, 1458 and 1365 c m 1; 6 H 1.44 (9H, s, C(C//3)3), 
2.57 (2H, t, J  5.5 Hz, C //2C 0 2H), 3.40 (2H, q, J  5.5 Hz, NHC//2), 5.28 (1H, t, NH) 
and 10.44 (1H, bs, OH); 6 C 28.2 (q, C(CH3)3), 34.3 and 35.8 (t, NHCH2 CH2), 79.6 
(s, C(CH3)3), 156.0 (s, NHCO), 177.1 (s, C 0 2H); m/z 190, 133, 116, 98, 90, 70 and 
57 (Found: C, 50.58; H, 7.92; N, 7.27. C8H 15N 0 4  requires C, 50.79; H, 7.94; N, 
7.41%).
Ar'-f-ButoxycarbonyIaminoA,A-bis(2-chloroethyl)propanamide (200)
f-Butoxycarbonylaminopropanoic acid (5.0 g, 26.6 mmol) and distilled triethylamine 
(3.05 g, 30 mmol) were cooled to -5 °C in distilled acetonitrile. Added dropwise to this 
was i-butylchloroformate (4.12 g, 30 mmol) whilst stirring. After a white precipitate 
formed, bis-(2-chloroethyl)amine hydrochloride (4.75 g, 26.6 mmol) was added. 
Triethylamine (3.0 g, 30 mmol) was then added dropwise and the solution was stirred for 
2 h at room temperature. The solution was then concentrated to leave a solid yellow 
residue which was taken up in water (30 ml) and extracted with ethyl acetate (3 x 30 ml).
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The combined extracts were then dried, filtered and concentrated to leave a yellow oil. 
After flash chromatography on alumina using ethyl acetate the product was left as white 
crystals (6.2 g, 74%), m.p. 100-102 °C, Rp 0.70 (EtOAcrpet. ether, 1:1), v max 3370, 
2977, 1740, 1690, 1367 and 670 c m 1; 6 H 1.42 (9H, s, C(CH3)3), 2.63 (2H, t, 
NHCH2) 3.48 (8 H, t, NCH2CH2C1), 4.04 (2H, d, NCOCH2) and 5.45 (1H, t, NH); 6 C
28.4 (q, C(CH3)3), 35.0 (t, NHCH2) 36.3 (t, CH2C1), 38.8 (t, NCH2CH 2C1), 49.0 (t, 
NCOCH2), 79.5 (s, C(CH3)3), 156.2 (s, OCONH) and 171.9 (s, NCOCH2); m/z 221, 
185, 131, 105 92 (100%) and 8 8  (Found: M+ -(-C H 3)3C and -Cl 221.0676. 
CgHi3N20 3Cl requires 221.0686).
2-Amino-./V,Af-Bis(2-chloroethyl)propanamide (201)
N'-r-ButoxycarbonylaminoA^,Ar-bis(2-chloroethyl)propanamide (2.0 g, 6.4 mmol) was 
dissolved in dry dichloromethane (25 ml) under nitrogen and trifluoroacetic acid (5 ml) 
was added dropwise at 0 °C. The solution was allowed to return to room temperature and 
left to stir for 1 h. The solution was concentrated to a thick oil and was dissolved in 
dichloromethane (20 ml). Sodium bicarbonate solution was added untill there was no 
more effervescing. The organic layer was removed and the aqueous layer was extracted 
twice more with dichloromethane (20 ml). The combined organic extracts were dried, 
Filtered and concentrated to leave a clear oil (1.30 g, 95%), Rp 0.56 (EtOAc), vmax 3430, 
2972, 1682, 1434 and 722 cm '1; 6 H 3.70 (10H, m, NCH2CH2C\ and C //2NH2) and 
4.37 (2H, t, J  8  Hz, CH2CON); 6 C 41.7 (t, CH 2C1), 45.2 (t, CH 2N H 2), 45.9 (t, 
NCH2CH2C1), 62.0 (t, CH2CON) and 158.3 (s, C=O); m/z 178, 170, 168, 142, 141,
114, 8 6  and 72 (Found: M+ -Cl 178.0795. C7H 14N20C1 requires 178.0798).
N ,A -Bis(2-chloroethyl)propane-l,3-diam ine Dihydrochloride (202)
2-Amino-A,A-Bis(2-chloroethyl)propanarnide (1.0 g, 4.7 mmol) was placed in a dry 
flask under nitrogen. Dry THF (10 ml) was added to form a slurry which was then
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cooled to 0 °C. 1 M Borane-THF (15 ml, 15 mmol) was added dropwise over 10 min in 
which time the solution became clear. The solution was then heated at reflux for 2 h. The 
reaction was then quenched with 6 M HC1 (5 ml) followed by water (10 ml). The THF 
was removed by distillation and the remaining solution was concentrated to leave a white 
residue. This was dissolved in methanol (10 ml) and conc. HC1 (2 drops) which was 
subsequently evaporated in vacuo to remove the methyl borate ester formed. This 
procedure was repeated twice until no more weight loss was recorded. The residue was 
then crystallised from ethanol to give the product (1.0 g, 80%), m.p. 152-153 °C, vmax 
2953, 2515, 1643, 1454 and 674 c m 1; 8 H 1.80 (2H, NH2CH2CH2CH2N), 3.07, 3.25 
(2H, m, C //2NH2), 3.53 and 3.67 (8 H, m, N C//2CH2C1) and 3.93 (4H, m, CH2Cl); 8 C
29.9 (t, NCH2CH2CH2N), 37.9 (t, CH2NH2), 40.1 (t, CH2C1), 49.4 (t, CH2NR2) and
57.3 (NCH2CH2C1); m/z 183, 170, 127, 113, 100, 8 8  (100%) and 8 6 .
l-Butoxycarbonylaminodiacetic acid (204)
To a stirred solution of iminodiacetic acid (2.0 g, 15 mmol), in distilled triethylamine (4.0 
g, 40 mmol), was added a mixture of BOC-ON (4.93 g, 20 mmol) in 1,4-dioxane (75 
ml) and water (75 ml). The solution became homogeneous and was left to stir for 18 h at 
room temperature. The solution was then washed with ethyl acetate (5 x 40 ml) followed 
by acidification with 5% citric acid. The aqueous layer was then extracted with ethyl 
acetate ( 6  x 30 ml) and the organic extracts were dried, filtered and concentrated to leave a 
residue which was crystallised from dichloromethane/hexane to leave white crystals (2 .1  
g, 60%), m.p. 132-134 °C, vmax 3413, 2947, 2657, 1731, 1661, 1465, 1369 and 1248 
cm-1; 8 h (D 20 ) 1.20 (9H, s, CH3C) and 3.86 (4H, d, J  3 Hz, CH2N); 8 C 28.2 (q, 
CH3C), 50.7 (t, CH2N), 83.8 (s, CH3C), 157.5 (s, NCO) and 174.7 (COOH); m/z 111 
(1.2%), 172, 161, 144, 133, 116 and 89(100%) (Found: M+ -C(CH3 ) 3 177.0273. 
C5H6NO6 requires M+ 177.0273).
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yVr'-bis(2-chloroethyl)-NM-bis(2-chloroethyl)-f-butoxycarbonyIamiiio-
diethanamide (205)
f-Butoxycarbonylaminodiacetic acid (1.75 g, 7.5 mmol) and distilled triethylamine (1.80 
g, 18 mmol) were cooled to -5 °C in distilled acetonitrile. Added dropwise to this was i- 
butylchloroformate (2.46 g, 18 mmol) whilst stirring. After a white precipitate formed, 
bis(2-chloroethyl)amine hydrochloride (2.8 g, 15 mmol) was added. Triethylamine (1.80 
g, 18 mmol) was then added dropwise and the solution was stirred for 2  h at room 
temperature. The solution was then concentrated to leave a solid yellow residue which 
was taken up in water (30 ml) and extracted with ethyl acetate (3 x 30 ml). The combined 
extracts were then dried, filtered and concentrated to leave a yellow oil. After flash 
chromatography on alumina using ethyl acetate the product was left as white crystals 
(1.87 g, 52%), RF 0.43 (EtOAc), vmax 3390, 2968, 1755, 1698, 1368, 1253 and 733 
c m 1; 5h 1.36 (9H, s, CH3C), 3.43 (8 H, m, N C//2CH2C1), 3.62-3.83 (8 H, m, C tf2Cl) 
and 4.23 (4H, s, N C tf2CO); 6 C 28.1 and 28.2 (q, CH 3C), 38.1, 38.2 and 38.5 
(CH 2C1), 41.4 (t, NCH2CO), 46.3, 48.4, 48.9 and 49.9 (t, NCH2 CH 2C1), 81.2 (s, 
(CH3)3C), 155.2 and 155.3 (s, NCOO) and 169.5 and 169.9 (s, NCOCH2);
vV'-bis(2-chloroethyl)-N"-bis(2-chloroethyl)diethanam ide (206)
Af-bis(2-chloroethyl)-N"-bis(2-chloroethyl)-f-butoxycarbonylaminodiethanamide (2 . 0  
g, 4.2 mmol) was dissolved in dry dichloromethane (25 ml) under nitrogen and 
trifluoroacetic acid (5 ml) was added dropwise at 0 °C. The solution was allowed to 
return to room temperature and was left to stir for 1 h. The solution was concentrated to a 
thick oil and basified with NaHC03 solution. The aqueous layer was then extracted with 
ethyl acetate (3 x 30 ml) and the combined extracts were dried, filtered and concentrated 
to leave an oil (1.15 g, 72%), Rp 0.52 (EtOAc : hexane, 1:1), vmax 3395, 2967, 1677 
and 722 c m 1; 8 H 3.72 (16H, m, NCH2CH2C\), 4.34 (4H, d, J 3 Hz, CH2NH) and 9.87 
(1H, bs, NH); 6 C 41.2 and 41.4 (t, C H 2 C1), 48.8, 48.9, 49.8 and 49.9 (t,
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NCH 2 CH 2 C1), 72.3 (t, CH2 NH) and 169.0 and 169.5 (s, C=0); m/z 216, 215, 194,
192, 136 and 92 (100%).
A -B is(2-ch loroethyl)am inoethyl-W -bis(2-ch loroethyl)(ethane-l,2-  
diamine Trihydrochloride (207)
N'-bis(2-chloroethyl)-N"-bis(2-chloroethyl)diethanamide (0.5 g, 1.3 mmol) was placed 
in a dry flask under nitrogen. Dry THF (10 ml) was added to form a slurry which was 
then cooled to 0 °C. 1 M Borane-THF (10 ml, 10 mmol) was added dropwise over 10 
min in which time the solution became clear. The solution was then heated at reflux for 2 
h. The reaction was then quenched with 6 M HC1 (5 ml) followed by water (10 ml). The 
THF was removed by distillation and the remaining solution was concentrated to leave a 
white residue. This was dissolved in methanol (10 ml) and conc. HC1 (2 drops) which 
was subsequently evaporated in vacuo to remove the methyl borate ester formed. This 
procedure was repeated twice until no more weight loss was recorded. The residue was 
then crystallised from ethanol to give the product (0.48 g, 80%), m.p.> 300 °C, vmax 
2955, 1643, 1462 and 6 6 8  c m 1; 6 H (D20 ) 3.05 (4H, m, CH2NH), 3.33 and 3.54 (12H, 
m, CH2N) and 3.68 (8 H, m, CH2Cl); 8 C 37.6 and 38.0 (t, CH2C1), 39.3 and 40.0 (t, 
CH2NH), 49.1 and 49.3 (NHCH2 CH2NR) and 55.7 and 55.8 (t, NCH2CH2C1); m/z 
356 (M+ 3.8%), 354, 283, 255, 248, 226, 212, 199, 184 and 169 (Too involatile for 
high res. MS).
Ar,Ar'-[Bis(2-chloroethyl)aminocarbonylmethyl]oxalamide (208)
2-Amino-^V,A^-bis(2-chloroethyl)ethanamide trifluoroacetate (1.0 g, 3.2 mmol) was 
dissolved in chloroform (20 ml) and distilled triethylamine (0.7 g, 7 mmol) was added. 
The solution was then cooled to -5 °C and oxalyl chloride (0.14 ml, 1.6 mmol) was 
added dropwise. The solution was left to stir at room temperature for 4 h before the 
solvent was removed in vacuo . The residue was dissolved in water and was extracted
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with ethyl acetate (3 x 30 ml). The combined extracts were dried, filtered and 
concentrated to leave a clear oil (0.65 g, 90%), Rf 0.60 (EtOAc), vmax 3378, 2976, 
2874, 1732, 1682, 1514 and 1454 c n r1; 6 H 3.76 (16H, m, NCH2CH2C\), 4.27 (4H, m, 
N H C //2) and 7.69 (2H, bs, N//); 6 C 41.0, 41.1, 41.2 and 41.4 (t, CH2C1), 48.48 and
49.5 (t, NCH 2CH 2C1), 63.4 (t, NHCH2CO), 156.6, 159.7 (s, NHCOCONH) and
167.4 and 167.9 (s, CH2CON); m/z 336, 325, 263, 227, 225, 168, 142, 126, 106, 92 
and 63 (100%) (Found: M + (1/2 molecule), 227.0642. C7H n N 2 0 2C l2 requires 
227.0640).
Bis[A^>A '-b is(2-ch loroethyl)am inoethyl]ethane-l, 2-diam ine 
Tetrahydrochloride (209)
N,N'-[Bis(2-chloroethyl)aminocarbonylmethyl]oxalamide (2.12 g, 4.7 mmol) was 
placed in a dry flask under nitrogen. Dry THF (10 ml) was added to form a slurry which 
was then cooled to 0 °C. 1 M Borane-THF (40 ml, 40 mmol) was added dropwise over 
10 min in which time the solution became clear. The solution was then heated at reflux 
for 2 h. The reaction was then quenched with 6 M HC1 (5 ml) followed by water (10 ml). 
The THF was removed by distillation and the remaining solution was concentrated to 
leave a white residue. This was dissolved in methanol (10 ml) and conc. HC1 (2 drops) 
which was subsequently evaporated in vacuo to remove the methyl borate ester formed. 
This procedure was repeated twice until no more weight loss was recorded. The residue 
was then crystallised from methanol to give the product (2.20 g, 8 6 %), m.p.192-194 °C, 
vmax 2968, 2450 and 680 c n r1; 6 H (D20 ) 3.04 (4H, m, NHC//2C //2NH), 3.27 (4H, m, 
N H C //2C H 2NR), 3.65 (12H, m, CH2N) and 3.86 (8 H, m, CH2C1); 6 C 37.9 (t, 
CH2C1), 42.4 and 44.3 (NCH2 CH2N), 49.3 and 49.5 (t, CH2NH), 50.3 and 51.7 (t, 
CH2N) and 55.8 (t, NCH2CH2C1); m/z 322, 204, 163, 161, 154, 143, 127 and 118 
(Found: C, 28.07; H, 6.67; N, 8.81. C i4H26N4Cl4 .4 HC1.4 H20  requires C, 27.36; H, 
6.84; N, 9.12%. M+ (-2C1) 322.1650. C 14H26N4C12 requires 322.1661,).
214
Sodium H exanitrocobaltate(III)168 (212)
A solution of sodium nitrite (15 g) in water (15 ml) was cooled to 50-60 °C and cobalt 
nitrate hexahydrate (5 g) was added, followed by 50% acetic acid (5 ml) in small portions 
with stirring. A fast stream of air was then bubbled through the solution for 30 min. After 
standing for 2  h the brown precipitate was filtered off to leave a clear solution. The 
precipitate was then stirred with water (5 ml) at 70-80 °C and filtered again. The two 
filtrates were combined and treated with 96% methanol (25 ml). After 2 h, the resulting 
precipitate was filtered, washed with methanol (4 x 25 ml) then diethyl ether (2 x 20 ml) 
and air dried to leave a yellow powder (6.0 g, 8 6 %), m.p. 215 °C (dec), vmax 3423, 
1423, 1396, 1333, 1116, 847 and 832 c n r1; m/z 269, 239, 149, 105, 97, 81, 71 and 46.
Sodium Bis(3-m ethyl-2,4-pentanedionato)dinitrocobaltate(III) Hydrate160 
(213)
Sodium hexanitrocobaltate(III) (3.27 g, 8.1 mmol) was dissolved in water (11 ml) and 
added to a mixture of NaOH (0.7 g, 17.5 mmol) and 3-methyl-2,4-pentanedione (2.0 g,
17.5 mmol) in water ( 1 1  ml) which had been cooled in an ice bath. Rapid formation of 
red-brown crystals occurred in 10 min, and after cooling at 5 °C for 12 h these were 
collected by filtration and washed with acetone ( 2 0  ml) and diethyl ether ( 2 0  ml) (2.90 g, 
75%). This was recrystallised by dissolving 1 g in water (35 ml) and filtering into 
sodium nitrite solution (5 g in 15 ml water). The resulting crystalline product was washed 
with EtOH/acetone (2:1) and dried in air, m.p. 175 °C (dec), v max 3457, 1562, 1443, 
1359, 1328, 1298 and 1181 cm '1; 8 H (D20 ) 1.90 (6 H, s, CH 3C) and 2.23 (12H, s, 
CH3CO); 8 c 15.40 (q, CH3C), 26.3 (q, CH3CO), 100.3 (s, CCH3) and 187.4 (C=0); 
m/z 285, 270, 242, 172, 143, 114, 99 and 72.
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Bis(3-m ethyl-2,4-pentanedionato)(A ,A-bis(2-chloroethyl)ethane-l,2-
diamine)cobalt(III) Hexafluorophosphate160 (214)
Sodium bis(3-methyl-2,4-pentanedionato)dinitrocobaltate(III) hydrate (0.37 g, 0.87 
mmol) was dissolved in a mixture of methanol ( 6  ml) and water ( 6  ml). Activated 
charcoal (0 .1  g) was added to the solution followed by A^A^-bis(2-chloroethyl)ethane-
1,2-diamine dihydrochloride (0.25 g, 1 mmol) in methanol (2 ml) and water (2 ml). A 
solution of NaOH (0.08 g, 2 mmol) in water (4 ml) was added dropwise to the cobalt 
solution and the mixture was stirred for 1 h. The charcoal was filtered off through Celite 
and washed with methanol which was added to the filtrate. Ammonium 
hexafluorophosphate (0.3 g) was added to the filtrate which was then extracted with 
chloroform (3 x 25 ml). The combined extracts were concentrated to leave a green residue 
which was taken up in water ( 6  ml). Methanol ( 6  ml) was then added and the solution 
was left open to the air for slow evapouration of the methanol. After 1 week, the resulting 
green crystals were collected by filtration and washed with 2 0 % methanol/water, water 
and ether, m.p. 82-83 °C, vmax 2926, 1569, 1426, 1339, 1299, 843 and 737 cm '1; 8 H 
1.86, 1.92, 1.96 and 2.07 ( 12H, s, C //3CO), 2.23 and 2.32 (6 H, s, CH3C), 2.70 (2H, 
m, C //2N R 2), 2.97 (4H, m, N C //2C H 2C1), 3.62 (4H, m, CH2Cl), 3.84 (2H, m, 
C //2NH2) and 4.06 (2H, bs, NH2)\ 8 c 14.6 and 14.9 (q, CH3C), 25.6, 26.2, 26.3 and
26.4 (q, CH3CO), 36.0 and 38.2 (t, CH 2C1), 41.7 (t, CH 2N H 2), 53.5 and 55.7 (t, 
CH2CH 2C1), 61.0 (t, CH2NR2), 1 0 2 .1  and 103.9 (s, CH3C) and 187.7, 188.9, 189.2 
and 189.5 (s, C=0); m/z 371, 343, 341, 329, 285, 172, 151, 123 and 107 (100%) 
(Found C, 35.13; H, 5.42; N, 4.31. Q ^ ^ C X iC h C o P F o  requires C, 35.12; H, 5.20; 
N, 4.55%).
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Bis(3-methyl-2,4-pentanedionato)(/?5-A^,^V,-bis(2-chloroethyl)ethane-l,2-
diamine)cobalt(III) Hexafluorophosphate160 (215)
Sodium bis(3-methyl-2,4-pentanedionato)dinitrocobaltate(III) hydrate (0.50 g, 1.2 
mmol) was dissolved in a mixture of methanol ( 6  ml) and water ( 6  ml). Activated 
charcoal (0.1 g) was added to the solution followed by Af,Af’-bis(2-chloroethyl)ethane-
1,2-diamine dihydrochloride (0.34 g, 1.3 mmol) in methanol (2 ml) and water (2 ml). A 
solution of NaOH (0.08 g, 2 mmol) in water (4 ml) was added dropwise to the cobalt 
solution and the mixture was stirred for 1 h. The charcoal was filtered off through Celite 
and washed with methanol which was added to the filtrate. Ammonium 
hexafluorophosphate (0.3 g) was added to the filtrate which was then extracted with 
chloroform (3 x 25 ml). The combined extracts were concentrated to leave a purple 
residue which was taken up in water ( 6  ml). Methanol ( 6  ml) was then added and the 
solution was left open to the air for slow evaporation of the methanol. After 48 h, the 
resulting purple needles were filtered and washed with water ( 1 0  ml) and ether ( 1 0  ml) 
and finally dried in air, m.p. 141-142 °C, vmax 2926, 1569, 1426, 1339, 1299, 842 and 
737 c m 1; 6 h 1.88 and 1.98 (6 H, s, CH3C), 2.15, 2.17, 2.22 and 2.24 (12H, s, 
C / / 3CO), 2.53-2.90 (4H, m, C/72C H 2C1), 3.03 (2H, m, CH2NH), 3.66 (4H, m, 
CH2C1), 3.94 (2H, m, CH2NH) and 4.61 (2H, bs, NH); 6 C 14.9 (q, CH 3C), 26.1,
26.2, 26.4 and 26.5 (q, CH 3CO), 48.9, 49.4, 50.0 and 50.9 (t, CH2 CH 2 C1 and 
CH2NHR), 51.4 and 56.9 (t, CH2CH2C1), 102.2 (s, CH3 C) and 188.1 and 188.9 (s, 
CH3CO); m/z 285, 172, 151, 123, 107 and 85 (100%) (Found C, 36.69; H, 5.30; N, 
4.70. C i8H32N20 4C12CoPF6 requires C, 35.12; H, 5.20; N, 4.55%).
B is(3-m ethyl-2 ,4-pentanedionato)(A ,A -bis(2-chloroethyl)propane-l,3-  
diamine)cobalt(III) Hexafluorophosphate (216)
Sodium bis(3-methyI-2,4-pentanedionato)dinitrocobaltate(III) hydrate (0.31 g, 0.74 
mmol) was dissolved in a mixture of methanol ( 6  ml) and water ( 6  ml). Activated
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charcoal (0.1 g) was added to the solution followed by N,A-bis(2-chloroethyl)propane-
1,3-diamine (0.20 g, 0.74 mmol) in methanol (2 ml) and water (2 ml). A solution of 
NaOH (0.06 g, 1.48 mmol) in water (4 ml) was added dropwise to the cobalt solution 
and the mixture was stirred for 1 h. The charcoal was filtered off through Celite and 
washed with methanol which was added to the filtrate. Ammonium hexafluorophosphate 
(0.3 g) was added to the filtrate which was then extracted with chloroform (3 x 25 ml). 
The combined extracts were concentrated to leave a brown residue which was taken up in 
water ( 6  m l) . Methanol ( 6  ml) was then added and the solution left open to the air for 
slow evaporation of the methanol. After 1 week, the resulting dark crystals were collected 
by filtration and washed with 20% methanol/water, water and ether (0.08 g, 17%), m.p. 
136-137 °C, vmax 2930, 1568, 1424, 1339, 1299, 845 and 737 cm '1; 6 H (CD3OD) 1.24 
(2H, m, NCH2C //2CH 2N), 1.44, 1.46, 1.49 and 1.53 ( 12H, s, CH3CO), 1.55 and 
1.66 (6 H, s, C //3C), 2.41 (2H, m, C //2NR2), 2.86 (8 H, m, N C//2CH2C1 and CH2C1) 
and 3.16 (2H, m, C tf2 N H 2); 6 C 13.5 (q, C H 3C), 27.0 (q, C H 3 CO), 31.3 (t, 
NCH 2C //2CH2N) 38.8 (t, CH2C1), 40.6 (t, CH2NH2), 43.0 (t, CH2CH2C1), 58.9 (t, 
CH2NR2), 100.8 (s, CH3C) and 187.9 (s, C=0); m/z 285, 242, 143, 123 99 and 72 
(Found C, 37.78; H, 5.18; N, 4.00. C i9H34N20 4C12CoPF6 requires C, 36.25; H, 5.41; 
N, 4.45%).
B is(3-m ethyl-2,4-pentanedionato)(A , A '-(l,4 -P rop an ed iy l)b is(2 -  
chloropiperidine)-cobalt(III) Hexafluorophosphate (218).
Sodium bis(3-methyl-2,4-pentanedionato)dinitrocobaltate(III) hydrate (0.31 g, 0.74 
mmol) was dissolved in a mixture of methanol ( 6  ml) and water ( 6  ml). Activated 
charcoal (0.1 g) was added to the solution. N ,N '-(  1,3 -p ro p a n e d iy l)b is (2 -  
chloropiperidine) (0.22 g, 0.74 mmol) in methanol (4 ml) was added dropwise to the 
cobalt solution and the mixture was stirred for 1 h. The charcoal was filtered off through 
Celite and washed with methanol which was added to the filtrate. Ammonium 
hexafluorophosphate (0.3 g) was added to the filtrate which was then extracted with
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chloroform (3 x 25 ml). The combined extracts were concentrated to leave a red residue 
which was taken up in water ( 6  ml). Methanol ( 6  ml) was then added and the solution 
was left open to the air for slow evapouration of the methanol. After 1 week, the resulting 
red-brown crystals were collected by filtration and washed with 2 0 % methanol/water, 
water and ether, (0.05 g, 9%), m.p. 144-145 °C, vmax 2932, 1575, 1426, 1339, 1299, 
843 and 735 c m 1; 5H 1.48-1.98 (14H, m, ring CH2 and NCH2Cff2CH2N), 1.78, 1.86,
2.02, 2.10 (12H, s, CH3CO), 2.18, 2.21 (6 H, C //3C), 2.86-3.07 (8 H, m, CH2N), 
3.29 (4H, m, CH2C1) and 3.58 (2H, m, CHN); m/z 415, 271, 257, 242, 158 (100%), 
143, 115 and 100.
Bis(3-m ethyl-2,4-pentanedionato)[A r,A r'-(l,4-butanediyl)bis(2-chloro- 
piperidine)]cobalt(III) Hexafluorophosphate (217)
Sodium bis(3-methyl-2,4-pentanedionato)dinitrocobaltate(III) hydrate (0.15 g, 0.87 
mmol) was dissolved in a mixture of methanol ( 6  ml) and water ( 6  ml). Activated 
charcoal (0.1 g) was added to the solution. A,A’-(l,4-butanediyl)bis(2-chloropiperidine) 
(0.10 g, 0.34 mmol) in methanol (4 ml) was added dropwise to the cobalt solution and 
the mixture was stirred for 1 h. The charcoal was filtered off through Celite and washed 
with methanol which was added to the filtrate. Ammonium hexafluorophosphate (0.3 g) 
was added to the filtrate which was then extracted with chloroform (3 x 25 ml). The 
combined extracts were concentrated to leave a red residue which was taken up in water 
( 6  m l). Methanol ( 6  ml) was then added and the solution was left open to the air for slow 
evaporation of the methanol. After 1 week, the resulting red-brown crystals were 
collected by filtration and washed with 20% methanol/water, water and ether, (0.04 g, 
16%), m.p. 145-147 °C, vmax 2924, 1564, 1428, 1339, 1299, 850 and 737 cm-1; 5H
1.55-2.05 (16H, m, ring CH2 and NCH2C //2C //2CH 2 N), 1.86, 1.92, 2.12, 2.16 
(12H, s, CJ/3CO), 2.21, 2.26 (6 H, C //3C), 2.90-3.10 (8 H, m, CH2N), 3.38 (4H, m, 
C //2C1) and 3.64 (2H, m, C//N); m/z 415, 271, 257, 242, 158 (100%), 143, 115 and
100 .
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Experimental to Chapter 8
Biological Testing 
Materials
Microtitre plates (Linbro, ICN flow)
Multichannel pipette (Costar)
Tip box, autoclavable (ICN flow)
Pipette tips (ICN flow)
Petri dishes, 5 cm and 10 cm (Sterilin)
Universal containers, 30 ml and 100 ml (Sterilin)
Plastic lunch box 
Growth medium
Trypsin (0.25% + EDTA 1 mmol in PBS)
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT, Sigma)
Sorensen's glycine buffer (0.1 M glycine, 0.1 M NaCl adjusted to pH 10.5 with 1 M 
NaOH)
Dimethylsulphoxide (DMSO)
DMSO dispenser (Well-fill, Denley)
ELIZA plate reader-Emax from Molecular Devices-Mento Park, California with 
Softmax® software.
Cell lines
Two human colon-carcinoma cell lines were used: HT 29 was obtained from the ATCC 
(Rockville, MD) and BE from Dr. N. Gibson (School of Pharmacy, University of 
Southern California, Los Angeles, CA). Both were grown as monolayer cultures in a 
mixture of Ham's F10 and Dulbecco's modified Eagle’s medium (50:50, Life
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Technologies, Paisley, UK) supplemented with glutamine (2 mM) and FCS (10%). Both 
cell lines had a doubling time of about 24 h.
Cytotoxicity assay : Protocol
1) Plating out cells
Growth medium was removed from cell culture and trypsin (2 ml) was added. After a 
couple of minutes, the trypsin was removed and the cells were seen to be sliding down 
the plate indicating that they were loosened. The cells were then collected in growth 
medium (10 ml) containing serum and counted using the Coulter counter. Dilution of the 
cells to the required concentration (which depends on the cell line) with medium, 
allowing 20 ml per microtitre plate was then carried out. The resulting cell suspension 
was transfered to a 1 0  cm petri dish from which 2 0 0  pi was added to each well of the 
central 10 columns of a flat bottomed 96 well plate (80 wells per plate) using a 
multichannel pipette, starting with column 2  and ending with column 11 ( 6  x 1 0 2 
cells/well for HT 29 and 1 x 103 cells/well for BE). 200 pi of growth medium was added 
to the eight wells in column 1 and column 12 as blanks. The plates were placed in a 
plastic lunch box and incubated in a humidified atmosphere at 37 °C and 2% CO2 for two 
days so that the cells would be in the exponential phase of growth for drug addition.
2) Drug addition
A serial 5-fold dilution of the cytotoxic drug was prepared in growth medium to give 4 
concentrations, starting at 1 mmol. Two plates was used for each drug to give duplicate 
determinations within one experiment.
The medium was then removed from the wells in columns 2 to 11. This was 
achieved using a hypodermic needle attatched to a suction line. The cells in the eight wells 
in columns 2  and 11 were fed with 2 0 0  pi of fresh growth medium and these cells were
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used as controls. The cytotoxic drugs were then added to the cells in columns 3 to 10. 
Only four wells were needed for each drug concentration so in this way, four compounds 
were screened in one plate, each drug with 16 wells. The drug solutions were transferred 
to 5 cm petri dishes and 200 jxl added to the wells. The plates were returned to the lunch 
box and incubated for 24 h.
3) Growth period.
At the end of the drug exposure period, the medium was removed from all the wells 
containing cells and the cells fed were with 200 pi of fresh medium, and incubated for 4 
days.
4) Estimation of surviving cell numbers
The plates were fed with 200 pi of fresh medium and 50 pi of MTT (5 mg/ml in PBS and 
filter sterilised) was added to all wells in columns 1 to 11. The plates were then wrapped 
in aluminium foil and incubated for 4 h in a humidified atmosphere at 37 °C. This is a 
minimum incubation time and plates can be left for up to 8  h. The medium and MTT were 
then removed from the wells and the MTT-formazan crystals were dissolved by addition 
of 200 pi of DMSO to all wells in columns 1 to 11. Glycine buffer was added (25 pi per 
well, 0.1M, pH 10.5) to all wells containing DMSO. Absorbance was recorded at 570 
nm immediately since the product is unstable. The wells in column 1, which contained 
medium, MTT but no cells was used to blank the plate reader.
5) Analysis of results
A graph was plotted of absorbance (y axis) against drug concentration (x axis). The mean 
absorbance reading from the wells in columns 2  and 11 were used as the control 
absorbance and the IC50 concentration was determined as the drug concentration required
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to reduce the absorbance to half that of the control. The absorbance values in columns 2 
and 11 should be the same, but on occasion they were not and this was taken to indicate 
uneven plating of cells across the plate.
Hypoxic cytotoxicity assay
For estimation of the oxicihypoxic cytotoxicity ratio, cells were grown on glass petri 
dishes for drug exposure under hypoxic conditions and on plastic petri dishes for oxic 
conditions. Cells were plated out at a density of 1 x 105 cells per 5 cm petri dish for the 
HT 29 cells and a density of 2 x 105 cells per 5 cm petri dish for the BE cells. The cells 
were allowed to attach and grow for 2 d. The medium was removed from the dishes and 
replaced with 2 ml of fresh medium containing the drug. Then the dishes were exposed to 
the drug for 3 h in a humidified atmosphere in oxic (2% CO2 in air) or hypoxic (2% CO2 
in N2) conditions. The medium was removed and the dishes were fed with fresh medium 
and incubated for 36 h. After removal of the medium, cells were detached with trypsin (1 
ml per dish). After 5-10 min, medium was added (1 ml) and the number of live cells 
counted using the Coulter Counter.
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